archetype #,Feature Name,P value (Mann-Whitney),Median Difference,Mean Difference,Significant after Benjamini-Hochberg correction?,Is first bin maximal?
1,PID INTEGRIN4 PATHWAY,5.6999e-08,1.4589,1.3862,1,1
1,INTERCELLULAR JUNCTION ASSEMBLY,6.93e-08,1.1892,1.0936,1,1
1,REACTOME SMOOTH MUSCLE CONTRACTION,2.8496e-08,1.1892,1.3187,1,1
1,BIOCARTA PLATELETAPP PATHWAY,2.1702e-06,1.1877,0.98736,1,1
1,REACTOME EXTRINSIC PATHWAY FOR APOPTOSIS,6.8936e-07,1.1664,1.0976,1,1
1,REACTOME ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I MHC,5.508e-06,1.1564,1.0611,1,1
1,PID INTEGRIN5 PATHWAY,2.3654e-06,1.0719,0.96848,1,1
1,BIOCARTA IL4 PATHWAY,1.8084e-07,1.0425,1.0236,1,1
1,OXIDOREDUCTASE ACTIVITY ACTING ON SULFUR GROUP OF DONORS,4.6826e-08,1.0254,1.0213,1,1
1,CYTOPLASM ORGANIZATION AND BIOGENESIS,4.9191e-08,1.0111,0.923,1,1
1,EXTRACELLULAR MATRIX STRUCTURAL CONSTITUENT,6.6003e-08,0.97894,1.0229,1,1
1,SA MMP CYTOKINE CONNECTION,1.2862e-06,0.92128,0.92703,1,1
1,PID INTEGRIN1 PATHWAY,5.6999e-08,0.91345,1.0017,1,1
1,INTERCELLULAR JUNCTION ASSEMBLY AND MAINTENANCE,1.8084e-07,0.90925,0.86749,1,1
1,REACTOME CELL EXTRACELLULAR MATRIX INTERACTIONS,1.1964e-05,0.90812,0.9845,1,1
1,POSITIVE REGULATION OF ANGIOGENESIS,3.17e-07,0.90145,0.78638,1,1
1,PID INTEGRIN3 PATHWAY,5.0194e-07,0.88711,0.88476,1,1
1,KEGG ALLOGRAFT REJECTION,1.1493e-05,0.88557,0.75361,1,1
1,BIOCARTA VITCB PATHWAY,7.547e-05,0.88459,0.674,1,1
1,REACTOME IL 6 SIGNALING,6.5149e-05,0.87687,0.75241,1,1
1,REACTOME YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION,1.1788e-07,0.8426,0.75541,1,1
1,BIOCARTA AMI PATHWAY,3.7145e-05,0.83775,0.61897,1,1
1,BIOCARTA FIBRINOLYSIS PATHWAY,1.4674e-06,0.8342,0.83257,1,1
1,POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS,4.6826e-08,0.8287,0.89107,1,1
1,REACTOME METABOLISM OF PORPHYRINS,6.5896e-07,0.82321,0.81342,1,1
1,PID A6B1 A6B4 INTEGRIN PATHWAY,5.2533e-07,0.8216,0.70286,1,1
1,PID UPA UPAR PATHWAY,5.1671e-08,0.80786,0.99585,1,1
1,POSITIVE REGULATION OF CELL CYCLE,1.7806e-05,0.79532,0.61425,1,1
1,BIOCARTA SODD PATHWAY,2.0784e-06,0.78442,0.90777,1,1
1,REACTOME ANTIGEN PROCESSING CROSS PRESENTATION,4.7955e-07,0.78193,0.7139,1,1
1,COLLAGEN,6.4994e-06,0.77495,0.87419,1,1
1,KEGG ECM RECEPTOR INTERACTION,4.6826e-08,0.77305,0.83156,1,1
1,REACTOME COLLAGEN FORMATION,1.6729e-06,0.76633,0.7354,1,1
1,POSITIVE REGULATION OF PHOSPHORYLATION,9.2696e-08,0.75502,0.78639,1,1
1,REACTOME SIGNALING BY HIPPO,9.3916e-06,0.74033,0.71474,1,1
1,REACTOME INTERFERON ALPHA BETA SIGNALING,5.4121e-05,0.73772,0.80672,1,1
1,BIOCARTA TOB1 PATHWAY,9.7801e-06,0.73421,0.63622,1,1
1,REACTOME CASPASE MEDIATED CLEAVAGE OF CYTOSKELETAL PROTEINS,2.6322e-07,0.7276,0.75047,1,1
1,REACTOME ER PHAGOSOME PATHWAY,1.6729e-06,0.72723,0.63561,1,1
1,KEGG AUTOIMMUNE THYROID DISEASE,2.4346e-05,0.72535,0.58475,1,1
1,PID SYNDECAN 1 PATHWAY,3.4772e-07,0.72206,0.82676,1,1
1,REGULATION OF PROTEIN AMINO ACID PHOSPHORYLATION,3.8131e-07,0.72159,0.68339,1,1
1,REACTOME MUSCLE CONTRACTION,6.2859e-08,0.72116,0.76099,1,1
1,REGULATION OF PROTEIN IMPORT INTO NUCLEUS,2.6322e-07,0.71954,0.69676,1,1
1,BIOCARTA RELA PATHWAY,1.3605e-07,0.71128,0.63692,1,1
1,PID ERBB NETWORK PATHWAY,3.1904e-06,0.71026,0.6649,1,1
1,PID SYNDECAN 4 PATHWAY,1.6729e-06,0.70708,0.75806,1,1
1,KEGG OTHER GLYCAN DEGRADATION,1.104e-05,0.69845,0.63779,1,1
1,REGULATION OF CELL MIGRATION,1.1237e-07,0.69518,0.72719,1,1
1,REACTOME NFKB ACTIVATION THROUGH FADD RIP1 PATHWAY MEDIATED BY CASPASE 8 AND10,2.0033e-05,0.69414,0.62615,1,1
1,SARCOMERE,1.906e-06,0.6892,0.65634,1,1
1,PID INTEGRIN CS PATHWAY,1.6452e-07,0.68519,0.79337,1,1
1,REACTOME HYALURONAN METABOLISM,4.5813e-07,0.68492,0.63152,1,1
1,KEGG GLYCOSAMINOGLYCAN DEGRADATION,3.4728e-06,0.68206,0.53168,1,1
1,POSITIVE REGULATION OF PROTEIN AMINO ACID PHOSPHORYLATION,4.4712e-06,0.68198,0.67869,1,1
1,BIOCARTA PML PATHWAY,5.4977e-07,0.68109,0.63563,1,1
1,REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION,3.3287e-06,0.67727,0.65996,1,1
1,KEGG GRAFT VERSUS HOST DISEASE,1.5201e-05,0.67474,0.68451,1,1
1,BIOCARTA CASPASE PATHWAY,3.1888e-05,0.67456,0.6168,1,1
1,EUKARYOTIC TRANSLATION INITIATION FACTOR 3 COMPLEX,0.00074557,0.66074,0.46093,1,1
1,REACTOME INTEGRIN CELL SURFACE INTERACTIONS,5.4977e-07,0.6604,0.59174,1,1
1,REACTOME EXTRACELLULAR MATRIX ORGANIZATION,6.0198e-07,0.65841,0.6668,1,1
1,BIOCARTA EXTRINSIC PATHWAY,6.0504e-05,0.65484,0.57998,1,1
1,BIOCARTA TH1TH2 PATHWAY,8.3127e-06,0.65327,0.59658,1,1
1,BIOCARTA IL10 PATHWAY,3.6228e-06,0.65147,0.69598,1,1
1,POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB CASCADE,3.6414e-07,0.64746,0.64575,1,1
1,REACTOME CALNEXIN CALRETICULIN CYCLE,6.2367e-06,0.64491,0.56078,1,1
1,BIOCARTA INTRINSIC PATHWAY,0.00021909,0.64288,0.52985,1,1
1,REGULATION OF I KAPPAB KINASE NF KAPPAB CASCADE,3.17e-07,0.63887,0.65013,1,1
1,BIOCARTA DEATH PATHWAY,1.3441e-06,0.63697,0.59497,1,1
1,REACTOME TRAF3 DEPENDENT IRF ACTIVATION PATHWAY,1.7806e-05,0.63541,0.54423,1,1
1,REACTOME NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING,4.6623e-06,0.62909,0.52421,1,1
1,EXTRACELLULAR MATRIX PART,5.0194e-07,0.6215,0.66929,1,1
1,PID NFKAPPABCANONICALPATHWAY,2.6902e-06,0.62119,0.55847,1,1
1,BIOCARTA CARDIACEGF PATHWAY,7.8282e-05,0.61927,0.58626,1,1
1,PID FRA PATHWAY,9.2696e-08,0.61697,0.82533,1,1
1,REACTOME RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 ,3.3202e-07,0.61295,0.62817,1,1
1,I KAPPAB KINASE NF KAPPAB CASCADE,5.2533e-07,0.61158,0.59793,1,1
1,REACTOME CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES,9.8628e-07,0.61091,0.52824,1,1
1,LIPID HOMEOSTASIS,2.9301e-06,0.60831,0.61759,1,1
1,REACTOME CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM,2.8077e-06,0.60604,0.55157,1,1
1,PID AVB3 INTEGRIN PATHWAY,6.2859e-08,0.60579,0.68987,1,1
1,REACTOME N GLYCAN TRIMMING IN THE ER AND CALNEXIN CALRETICULIN CYCLE,4.8612e-06,0.59925,0.54876,1,1
1,REACTOME ASSOCIATION OF TRIC CCT WITH TARGET PROTEINS DURING BIOSYNTHESIS,1.9873e-07,0.59725,0.49886,1,1
1,BIOCARTA TID PATHWAY,1.3441e-06,0.59295,0.51767,1,1
1,BASEMENT MEMBRANE,7.5427e-07,0.59262,0.58553,1,1
1,BIOCARTA CD40 PATHWAY,8.2505e-07,0.59119,0.66559,1,1
1,REGULATION OF INTRACELLULAR TRANSPORT,2.0833e-05,0.59053,0.47347,1,1
1,BIOCARTA INFLAM PATHWAY,3.17e-07,0.57915,0.75754,1,1
1,PID AP1 PATHWAY,1.8521e-05,0.57889,0.51982,1,1
1,PROTEASE INHIBITOR ACTIVITY,0.00010462,0.57813,0.46179,1,1
1,OXIDOREDUCTASE ACTIVITY ACTING ON THE CH CH GROUP OF DONORS,9.389e-05,0.57631,0.41377,1,1
1,BIOCARTA NFKB PATHWAY,1.4674e-06,0.57552,0.5593,1,1
1,ENDOPLASMIC RETICULUM LUMEN,1.6729e-06,0.57439,0.65182,1,1
1,LIPID TRANSPORT,4.1112e-06,0.57267,0.46772,1,1
1,REACTOME DESTABILIZATION OF MRNA BY AUF1 HNRNP D0,1.9904e-06,0.57117,0.4832,1,1
1,REACTOME SMAD2 SMAD3 SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION,9.4334e-07,0.56866,0.58429,1,1
1,REACTOME 3 UTR MEDIATED TRANSLATIONAL REGULATION,0.011326,0.56857,0.35751,1,1
1,EPITHELIAL TO MESENCHYMAL TRANSITION,4.4878e-05,0.56821,0.71685,1,1
1,PID AVB3 OPN PATHWAY,0.00047456,0.56697,0.47523,1,1
1,REACTOME A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS,0.0045306,0.56647,0.43662,1,1
1,BASAL LAMINA,1.7118e-05,0.56618,0.55314,1,1
1,REACTOME PEPTIDE CHAIN ELONGATION,0.02166,0.56532,0.35635,1,1
1,BIOCARTA CLASSIC PATHWAY,8.3127e-06,0.56396,0.60231,1,1
1,PID TNFPATHWAY,2.2879e-07,0.56132,0.54034,1,1
1,POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS,4.7955e-07,0.56091,0.60879,1,1
1,KEGG RIBOSOME,0.02166,0.56021,0.34323,1,1
1,POSITIVE REGULATION OF DNA METABOLIC PROCESS,4.6623e-06,0.55833,0.5462,1,1
1,REGULATION OF PROTEIN MODIFICATION PROCESS,1.2366e-07,0.55769,0.5893,1,1
1,POSITIVE REGULATION OF SIGNAL TRANSDUCTION,6.8936e-07,0.55689,0.53686,1,1
1,PROTEASOME COMPLEX,1.9263e-05,0.55579,0.45819,1,1
1,BIOCARTA CBL PATHWAY,4.0073e-05,0.55545,0.516,1,1
1,EXTRACELLULAR MATRIX,9.2696e-08,0.55503,0.67883,1,1
1,PROTEINACEOUS EXTRACELLULAR MATRIX,9.7275e-08,0.55419,0.68169,1,1
1,PID TOLL ENDOGENOUS PATHWAY,0.0049174,0.55364,0.40185,1,1
1,REACTOME REGULATION OF COMPLEMENT CASCADE,2.1663e-05,0.55319,0.65332,1,1
1,PID MYC REPRESSPATHWAY,1.1237e-07,0.5513,0.515,1,1
1,BIOCARTA IL22BP PATHWAY,0.00044439,0.54586,0.47456,1,1
1,REACTOME ACYL CHAIN REMODELLING OF PI,5.2139e-05,0.54572,0.4369,1,1
1,BIOCARTA RHO PATHWAY,4.3763e-07,0.54535,0.50634,1,1
1,REGULATION OF CELL SHAPE,6.4994e-06,0.54027,0.48371,1,1
1,REACTOME CDK MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6,5.2837e-06,0.53966,0.46207,1,1
1,TYROSINE PHOSPHORYLATION OF STAT PROTEIN,9.0179e-06,0.53902,0.64866,1,1
1,KEGG ASTHMA,0.00072223,0.53895,0.34652,1,1
1,OXIDOREDUCTASE ACTIVITY GO 0016706,0.011612,0.53531,0.42632,1,1
1,BIOCARTA P53HYPOXIA PATHWAY,0.00059588,0.53324,0.40442,1,1
1,REACTOME NOTCH HLH TRANSCRIPTION PATHWAY,1.4044e-06,0.53223,0.54445,1,1
1,PID CASPASE PATHWAY,0.00030804,0.5321,0.41188,1,1
1,PID SYNDECAN 2 PATHWAY,1.3441e-06,0.53025,0.56494,1,1
1,REACTOME HS GAG DEGRADATION,0.00055855,0.53019,0.48185,1,1
1,FOCAL ADHESION,0.00095906,0.52776,0.48592,1,1
1,REACTOME VIF MEDIATED DEGRADATION OF APOBEC3G,2.9301e-06,0.52775,0.48959,1,1
1,KEGG VIRAL MYOCARDITIS,8.628e-07,0.5267,0.5332,1,1
1,STRUCTURAL CONSTITUENT OF RIBOSOME,0.027188,0.52658,0.32664,1,1
1,KEGG PROTEASOME,7.3528e-06,0.52528,0.48275,1,1
1,BIOCARTA NTHI PATHWAY,4.6623e-06,0.52485,0.4963,1,1
1,FATTY ACID BETA OXIDATION,4.8612e-06,0.52414,0.62851,1,1
1,PID TRAIL PATHWAY,1.0779e-06,0.52298,0.48767,1,1
1,MYELOID LEUKOCYTE DIFFERENTIATION,0.016734,0.52273,0.41108,1,1
1,KEGG ANTIGEN PROCESSING AND PRESENTATION,4.1617e-05,0.52182,0.49426,1,1
1,BIOCARTA COMP PATHWAY,1.3441e-06,0.52102,0.55175,1,1
1,CONTRACTILE FIBER PART,1.8958e-07,0.51809,0.54159,1,1
1,REACTOME FORMATION OF THE TERNARY COMPLEX AND SUBSEQUENTLY THE 43S COMPLEX,0.01282,0.51712,0.34724,1,1
1,REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EMI1,3.7791e-06,0.51501,0.45549,1,1
1,REACTOME SEMA4D IN SEMAPHORIN SIGNALING,3.1491e-08,0.51429,0.57909,1,1
1,REGULATION OF CELL MORPHOGENESIS,5.2837e-06,0.5117,0.47292,1,1
1,REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT,3.0689e-05,0.51118,0.45838,1,1
1,REACTOME STRIATED MUSCLE CONTRACTION,2.4692e-06,0.51101,0.47165,1,1
1,PID TGFBRPATHWAY,1.4268e-07,0.51078,0.49484,1,1
1,PID IL27PATHWAY,6.0198e-07,0.5106,0.58819,1,1
1,PID PDGFRAPATHWAY,6.5149e-05,0.51007,0.41516,1,1
1,KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE,3.9418e-06,0.5075,0.50046,1,1
1,BIOCARTA RANKL PATHWAY,0.00010092,0.50528,0.56831,1,1
1,REACTOME ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S,0.0079323,0.5049,0.32564,1,1
1,PID INTEGRIN A9B1 PATHWAY,5.0683e-06,0.50452,0.64634,1,1
1,KEGG BLADDER CANCER,3.0689e-05,0.50424,0.39214,1,1
1,KEGG FOCAL ADHESION,2.2167e-08,0.50401,0.60004,1,1
1,CELL MATRIX JUNCTION,6.7596e-05,0.50333,0.50932,1,1
1,KEGG LYSOSOME,5.2837e-06,0.5029,0.42886,1,1
1,PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION,5.9841e-06,0.50263,0.54748,1,1
1,REACTOME PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS,0.0094949,0.50249,0.33745,1,1
1,PID ECADHERIN STABILIZATION PATHWAY,1.0779e-06,0.50105,0.48463,1,1
1,REACTOME SEMA4D INDUCED CELL MIGRATION AND GROWTH CONE COLLAPSE,8.0176e-08,0.50105,0.53819,1,1
1,ST TUMOR NECROSIS FACTOR PATHWAY,7.889e-07,0.4989,0.59424,1,1
1,REACTOME DOWNREGULATION OF TGF BETA RECEPTOR SIGNALING,3.4772e-07,0.49663,0.57696,1,1
1,STEROL BINDING,2.4346e-05,0.49657,0.53083,1,1
1,JAK STAT CASCADE,2.1663e-05,0.49636,0.48902,1,1
1,BIOCARTA CELL2CELL PATHWAY,2.2524e-05,0.49588,0.49596,1,1
1,PID HIF2PATHWAY,0.00031859,0.49549,0.43639,1,1
1,NITROGEN COMPOUND BIOSYNTHETIC PROCESS,9.0179e-06,0.49544,0.47542,1,1
1,SA CASPASE CASCADE,1.1267e-06,0.49415,0.50526,1,1
1,REGULATION OF VIRAL REPRODUCTION,0.0010206,0.49324,0.36438,1,1
1,BIOCARTA UCALPAIN PATHWAY,6.8936e-07,0.4931,0.62365,1,1
1,REACTOME REGULATION OF ORNITHINE DECARBOXYLASE ODC,3.4728e-06,0.49233,0.46018,1,1
1,PID DELTANP63PATHWAY,4.3218e-05,0.49086,0.5439,1,1
1,REACTOME GAP JUNCTION DEGRADATION,8.3127e-06,0.49056,0.47496,1,1
1,REACTOME AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1,4.1112e-06,0.49001,0.47849,1,1
1,REACTOME RIP MEDIATED NFKB ACTIVATION VIA DAI,7.5427e-07,0.48606,0.46776,1,1
1,BIOCARTA TEL PATHWAY,2.3418e-05,0.48591,0.5177,1,1
1,REACTOME CHONDROITIN SULFATE BIOSYNTHESIS,3.0576e-06,0.48475,0.64018,1,1
1,REACTOME INTERFERON SIGNALING,1.5201e-05,0.48399,0.46132,1,1
1,BIOCARTA PROTEASOME PATHWAY,2.0033e-05,0.48229,0.38588,1,1
1,REACTOME ADVANCED GLYCOSYLATION ENDPRODUCT RECEPTOR SIGNALING,9.0221e-07,0.48146,0.5205,1,1
1,COLLAGEN BINDING,0.016734,0.47876,0.52859,1,1
1,REACTOME PTM GAMMA CARBOXYLATION HYPUSINE FORMATION AND ARYLSULFATASE ACTIVATION,0.00026003,0.47833,0.36716,1,1
1,KEGG SMALL CELL LUNG CANCER,4.3763e-07,0.47473,0.441,1,1
1,REACTOME ACTIVATION OF NF KAPPAB IN B CELLS,1.3441e-06,0.47362,0.4265,1,1
1,KEGG SULFUR METABOLISM,0.00030804,0.4736,0.38077,1,1
1,REACTOME TRAF6 MEDIATED NFKB ACTIVATION,9.8628e-07,0.4728,0.4715,1,1
1,PID ILK PATHWAY,4.3763e-07,0.47253,0.55056,1,1
1,BIOCARTA SPRY PATHWAY,0.00027832,0.47173,0.42104,1,1
1,REACTOME INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION,0.023741,0.47168,0.30053,1,1
1,LIPID RAFT,4.6597e-05,0.4695,0.45273,1,1
1,TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY,4.5813e-07,0.46937,0.50355,1,1
1,PID FAK PATHWAY,1.5691e-07,0.46806,0.50334,1,1
1,BIOCARTA FAS PATHWAY,4.1112e-06,0.46806,0.46044,1,1
1,LYSOSOMAL TRANSPORT,2.8891e-07,0.46737,0.52095,1,1
1,REACTOME SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE,0.014841,0.46701,0.29822,1,1
1,REACTOME P53 DEPENDENT G1 DNA DAMAGE RESPONSE,1.1964e-05,0.46697,0.35858,1,1
1,REACTOME REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU RICH ELEMENTS,5.753e-07,0.46493,0.41456,1,1
1,INTEGRIN COMPLEX,9.3916e-06,0.46424,0.63126,1,1
1,REACTOME HDL MEDIATED LIPID TRANSPORT,3.5759e-05,0.46381,0.45326,1,1
1,REACTOME TRANSLATION,0.0059384,0.46357,0.3049,1,1
1,REACTOME TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION,1.2962e-05,0.46309,0.5017,1,1
1,PROTEIN TARGETING TO MITOCHONDRION,0.00029782,0.46271,0.38384,1,1
1,BIOCARTA LAIR PATHWAY,4.1112e-06,0.46075,0.61309,1,1
1,REACTOME CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX,1.7806e-05,0.46051,0.39019,1,1
1,PEPTIDYL TYROSINE MODIFICATION,3.3202e-07,0.46014,0.52433,1,1
1,REACTOME DEGRADATION OF THE EXTRACELLULAR MATRIX,4.3218e-05,0.45996,0.50154,1,1
1,DNA DAMAGE RESPONSESIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR,0.00057693,0.45958,0.40017,1,1
1,REACTOME TRAF6 MEDIATED IRF7 ACTIVATION,0.00030804,0.45902,0.38858,1,1
1,PEPTIDYL TYROSINE PHOSPHORYLATION,6.2985e-07,0.45719,0.51566,1,1
1,KEGG COMPLEMENT AND COAGULATION CASCADES,2.1702e-06,0.45468,0.50685,1,1
1,REACTOME P53 INDEPENDENT G1 S DNA DAMAGE CHECKPOINT,7.6603e-06,0.45446,0.44134,1,1
1,REACTOME RIG I MDA5 MEDIATED INDUCTION OF IFN ALPHA BETA PATHWAYS,2.4692e-06,0.45365,0.4679,1,1
1,COFACTOR METABOLIC PROCESS,0.00013917,0.45188,0.31938,1,1
1,REACTOME KERATAN SULFATE DEGRADATION,1.9263e-05,0.45163,0.61141,1,1
1,REGULATION OF MUSCLE CONTRACTION,4.6597e-05,0.45087,0.46599,1,1
1,PID TAP63PATHWAY,3.7145e-05,0.45086,0.47328,1,1
1,REACTOME GRB2 EVENTS IN ERBB2 SIGNALING,1.1237e-07,0.45073,0.45449,1,1
1,REACTOME GLYCOSPHINGOLIPID METABOLISM,0.00021909,0.44995,0.31874,1,1
1,PROTEIN IMPORT INTO NUCLEUS,2.6902e-06,0.44791,0.38046,1,1
1,REACTOME SYNTHESIS OF SUBSTRATES IN N GLYCAN BIOSYTHESIS,0.00037661,0.44695,0.33841,1,1
1,SULFUR COMPOUND BIOSYNTHETIC PROCESS,1.4963e-07,0.44598,0.58957,1,1
1,REACTOME SIGNALING BY WNT,2.3654e-06,0.4444,0.38398,1,1
1,TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY,1.0311e-06,0.44284,0.41251,1,1
1,HEPARIN BINDING,6.5149e-05,0.44263,0.36378,1,1
1,REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM,1.1493e-05,0.44221,0.36573,1,1
1,AMINE BIOSYNTHETIC PROCESS,0.00047456,0.44124,0.37461,1,1
1,REACTOME AUTODEGRADATION OF CDH1 BY CDH1 APC C,6.4994e-06,0.44109,0.39319,1,1
1,BIOCARTA CTL PATHWAY,4.6597e-05,0.44108,0.48952,1,1
1,FATTY ACID OXIDATION,2.3418e-05,0.44102,0.44418,1,1
1,REACTOME P75NTR RECRUITS SIGNALLING COMPLEXES,6.7596e-05,0.43939,0.45615,1,1
1,PID INTEGRIN A4B1 PATHWAY,0.00040247,0.43882,0.36492,1,1
1,REGULATION OF PHOSPHORYLATION,7.6603e-06,0.43878,0.41082,1,1
1,HEME METABOLIC PROCESS,7.2754e-05,0.43875,0.45048,1,1
1,BIOCARTA GCR PATHWAY,7.013e-05,0.43837,0.40843,1,1
1,REACTOME P75NTR SIGNALS VIA NFKB,4.4878e-05,0.43806,0.46106,1,1
1,INTRINSIC TO GOLGI MEMBRANE,1.4039e-05,0.4362,0.37274,1,1
1,BASOLATERAL PLASMA MEMBRANE,0.0001165,0.43576,0.3529,1,1
1,BIOCARTA EIF PATHWAY,0.0028141,0.43467,0.27381,1,1
1,BIOCARTA HIVNEF PATHWAY,4.1112e-06,0.43424,0.42243,1,1
1,HEMATOPOIETIN INTERFERON CLASSD200 DOMAIN CYTOKINE RECEPTOR ACTIVITY,1.5201e-05,0.43371,0.46901,1,1
1,INTERLEUKIN BINDING,4.2876e-06,0.43364,0.52297,1,1
1,CELLULAR DEFENSE RESPONSE,7.013e-05,0.43185,0.42508,1,1
1,INTERLEUKIN RECEPTOR ACTIVITY,2.0833e-05,0.43166,0.58364,1,1
1,REACTOME NONSENSE MEDIATED DECAY ENHANCED BY THE EXON JUNCTION COMPLEX,0.014486,0.43153,0.28484,1,1
1,REGULATION OF DNA REPLICATION,0.00032948,0.43095,0.37543,1,1
1,BIOCARTA GSK3 PATHWAY,1.5816e-05,0.42993,0.39163,1,1
1,REACTOME CS DS DEGRADATION,0.00016595,0.42948,0.67709,1,1
1,BIOCARTA IL1R PATHWAY,0.00052342,0.42899,0.41908,1,1
1,CELL SUBSTRATE ADHERENS JUNCTION,0.00021909,0.42756,0.47671,1,1
1,REACTOME ACTIVATION OF CHAPERONE GENES BY XBP1S,9.3916e-06,0.42716,0.37486,1,1
1,NUCLEOTIDE SUGAR METABOLIC PROCESS,0.00022676,0.427,0.39444,1,1
1,RAS GTPASE ACTIVATOR ACTIVITY,0.00018427,0.42621,0.36099,1,1
1,REACTOME LIPOPROTEIN METABOLISM,1.0604e-05,0.42504,0.40069,1,1
1,VIRAL REPRODUCTIVE PROCESS,3.8131e-07,0.42501,0.42815,1,1
1,BIOCARTA TNFR2 PATHWAY,1.8521e-05,0.42406,0.4926,1,1
1,SPHINGOID METABOLIC PROCESS,1.9904e-06,0.42381,0.40639,1,1
1,PID IL6 7PATHWAY,4.0073e-05,0.42319,0.42754,1,1
1,KEGG PORPHYRIN AND CHLOROPHYLL METABOLISM,4.2876e-06,0.42309,0.4024,1,1
1,RUFFLE,0.00063551,0.42193,0.40898,1,1
1,REGULATION OF CELL GROWTH,3.4728e-06,0.42085,0.41752,1,1
1,REACTOME REGULATION OF INSULIN LIKE GROWTH FACTOR IGF ACTIVITY BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS,0.023741,0.41884,0.45028,1,1
1,CYTOKINE BINDING,9.3916e-06,0.41876,0.36508,1,1
1,KEGG RENIN ANGIOTENSIN SYSTEM,0.00042998,0.41853,0.40971,1,1
1,REACTOME TGF BETA RECEPTOR SIGNALING ACTIVATES SMADS,1.2308e-06,0.41821,0.50423,1,1
1,REACTOME FORMATION OF FIBRIN CLOT CLOTTING CASCADE,2.7343e-05,0.41688,0.32319,1,1
1,ST GAQ PATHWAY,6.7728e-06,0.41681,0.40413,1,1
1,VIRAL GENOME REPLICATION,1.4674e-06,0.41664,0.41358,1,1
1,PID LYMPHANGIOGENESIS PATHWAY,1.0604e-05,0.41525,0.5233,1,1
1,KEGG HEMATOPOIETIC CELL LINEAGE,1.1267e-06,0.41501,0.50594,1,1
1,PROTEIN TYROSINE KINASE ACTIVITY,2.5308e-05,0.41336,0.34054,1,1
1,REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL,2.1663e-05,0.41294,0.43801,1,1
1,PID ARF 3PATHWAY,9.8628e-07,0.41232,0.39599,1,1
1,STEROID BINDING,0.00023468,0.41231,0.38231,1,1
1,PID P53DOWNSTREAMPATHWAY,0.0022332,0.41197,0.30148,1,1
1,BIOCARTA ARAP PATHWAY,1.7474e-06,0.41061,0.41553,1,1
1,REACTOME ACTIVATION OF IRF3 IRF7 MEDIATED BY TBK1 IKK EPSILON,0.0001547,0.41033,0.46487,1,1
1,PID IL23PATHWAY,0.0047853,0.41032,0.37512,1,1
1,PROTEOGLYCAN METABOLIC PROCESS,0.00011241,0.40995,0.36058,1,1
1,REACTOME CHYLOMICRON MEDIATED LIPID TRANSPORT,0.00021909,0.40965,0.36297,1,1
1,REACTOME CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION ,1.2962e-05,0.40945,0.35142,1,1
1,REACTOME REGULATION OF APOPTOSIS,2.6902e-06,0.40934,0.37844,1,1
1,REACTOME SHC1 EVENTS IN EGFR SIGNALING,3.8583e-05,0.4092,0.37455,1,1
1,AGING,0.00011241,0.40869,0.40071,1,1
1,PID HIVNEFPATHWAY,6.7596e-05,0.40866,0.38388,1,1
1,COFACTOR BIOSYNTHETIC PROCESS,7.8282e-05,0.40744,0.3818,1,1
1,KEGG APOPTOSIS,2.0784e-06,0.40637,0.38631,1,1
1,STEROID HORMONE RECEPTOR ACTIVITY,2.9532e-05,0.40593,0.33401,1,1
1,OXIDOREDUCTASE ACTIVITY ACTING ON THE ALDEHYDE OR OXO GROUP OF DONORS,4.3218e-05,0.40554,0.45946,1,1
1,RESPONSE TO OXIDATIVE STRESS,4.8612e-06,0.40438,0.34552,1,1
1,NUCLEAR IMPORT,8.3127e-06,0.40343,0.34734,1,1
1,REACTOME APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1,1.4039e-05,0.40341,0.36542,1,1
1,REACTOME FACILITATIVE NA INDEPENDENT GLUCOSE TRANSPORTERS,0.0031536,0.40248,0.37207,1,1
1,MEMBRANE COAT,5.0683e-06,0.4017,0.34018,1,1
1,COATED MEMBRANE,5.0683e-06,0.4017,0.34018,1,1
1,KEGG VALINE LEUCINE AND ISOLEUCINE BIOSYNTHESIS,0.011326,0.40047,0.3713,1,1
1,REACTOME ASSEMBLY OF THE PRE REPLICATIVE COMPLEX,6.2786e-05,0.40005,0.29597,1,1
1,REACTOME METABOLISM OF MRNA,0.00013917,0.39997,0.31121,1,1
1,TRANSITION METAL ION TRANSPORT,4.2876e-06,0.39848,0.39099,1,1
1,INTERFERON GAMMA PRODUCTION,4.6597e-05,0.39787,0.37456,1,1
1,BIOCARTA EGFR SMRTE PATHWAY,0.0031536,0.39612,0.42962,1,1
1,RESPONSE TO DRUG,0.00065623,0.39538,0.33284,1,1
1,REACTOME APC C CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS,9.3916e-06,0.39525,0.36966,1,1
1,AMINOPEPTIDASE ACTIVITY,5.7413e-06,0.39322,0.43891,1,1
1,REACTOME INFLUENZA LIFE CYCLE,0.0079323,0.39313,0.27396,1,1
1,PID TCPTP PATHWAY,1.0311e-06,0.392,0.43213,1,1
1,RHO GTPASE ACTIVATOR ACTIVITY,9.389e-05,0.39196,0.38422,1,1
1,OXIDOREDUCTASE ACTIVITY ACTING ON THE ALDEHYDE OR OXO GROUP OF DONORSNAD OR NADP AS ACCEPTOR,0.0013872,0.39182,0.46715,1,1
1,REACTOME PRE NOTCH TRANSCRIPTION AND TRANSLATION,7.9801e-06,0.39062,0.37079,1,1
1,REACTOME RECEPTOR LIGAND BINDING INITIATES THE SECOND PROTEOLYTIC CLEAVAGE OF NOTCH RECEPTOR,0.0081404,0.38997,0.31125,1,1
1,REACTOME COMPLEMENT CASCADE,3.7791e-06,0.38988,0.4859,1,1
1,BIOCARTA SALMONELLA PATHWAY,1.6015e-06,0.38958,0.42404,1,1
1,ER GOLGI INTERMEDIATE COMPARTMENT,7.547e-05,0.38922,0.45653,1,1
1,REACTOME GAP JUNCTION ASSEMBLY,0.00052342,0.3886,0.32859,1,1
1,TRANSITION METAL ION TRANSMEMBRANE TRANSPORTER ACTIVITY,5.508e-06,0.38845,0.40732,1,1
1,REACTOME TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD3 SMAD4 HETEROTRIMER,9.0179e-06,0.38753,0.4336,1,1
1,REACTOME INTERFERON GAMMA SIGNALING,0.0032441,0.3852,0.42254,1,1
1,ANTI APOPTOSIS,2.5122e-07,0.38464,0.39228,1,1
1,PID WNT SIGNALING PATHWAY,0.00016595,0.38422,0.41077,1,1
1,LYSOSOME ORGANIZATION AND BIOGENESIS,0.001228,0.38253,0.33417,1,1
1,REACTOME SCFSKP2 MEDIATED DEGRADATION OF P27 P21,2.3418e-05,0.3824,0.32406,1,1
1,BIOCARTA CDC42RAC PATHWAY,4.8612e-06,0.38207,0.42119,1,1
1,REACTOME NFKB IS ACTIVATED AND SIGNALS SURVIVAL,0.0028141,0.38112,0.39947,1,1
1,KEGG AMINO SUGAR AND NUCLEOTIDE SUGAR METABOLISM,2.8418e-05,0.38109,0.30518,1,1
1,PID ARF6 PATHWAY,2.7578e-07,0.38016,0.46743,1,1
1,KEGG GALACTOSE METABOLISM,0.00032948,0.37913,0.28035,1,1
1,PID RAS PATHWAY,3.1904e-06,0.37487,0.4389,1,1
1,PID GLYPICAN 1PATHWAY,9.7801e-06,0.37168,0.39289,1,1
1,PID AURORA B PATHWAY,9.7346e-05,0.37153,0.37583,1,1
1,BIOCARTA CERAMIDE PATHWAY,0.0013054,0.37112,0.29126,1,1
1,REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION,1.5331e-06,0.37086,0.37358,1,1
1,GROWTH FACTOR ACTIVITY,7.0571e-06,0.36884,0.40084,1,1
1,REACTOME SIGNALING BY CONSTITUTIVELY ACTIVE EGFR,1.1493e-05,0.36594,0.36984,1,1
1,PROTEIN IMPORT,6.0198e-07,0.36524,0.32147,1,1
1,SIGNAL SEQUENCE BINDING,0.00011241,0.36418,0.2903,1,1
1,BIOCARTA WNT PATHWAY,0.00019079,0.36219,0.32209,1,1
1,BIOCARTA EPONFKB PATHWAY,0.018836,0.36127,0.28338,1,1
1,BIOCARTA IL6 PATHWAY,0.00019753,0.36097,0.43226,1,1
1,LIGAND DEPENDENT NUCLEAR RECEPTOR ACTIVITY,9.7801e-06,0.36061,0.41925,1,1
1,DRUG BINDING,2.8418e-05,0.36056,0.35259,1,1
1,BIOCARTA MCALPAIN PATHWAY,5.0683e-06,0.3602,0.47889,1,1
1,MYOBLAST DIFFERENTIATION,0.012508,0.36002,0.35832,1,1
1,VESICLE COAT,2.0833e-05,0.35944,0.31887,1,1
1,COENZYME METABOLIC PROCESS,0.0021062,0.35894,0.25632,1,1
1,NEGATIVE REGULATION OF APOPTOSIS,1.4044e-06,0.35838,0.34677,1,1
1,KEGG THYROID CANCER,3.8583e-05,0.35824,0.33959,1,1
1,REGULATION OF ACTIN POLYMERIZATION AND OR DEPOLYMERIZATION,0.00049035,0.35796,0.40231,1,1
1,KEGG SELENOAMINO ACID METABOLISM,7.013e-05,0.35781,0.29227,1,1
1,GOLGI MEMBRANE,7.2111e-07,0.35778,0.34351,1,1
1,PID IL12 STAT4PATHWAY,6.5149e-05,0.3573,0.33934,1,1
1,REGULATION OF ANGIOGENESIS,1.349e-05,0.35708,0.3821,1,1
1,INFLAMMATORY RESPONSE,0.00013917,0.35703,0.35301,1,1
1,BIOCARTA TGFB PATHWAY,0.014486,0.35652,0.3331,1,1
1,BIOCARTA TNFR1 PATHWAY,0.00017796,0.35539,0.30564,1,1
1,REACTOME RORA ACTIVATES CIRCADIAN EXPRESSION,0.00090094,0.3551,0.27754,1,1
1,PID RXR VDR PATHWAY,2.5774e-06,0.35428,0.39199,1,1
1,TRANSLATION,0.00032948,0.35375,0.2802,1,1
1,REACTOME TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX,2.7578e-07,0.3533,0.42057,1,1
1,COATED VESICLE MEMBRANE,2.2524e-05,0.35309,0.32057,1,1
1,REACTOME ORC1 REMOVAL FROM CHROMATIN,3.7145e-05,0.35304,0.28932,1,1
1,REACTOME SIGNALING BY TGF BETA RECEPTOR COMPLEX,2.2879e-07,0.35251,0.41703,1,1
1,REACTOME SHC1 EVENTS IN ERBB4 SIGNALING,7.3528e-06,0.35229,0.3546,1,1
1,REACTOME NUCLEAR SIGNALING BY ERBB4,3.8131e-07,0.35084,0.34141,1,1
1,KEGG PRIMARY IMMUNODEFICIENCY,0.00012074,0.35054,0.28488,1,1
1,REACTOME GLYCOSAMINOGLYCAN METABOLISM,1.2454e-05,0.35029,0.36316,1,1
1,NEGATIVE REGULATION OF PROGRAMMED CELL DEATH,1.7474e-06,0.35007,0.34963,1,1
1,KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION,5.0683e-06,0.34932,0.38413,1,1
1,PID SHP2 PATHWAY,3.7145e-05,0.34909,0.33493,1,1
1,REACTOME PLATELET ADHESION TO EXPOSED COLLAGEN,0.029068,0.34836,0.34278,1,1
1,REACTOME METABOLISM OF RNA,9.7346e-05,0.34817,0.28393,1,1
1,REACTOME COMMON PATHWAY,0.001872,0.34805,0.25792,1,1
1,REACTOME PYRIMIDINE METABOLISM,0.00012964,0.34786,0.46492,1,1
1,BIOCARTA ALK PATHWAY,4.0073e-05,0.34776,0.36516,1,1
1,SKELETAL DEVELOPMENT,2.0033e-05,0.34762,0.37713,1,1
1,REACTOME DOWNREGULATION OF SMAD2 3 SMAD4 TRANSCRIPTIONAL ACTIVITY,0.00013917,0.34752,0.32804,1,1
1,MITOCHONDRIAL MATRIX,0.0014299,0.34717,0.24499,1,1
1,MITOCHONDRIAL LUMEN,0.0014299,0.34717,0.24499,1,1
1,HETEROCYCLE METABOLIC PROCESS,1.4609e-05,0.34697,0.3682,1,1
1,ENDOSOME TRANSPORT,7.547e-05,0.346,0.31463,1,1
1,REACTOME REGULATION OF MITOTIC CELL CYCLE,2.5308e-05,0.34329,0.31545,1,1
1,BIOCARTA KERATINOCYTE PATHWAY,0.024846,0.34321,0.24057,1,1
1,SULFUR METABOLIC PROCESS,1.2454e-05,0.34284,0.34491,1,1
1,ER TO GOLGI VESICLE MEDIATED TRANSPORT,0.00016595,0.34258,0.29272,1,1
1,VACUOLE ORGANIZATION AND BIOGENESIS,0.0013872,0.34191,0.30096,1,1
1,PID INTEGRIN2 PATHWAY,6.2367e-06,0.34154,0.50485,1,1
1,PROTEOGLYCAN BIOSYNTHETIC PROCESS,0.00042998,0.34042,0.32523,1,1
1,BIOCARTA TFF PATHWAY,3.6228e-06,0.33815,0.39581,1,1
1,PID ALK1PATHWAY,9.389e-05,0.3379,0.38648,1,1
1,REACTOME M G1 TRANSITION,0.00057693,0.3367,0.22954,1,1
1,REGULATION OF MITOTIC CELL CYCLE,2.0829e-07,0.33642,0.39544,1,1
1,REGULATION OF SIGNAL TRANSDUCTION,1.2862e-06,0.33625,0.34345,1,1
1,POSITIVE REGULATION OF TRANSLATION,2.0784e-06,0.33579,0.41581,1,1
1,KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY,6.7596e-05,0.33533,0.39915,1,1
1,KEGG HYPERTROPHIC CARDIOMYOPATHY HCM,5.7413e-06,0.33279,0.35632,1,1
1,RESPONSE TO WOUNDING,1.0604e-05,0.33204,0.35157,1,1
1,RECEPTOR COMPLEX,0.00019753,0.33178,0.31581,1,1
1,PID FOXM1PATHWAY,1.2454e-05,0.33123,0.35241,1,1
1,REACTOME ANTIVIRAL MECHANISM BY IFN STIMULATED GENES,3.0576e-06,0.33105,0.30406,1,1
1,CORNIFIED ENVELOPE,0.011326,0.33089,0.29528,1,1
1,POSITIVE REGULATION OF CELL ADHESION,0.0013872,0.33082,0.56428,1,1
1,GROWTH,1.4674e-06,0.32988,0.32773,1,1
1,BIOCARTA INTEGRIN PATHWAY,4.5813e-07,0.32957,0.48432,1,1
1,VIRAL REPRODUCTION,1.1493e-05,0.32952,0.30885,1,1
1,BIOCARTA RARRXR PATHWAY,0.00017796,0.32916,0.26036,1,1
1,TRNA PROCESSING,0.0006154,0.32909,0.32791,1,1
1,BIOCARTA EIF4 PATHWAY,2.6307e-05,0.32828,0.31335,1,1
1,BIOCARTA RANMS PATHWAY,0.0025083,0.32793,0.29241,1,1
1,NEGATIVE REGULATION OF TRANSPORT,0.00017186,0.32752,0.29726,1,1
1,BIOCARTA HER2 PATHWAY,9.0551e-05,0.32698,0.26462,1,1
1,VASCULATURE DEVELOPMENT,1.349e-05,0.32683,0.34605,1,1
1,KEGG JAK STAT SIGNALING PATHWAY,1.5201e-05,0.32648,0.30898,1,1
1,TRANSLATION REGULATOR ACTIVITY,0.0013872,0.32576,0.23782,1,1
1,INTERACTION WITH HOST,7.2754e-05,0.32558,0.34528,1,1
1,MANNOSYLTRANSFERASE ACTIVITY,0.0087944,0.32547,0.22146,1,1
1,BIOCARTA EGF PATHWAY,0.0020453,0.32522,0.27519,1,1
1,CYTOKINESIS,0.00055855,0.32473,0.31138,1,1
1,CELL DIVISION,0.00057693,0.32459,0.34596,1,1
1,REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION,2.1831e-07,0.32288,0.32828,1,1
1,REACTOME EGFR DOWNREGULATION,2.6902e-06,0.32239,0.366,1,1
1,REACTOME IKK COMPLEX RECRUITMENT MEDIATED BY RIP1,0.00079435,0.32201,0.38757,1,1
1,POSITIVE REGULATION OF MAP KINASE ACTIVITY,4.4878e-05,0.32196,0.25985,1,1
1,REACTOME LIPID DIGESTION MOBILIZATION AND TRANSPORT,3.9418e-06,0.32092,0.3657,1,1
1,ACETYLGALACTOSAMINYLTRANSFERASE ACTIVITY,0.024846,0.3204,0.23956,1,1
1,PID ANGIOPOIETINRECEPTOR PATHWAY,2.3418e-05,0.31991,0.33932,1,1
1,BIOCARTA MTOR PATHWAY,3.4421e-05,0.31851,0.27577,1,1
1,CONTRACTILE FIBER,1.4044e-06,0.31827,0.38148,1,1
1,MYOFIBRIL,6.7728e-06,0.31786,0.45486,1,1
1,REACTOME KERATAN SULFATE KERATIN METABOLISM,3.7145e-05,0.31697,0.34823,1,1
1,KEGG BASAL CELL CARCINOMA,0.0057817,0.31674,0.20971,1,1
1,KEGG FATTY ACID METABOLISM,0.0049174,0.31584,0.25238,1,1
1,REGULATION OF ENDOCYTOSIS,0.00010462,0.31579,0.30756,1,1
1,POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,4.8379e-05,0.31542,0.29934,1,1
1,STRIATED MUSCLE DEVELOPMENT,0.0032441,0.31539,0.24148,1,1
1,METALLOENDOPEPTIDASE ACTIVITY,0.0012662,0.3152,0.30469,1,1
1,BIOCARTA AKAP95 PATHWAY,0.007729,0.31505,0.23717,1,1
1,MUSCLE DEVELOPMENT,1.7118e-05,0.31485,0.29975,1,1
1,VIRAL INFECTIOUS CYCLE,7.547e-05,0.31476,0.28148,1,1
1,REACTOME SIGNALING BY BMP,0.014486,0.31432,0.25968,1,1
1,BIOCARTA AGR PATHWAY,0.004408,0.31405,0.22512,1,1
1,N TERMINAL PROTEIN AMINO ACID MODIFICATION,0.00079435,0.31319,0.24571,1,1
1,PID TELOMERASEPATHWAY,2.1663e-05,0.31297,0.27901,1,1
1,REACTOME BIOSYNTHESIS OF THE N GLYCAN PRECURSOR DOLICHOL LIPID LINKED OLIGOSACCHARIDE LLO AND TRANSFER TO A NASCENT PROTEIN,0.00045924,0.31213,0.27139,1,1
1,KEGG P53 SIGNALING PATHWAY,0.0018173,0.31177,0.26125,1,1
1,AMINO SUGAR METABOLIC PROCESS,2.6307e-05,0.31168,0.30725,1,1
1,ADHERENS JUNCTION,0.019739,0.31159,0.25966,1,1
1,KEGG INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION,0.00090094,0.31053,0.23993,1,1
1,PID VEGFR1 2 PATHWAY,8.6584e-06,0.31044,0.30102,1,1
1,KEGG ADHERENS JUNCTION,5.6174e-05,0.3103,0.2561,1,1
1,STRUCTURAL MOLECULE ACTIVITY,1.0604e-05,0.30966,0.32145,1,1
1,REGULATION OF ACTIN FILAMENT LENGTH,0.0032441,0.30912,0.32673,1,1
1,KEGG RIG I LIKE RECEPTOR SIGNALING PATHWAY,9.3916e-06,0.30854,0.31799,1,1
1,POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,2.9532e-05,0.30832,0.27357,1,1
1,REACTOME CYTOSOLIC TRNA AMINOACYLATION,0.0069616,0.30799,0.28724,1,1
1,NEGATIVE REGULATION OF DNA REPLICATION,0.023205,0.30757,0.26794,1,1
1,PID AR PATHWAY,9.0179e-06,0.30753,0.27808,1,1
1,BIOCARTA LONGEVITY PATHWAY,0.00055855,0.30657,0.25643,1,1
1,BIOCARTA VEGF PATHWAY,4.8379e-05,0.30626,0.27409,1,1
1,PID CD40 PATHWAY,0.00084609,0.30605,0.3552,1,1
1,REACTOME GLYCOGEN BREAKDOWN GLYCOGENOLYSIS,0.00054072,0.30539,0.28748,1,1
1,KEGG REGULATION OF ACTIN CYTOSKELETON,5.6999e-08,0.30507,0.32605,1,1
1,REGULATION OF CELLULAR COMPONENT SIZE,0.0025817,0.30503,0.32045,1,1
1,BIOCARTA AKAP13 PATHWAY,0.0017123,0.30444,0.28164,1,1
1,POSITIVE REGULATION OF CELL PROLIFERATION,1.1237e-07,0.30432,0.41585,1,1
1,KEGG NATURAL KILLER CELL MEDIATED CYTOTOXICITY,0.00014935,0.30431,0.24174,1,1
1,REACTOME PPARA ACTIVATES GENE EXPRESSION,1.4039e-05,0.30398,0.27476,1,1
1,REACTOME CELL SURFACE INTERACTIONS AT THE VASCULAR WALL,8.1192e-05,0.30306,0.27062,1,1
1,GLUCOSAMINE METABOLIC PROCESS,4.1802e-07,0.30293,0.33754,1,1
1,UNFOLDED PROTEIN BINDING,9.0551e-05,0.30283,0.25851,1,1
1,PID MYC PATHWAY,0.00069957,0.30262,0.22864,1,1
1,PID NECTIN PATHWAY,0.0025083,0.30204,0.29698,1,1
1,BIOCARTA ERK PATHWAY,1.1267e-06,0.3016,0.36182,1,1
1,NEGATIVE REGULATION OF CELL ADHESION,0.0011199,0.30137,0.3504,1,1
1,KEGG PANCREATIC CANCER,6.2367e-06,0.30082,0.3026,1,1
1,TRANSLATIONAL INITIATION,0.0018173,0.30081,0.20856,1,1
1,BIOCARTA ACTINY PATHWAY,3.4421e-05,0.30049,0.28339,1,1
1,PID CERAMIDE PATHWAY,3.8583e-05,0.30039,0.26191,1,1
1,PROTEIN FOLDING,5.0683e-06,0.29976,0.32384,1,1
1,REACTOME SULFUR AMINO ACID METABOLISM,3.1888e-05,0.29971,0.34415,1,1
1,KEGG PATHWAYS IN CANCER,1.104e-05,0.29813,0.25428,1,1
1,BIOCARTA STRESS PATHWAY,0.0059384,0.29797,0.24219,1,1
1,TRNA METABOLIC PROCESS,0.0021689,0.29793,0.26781,1,1
1,REACTOME NUCLEOTIDE LIKE PURINERGIC RECEPTORS,0.001986,0.29781,0.26447,1,1
1,PID P73PATHWAY,2.0833e-05,0.2978,0.3046,1,1
1,NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS,1.7474e-06,0.29777,0.30179,1,1
1,REGULATION OF CELL ADHESION,0.0014299,0.29737,0.34469,1,1
1,TRANSLATION INITIATION FACTOR ACTIVITY,0.00081984,0.297,0.2994,1,1
1,REGULATION OF DNA METABOLIC PROCESS,0.00017186,0.29677,0.27971,1,1
1,PID IL1PATHWAY,0.00052342,0.29654,0.30557,1,1
1,REACTOME DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BCR,9.3916e-06,0.29625,0.24968,1,1
1,KEGG DILATED CARDIOMYOPATHY,2.3418e-05,0.29565,0.29563,1,1
1,BIOCARTA VDR PATHWAY,0.00050664,0.29557,0.28413,1,1
1,PROTEOLYSIS,1.1964e-05,0.29481,0.23924,1,1
1,NEGATIVE REGULATION OF GROWTH,2.0033e-05,0.29354,0.26996,1,1
1,PROTEIN MATURATION,0.00084609,0.29336,0.29285,1,1
1,PID MYC ACTIVPATHWAY,0.0017123,0.29329,0.24854,1,1
1,REACTOME SPHINGOLIPID METABOLISM,0.0010206,0.29327,0.20197,1,1
1,CELLULAR BIOSYNTHETIC PROCESS,5.4121e-05,0.29194,0.24653,1,1
1,POSITIVE REGULATION OF CELLULAR PROCESS,1.5331e-06,0.29067,0.25633,1,1
1,POSITIVE REGULATION OF TRANSFERASE ACTIVITY,4.1617e-05,0.29038,0.21211,1,1
1,REACTOME REGULATED PROTEOLYSIS OF P75NTR,0.001662,0.29038,0.25263,1,1
1,KEGG CYTOSOLIC DNA SENSING PATHWAY,0.00041602,0.29034,0.30899,1,1
1,REACTOME ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION,0.00028792,0.29012,0.25303,1,1
1,REACTOME MITOCHONDRIAL TRNA AMINOACYLATION,0.041967,0.2895,0.15713,1,1
1,REACTOME NRIF SIGNALS CELL DEATH FROM THE NUCLEUS,0.0079323,0.2892,0.20076,1,1
1,NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT,0.007729,0.28774,0.2745,1,1
1,REACTOME CIRCADIAN REPRESSION OF EXPRESSION BY REV ERBA,0.0038387,0.28711,0.22515,1,1
1,REACTOME INNATE IMMUNE SYSTEM,0.00019079,0.28696,0.24277,1,1
1,PID PTP1BPATHWAY,0.00034072,0.28695,0.27912,1,1
1,POSITIVE REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS,2.6902e-06,0.28664,0.3815,1,1
1,RHO PROTEIN SIGNAL TRANSDUCTION,3.6228e-06,0.28636,0.28573,1,1
1,ST INTERLEUKIN 4 PATHWAY,0.00026003,0.2863,0.3306,1,1
1,CYTOKINE ACTIVITY,4.8379e-05,0.28592,0.33101,1,1
1,BIOCARTA P38MAPK PATHWAY,5.0683e-06,0.2859,0.32118,1,1
1,REACTOME IMMUNE SYSTEM,5.2837e-06,0.28523,0.24799,1,1
1,NEGATIVE REGULATION OF CELL MIGRATION,0.00031859,0.28482,0.42499,1,1
1,REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION,6.0504e-05,0.28443,0.25019,1,1
1,REACTOME GAP JUNCTION TRAFFICKING,5.9841e-06,0.28435,0.27037,1,1
1,REACTOME RNA POL I TRANSCRIPTION TERMINATION,0.00095906,0.2837,0.20262,1,1
1,REGULATION OF GROWTH,1.5816e-05,0.28361,0.28177,1,1
1,PID SMAD2 3NUCLEARPATHWAY,0.00098941,0.28346,0.24196,1,1
1,KEGG TGF BETA SIGNALING PATHWAY,0.00012512,0.28274,0.25677,1,1
1,CELL PROJECTION BIOGENESIS,0.001662,0.28245,0.20222,1,1
1,ANGIOGENESIS,0.00017186,0.28225,0.30974,1,1
1,REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS,4.7955e-07,0.2819,0.31868,1,1
1,PEPTIDYL AMINO ACID MODIFICATION,8.628e-07,0.28145,0.28853,1,1
1,TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY,0.0062634,0.2812,0.22508,1,1
1,ELECTRON TRANSPORT GO 0006118,0.00017186,0.28113,0.2566,1,1
1,REACTOME HOST INTERACTIONS OF HIV FACTORS,3.3132e-05,0.28078,0.23354,1,1
1,REACTOME UNFOLDED PROTEIN RESPONSE,2.0833e-05,0.28047,0.2711,1,1
1,ST STAT3 PATHWAY,0.00049035,0.27983,0.36434,1,1
1,REACTOME APOPTOSIS,5.2139e-05,0.2797,0.22673,1,1
1,REGULATION OF PROTEIN METABOLIC PROCESS,8.628e-07,0.27969,0.29505,1,1
1,N ACETYLGLUCOSAMINE METABOLIC PROCESS,8.2505e-07,0.2791,0.30107,1,1
1,STEROID HORMONE RECEPTOR BINDING,0.00057693,0.2777,0.29398,1,1
1,KEGG PYRUVATE METABOLISM,0.0040578,0.27761,0.22877,1,1
1,REACTOME FGFR LIGAND BINDING AND ACTIVATION,0.0020453,0.27756,0.20924,1,1
1,BLOOD COAGULATION,2.9532e-05,0.27698,0.33817,1,1
1,KEGG RETINOL METABOLISM,0.0007696,0.27675,0.21964,1,1
1,RAS PROTEIN SIGNAL TRANSDUCTION,2.3975e-07,0.27638,0.30294,1,1
1,CALCIUM MEDIATED SIGNALING,8.1192e-05,0.27595,0.36126,1,1
1,BIOCARTA HSP27 PATHWAY,0.00042998,0.27571,0.31762,1,1
1,PID RETINOIC ACID PATHWAY,0.00019753,0.27553,0.25033,1,1
1,PROTEIN TARGETING,3.4772e-07,0.27532,0.26446,1,1
1,PID IFNGPATHWAY,0.0027346,0.27527,0.23478,1,1
1,TRANSLATION FACTOR ACTIVITY NUCLEIC ACID BINDING,0.0042883,0.27421,0.20813,1,1
1,L AMINO ACID TRANSMEMBRANE TRANSPORTER ACTIVITY,0.0060989,0.27361,0.20199,1,1
1,BIOCARTA CHEMICAL PATHWAY,0.00059588,0.27304,0.24742,1,1
1,GOLGI VESICLE TRANSPORT,0.00055855,0.27218,0.22832,1,1
1,REACTOME NOD1 2 SIGNALING PATHWAY,0.0016129,0.27177,0.35153,1,1
1,REACTOME BASIGIN INTERACTIONS,0.0011199,0.27152,0.41534,1,1
1,REACTOME PROTEIN FOLDING,1.4039e-05,0.27043,0.25248,1,1
1,DEFENSE RESPONSE,0.00055855,0.27042,0.25955,1,1
1,KEGG PROSTATE CANCER,1.9263e-05,0.27035,0.27207,1,1
1,REGULATION OF MITOSIS,4.0073e-05,0.27014,0.24053,1,1
1,REACTOME METABOLISM OF PROTEINS,0.00055855,0.27006,0.19339,1,1
1,EPIDERMIS DEVELOPMENT,0.00026903,0.26922,0.37268,1,1
1,BIOCARTA G1 PATHWAY,0.0083534,0.26903,0.24586,1,1
1,KEGG LEUKOCYTE TRANSENDOTHELIAL MIGRATION,5.8301e-05,0.26839,0.25102,1,1
1,REACTOME XENOBIOTICS,0.036948,0.26825,0.13991,1,1
1,REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY,0.001872,0.26798,0.34192,1,1
1,POSITIVE REGULATION OF BIOLOGICAL PROCESS,1.9904e-06,0.26768,0.24545,1,1
1,BIOCARTA NKT PATHWAY,0.010773,0.26753,0.24917,1,1
1,REGULATION OF APOPTOSIS,4.1112e-06,0.2674,0.25183,1,1
1,REGULATION OF PROGRAMMED CELL DEATH,4.6623e-06,0.26721,0.2534,1,1
1,REACTOME INTRINSIC PATHWAY,0.0018173,0.26705,0.22023,1,1
1,LIGASE ACTIVITY FORMING CARBON NITROGEN BONDS,2.2658e-06,0.26615,0.20977,1,1
1,NUCLEAR TRANSPORT,5.6174e-05,0.26551,0.23068,1,1
1,REGULATION OF TRANSLATIONAL INITIATION,0.0025083,0.26428,0.22104,1,1
1,NEGATIVE REGULATION OF TRANSCRIPTION FACTOR ACTIVITY,0.010773,0.264,0.2594,1,1
1,REACTOME S PHASE,0.00063551,0.26398,0.1975,1,1
1,BIOCARTA CYTOKINE PATHWAY,0.00052342,0.2632,0.36174,1,1
1,INTEGRIN BINDING,0.00049035,0.26296,0.30643,1,1
1,NUCLEOCYTOPLASMIC TRANSPORT,5.8301e-05,0.26239,0.23409,1,1
1,PID PS1PATHWAY,1.5201e-05,0.26238,0.26488,1,1
1,ZINC ION BINDING,1.6455e-05,0.26203,0.21259,1,1
1,B CELL ACTIVATION,0.014138,0.26156,0.21521,1,1
1,POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS,4.1112e-06,0.25996,0.36306,1,1
1,BIOCARTA EDG1 PATHWAY,3.3132e-05,0.25984,0.29283,1,1
1,PROTEIN KINASE CASCADE,1.9263e-05,0.25889,0.25639,1,1
1,ACTIN POLYMERIZATION AND OR DEPOLYMERIZATION,0.0062634,0.2586,0.2048,1,1
1,RESPONSE TO HEAT,0.0054795,0.25843,0.19701,1,1
1,KEGG LEISHMANIA INFECTION,0.00024286,0.25821,0.28422,1,1
1,BIOCARTA EIF2 PATHWAY,0.0041716,0.2573,0.23309,1,1
1,PID S1P S1P1 PATHWAY,0.00069957,0.25713,0.3636,1,1
1,METALLOPEPTIDASE ACTIVITY,6.5149e-05,0.25614,0.32468,1,1
1,SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES,0.00016023,0.25577,0.30011,1,1
1,NEGATIVE REGULATION OF TRANSFERASE ACTIVITY,0.00084609,0.25561,0.20335,1,1
1,ST B CELL ANTIGEN RECEPTOR,2.5774e-06,0.25453,0.26421,1,1
1,REACTOME DESTABILIZATION OF MRNA BY BRF1,0.00012964,0.25452,0.261,1,1
1,KEGG TOLL LIKE RECEPTOR SIGNALING PATHWAY,0.00029782,0.25403,0.2253,1,1
1,SECONDARY METABOLIC PROCESS,0.00063551,0.25365,0.23454,1,1
1,ACID AMINO ACID LIGASE ACTIVITY,6.4994e-06,0.25354,0.2204,1,1
1,KEGG CIRCADIAN RHYTHM MAMMAL,0.010506,0.25219,0.28223,1,1
1,EXTRACELLULAR REGION PART,0.00012964,0.25185,0.28504,1,1
1,PROTEIN COMPLEX BINDING,0.00034072,0.25139,0.19913,1,1
1,OXIDOREDUCTASE ACTIVITY,0.00014935,0.25061,0.21501,1,1
1,CHAPERONE BINDING,0.00098941,0.25049,0.23726,1,1
1,NEGATIVE REGULATION OF SIGNAL TRANSDUCTION,2.3418e-05,0.25046,0.24811,1,1
1,REACTOME IL 7 SIGNALING,0.0023671,0.25021,0.27696,1,1
1,RIBOSOMAL SUBUNIT,0.025414,0.24994,0.18978,1,1
1,MITOTIC CELL CYCLE CHECKPOINT,5.0226e-05,0.24988,0.27134,1,1
1,REACTOME SHC MEDIATED CASCADE,0.00032948,0.24966,0.22546,1,1
1,REACTOME METABOLISM OF NUCLEOTIDES,0.00038934,0.24965,0.28868,1,1
1,MITOCHONDRIAL PART,0.0045306,0.24961,0.18364,1,1
1,COAGULATION,7.013e-05,0.24953,0.31485,1,1
1,KEGG AMINOACYL TRNA BIOSYNTHESIS,0.0094949,0.24934,0.2061,1,1
1,PID WNT CANONICAL PATHWAY,4.3218e-05,0.24884,0.23038,1,1
1,REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS,0.020205,0.24882,0.22273,1,1
1,REGULATION OF TRANSLATION,8.3127e-06,0.2485,0.257,1,1
1,CYTOPLASMIC VESICLE MEMBRANE,0.00045924,0.24821,0.17932,1,1
1,CYTOPLASMIC VESICLE PART,0.00045924,0.24821,0.17932,1,1
1,BIOCARTA HIF PATHWAY,0.00040247,0.24762,0.37114,1,1
1,CYCLIC NUCLEOTIDE METABOLIC PROCESS,0.021165,0.2475,0.29833,1,1
1,NEGATIVE REGULATION OF CELL CYCLE,7.3528e-06,0.24701,0.27536,1,1
1,KEGG ENDOCYTOSIS,2.1702e-06,0.24672,0.23697,1,1
1,PID ERBB4 PATHWAY,1.4044e-06,0.24565,0.2988,1,1
1,REACTOME ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION,3.1904e-06,0.24477,0.20798,1,1
1,KEGG HOMOLOGOUS RECOMBINATION,0.0021062,0.24438,0.19527,1,1
1,APOPTOSIS GO,4.8612e-06,0.24435,0.22841,1,1
1,DOUBLE STRANDED RNA BINDING,0.0054795,0.24398,0.17527,1,1
1,PID AMB2 NEUTROPHILS PATHWAY,0.00030804,0.24391,0.30399,1,1
1,PID IL12 2PATHWAY,0.00016023,0.24349,0.27967,1,1
1,BIOCARTA THELPER PATHWAY,0.033166,0.24325,0.28907,1,1
1,PROGRAMMED CELL DEATH,4.6623e-06,0.24301,0.22971,1,1
1,MEMBRANE FUSION,0.00030804,0.24207,0.23404,1,1
1,REACTOME ADAPTIVE IMMUNE SYSTEM,1.4044e-06,0.24152,0.21442,1,1
1,PID ECADHERIN KERATINOCYTE PATHWAY,0.020205,0.24056,0.2416,1,1
1,CELL MATRIX ADHESION,0.00044439,0.2405,0.28083,1,1
1,REGULATION OF DNA BINDING,1.5691e-07,0.24037,0.27511,1,1
1,REACTOME ENOS ACTIVATION AND REGULATION,0.017549,0.23954,0.16224,1,1
1,NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS,0.00018427,0.23939,0.26228,1,1
1,REACTOME FORMATION OF INCISION COMPLEX IN GG NER,3.3132e-05,0.2388,0.25153,1,1
1,TRANSITION METAL ION BINDING,1.5331e-06,0.23879,0.2391,1,1
1,MITOCHONDRIAL MEMBRANE,0.014841,0.23875,0.13711,1,1
1,CELL PROLIFERATION GO 0008283,2.2658e-06,0.23872,0.22243,1,1
1,ENDOSOME,4.6597e-05,0.23765,0.20968,1,1
1,PID ARF6 TRAFFICKINGPATHWAY,5.0683e-06,0.23763,0.33145,1,1
1,BIOCARTA TALL1 PATHWAY,0.00072223,0.23761,0.18159,1,1
1,BIOCARTA BCELLSURVIVAL PATHWAY,0.00038934,0.23749,0.32443,1,1
1,REACTOME MITOTIC M M G1 PHASES,0.00065623,0.23731,0.18348,1,1
1,PID ERBB1 DOWNSTREAM PATHWAY,0.00019753,0.23692,0.19678,1,1
1,REACTOME KERATAN SULFATE BIOSYNTHESIS,0.0041716,0.23666,0.23959,1,1
1,CELL SURFACE,7.013e-05,0.2361,0.2352,1,1
1,ST ERK1 ERK2 MAPK PATHWAY,2.6307e-05,0.23589,0.25884,1,1
1,WNT SIGNALING,2.9532e-05,0.23584,0.20772,1,1
1,REACTOME SYNTHESIS OF DNA,0.0011199,0.23556,0.18081,1,1
1,VACUOLAR TRANSPORT,0.00044439,0.23541,0.24942,1,1
1,REACTOME TRNA AMINOACYLATION,0.012508,0.23435,0.21114,1,1
1,REGULATION OF BINDING,1.9873e-07,0.2341,0.25937,1,1
1,RESPONSE TO HORMONE STIMULUS,0.00040247,0.23381,0.22371,1,1
1,REACTOME IL1 SIGNALING,0.00020448,0.23324,0.2751,1,1
1,ELECTRON CARRIER ACTIVITY,0.0015653,0.233,0.15818,1,1
1,PID SMAD2 3PATHWAY,0.023741,0.23295,0.17126,1,1
1,REACTOME SIGNALING BY PDGF,9.7346e-05,0.23239,0.21449,1,1
1,NEGATIVE REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS,0.00028792,0.23232,0.2716,1,1
1,GOLGI STACK,0.0067808,0.23174,0.20155,1,1
1,CELL SUBSTRATE ADHESION,0.00050664,0.2313,0.27021,1,1
1,INTRACELLULAR PROTEIN TRANSPORT,1.5331e-06,0.2313,0.22112,1,1
1,BIOCARTA IGF1MTOR PATHWAY,0.00084609,0.23081,0.20084,1,1
1,VACUOLE,0.0012662,0.23076,0.19138,1,1
1,KEGG ONE CARBON POOL BY FOLATE,0.011612,0.23035,0.17257,1,1
1,KEGG DORSO VENTRAL AXIS FORMATION,0.0017123,0.22947,0.25055,1,1
1,REACTOME TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE DIFFERENTIATION,0.00036427,0.22919,0.17076,1,1
1,REACTOME G1 S TRANSITION,0.00026003,0.22911,0.19987,1,1
1,CYTOKINE AND CHEMOKINE MEDIATED SIGNALING PATHWAY,0.0034322,0.22891,0.26602,1,1
1,KEGG DRUG METABOLISM OTHER ENZYMES,0.00025131,0.22865,0.25829,1,1
1,POSITIVE REGULATION OF DEVELOPMENTAL PROCESS,0.001228,0.22777,0.16918,1,1
1,RESPONSE TO EXTERNAL STIMULUS,0.00023468,0.22776,0.23427,1,1
1,REGULATION OF DEVELOPMENTAL PROCESS,1.2454e-05,0.22752,0.21225,1,1
1,RECEPTOR MEDIATED ENDOCYTOSIS,2.4346e-05,0.22732,0.21142,1,1
1,STRUCTURAL CONSTITUENT OF MUSCLE,9.7346e-05,0.22726,0.28639,1,1
1,TRANSFERASE ACTIVITY TRANSFERRING PENTOSYL GROUPS,0.009256,0.22707,0.19867,1,1
1,OXIDOREDUCTASE ACTIVITY ACTING ON NADH OR NADPH,0.0081404,0.22696,0.14664,1,1
1,NEGATIVE REGULATION OF DNA BINDING,0.010506,0.22656,0.21624,1,1
1,SMALL PROTEIN CONJUGATING ENZYME ACTIVITY,1.4609e-05,0.22595,0.19957,1,1
1,PID IL4 2PATHWAY,0.0060989,0.22528,0.22672,1,1
1,ESTABLISHMENT OF PROTEIN LOCALIZATION,3.0576e-06,0.22441,0.18999,1,1
1,REACTOME SIGNALING BY THE B CELL RECEPTOR BCR,4.3218e-05,0.22361,0.20562,1,1
1,SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION,3.7791e-06,0.22358,0.2122,1,1
1,CELLULAR PROTEIN COMPLEX ASSEMBLY,1.5331e-06,0.22267,0.2355,1,1
1,ATP DEPENDENT DNA HELICASE ACTIVITY,0.0056288,0.2224,0.22756,1,1
1,UBIQUITIN PROTEIN LIGASE ACTIVITY,3.9418e-06,0.22201,0.20609,1,1
1,REACTOME NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION,0.0040578,0.2217,0.18297,1,1
1,REGULATION OF CELL PROLIFERATION,3.7791e-06,0.22104,0.23794,1,1
1,NEGATIVE REGULATION OF BIOLOGICAL PROCESS,6.4994e-06,0.22064,0.19874,1,1
1,ORGANELLAR RIBOSOME,0.011904,0.22059,0.21729,1,1
1,MITOCHONDRIAL RIBOSOME,0.011904,0.22059,0.21729,1,1
1,KEGG ASCORBATE AND ALDARATE METABOLISM,0.034637,0.22039,0.18073,1,1
1,BIOCARTA ECM PATHWAY,0.00038934,0.22038,0.34639,1,1
1,NEGATIVE REGULATION OF BINDING,0.00081984,0.21937,0.24686,1,1
1,REACTOME REGULATION OF IFNG SIGNALING,0.026586,0.21932,0.22062,1,1
1,POSITIVE REGULATION OF CELLULAR METABOLIC PROCESS,3.17e-07,0.21932,0.22988,1,1
1,ATP DEPENDENT HELICASE ACTIVITY,0.012203,0.21882,0.17216,1,1
1,REACTOME DIABETES PATHWAYS,0.027803,0.21857,0.13629,1,1
1,NEGATIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,0.019283,0.21815,0.26064,1,1
1,PID NCADHERINPATHWAY,0.017549,0.21779,0.18245,1,1
1,BIOCARTA SARS PATHWAY,0.0075304,0.21764,0.40721,1,1
1,BIOCARTA GRANULOCYTES PATHWAY,0.00052342,0.21735,0.47344,1,1
1,PROTEIN COMPLEX ASSEMBLY,3.9418e-06,0.21716,0.20405,1,1
1,ST INTEGRIN SIGNALING PATHWAY,0.00072223,0.21702,0.22837,1,1
1,PID NFAT TFPATHWAY,2.9532e-05,0.21698,0.31322,1,1
1,POSITIVE REGULATION OF LYMPHOCYTE ACTIVATION,0.0022992,0.21678,0.27464,1,1
1,SMAD BINDING,0.0053338,0.21642,0.17836,1,1
1,NEGATIVE REGULATION OF CELLULAR PROCESS,1.104e-05,0.21641,0.19297,1,1
1,SMALL CONJUGATING PROTEIN LIGASE ACTIVITY,4.6623e-06,0.21573,0.20174,1,1
1,KEGG ADIPOCYTOKINE SIGNALING PATHWAY,0.00042998,0.21539,0.16898,1,1
1,KEGG PEROXISOME,0.0060989,0.21529,0.15431,1,1
1,PIGMENT BIOSYNTHETIC PROCESS,0.001191,0.21466,0.24283,1,1
1,RESPONSE TO STRESS,7.547e-05,0.21446,0.1795,1,1
1,KEGG NICOTINATE AND NICOTINAMIDE METABOLISM,0.026586,0.21419,0.21673,1,1
1,PROTEIN TRANSPORT,2.3654e-06,0.21391,0.20403,1,1
1,KEGG GLYCOLYSIS GLUCONEOGENESIS,0.0029794,0.21382,0.22573,1,1
1,REACTOME PLATELET ACTIVATION SIGNALING AND AGGREGATION,1.1493e-05,0.21371,0.26433,1,1
1,PID PDGFRBPATHWAY,8.4205e-05,0.21351,0.21997,1,1
1,REACTOME CIRCADIAN CLOCK,5.6174e-05,0.21339,0.26091,1,1
1,MITOCHONDRIAL OUTER MEMBRANE,0.0032441,0.21321,0.14429,1,1
1,ST P38 MAPK PATHWAY,0.0039469,0.2129,0.15913,1,1
1,ST FAS SIGNALING PATHWAY,1.8521e-05,0.21287,0.22244,1,1
1,POSITIVE REGULATION OF METABOLIC PROCESS,4.3763e-07,0.2119,0.22256,1,1
1,MAINTENANCE OF PROTEIN LOCALIZATION,0.0015653,0.21186,0.2463,1,1
1,BIOCARTA MET PATHWAY,0.00026903,0.21165,0.27457,1,1
1,REACTOME BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN EXPRESSION,0.0019282,0.21159,0.24911,1,1
1,VESICLE MEMBRANE,0.00049035,0.21156,0.17939,1,1
1,REACTOME METABOLISM OF CARBOHYDRATES,1.2308e-06,0.21148,0.24006,1,1
1,REACTOME MEMBRANE TRAFFICKING,0.00014935,0.21135,0.18665,1,1
1,REACTOME DOWNSTREAM TCR SIGNALING,0.010773,0.21113,0.13893,1,1
1,REGULATION OF CELL CYCLE,2.2524e-05,0.21105,0.18346,1,1
1,PROTEIN SECRETION,0.024288,0.21099,0.18811,1,1
1,ENDOPLASMIC RETICULUM,1.8521e-05,0.21095,0.21203,1,1
1,BIOCARTA RACCYCD PATHWAY,0.00092958,0.2109,0.242,1,1
1,POSITIVE REGULATION OF JNK ACTIVITY,0.0085714,0.21078,0.17387,1,1
1,NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS,0.0069616,0.21075,0.23471,1,1
1,BIOCARTA PTDINS PATHWAY,0.00074557,0.21048,0.21139,1,1
1,ECTODERM DEVELOPMENT,0.0016129,0.20977,0.30399,1,1
1,EXTRACELLULAR REGION,0.00030804,0.2091,0.23328,1,1
1,SEQUENCE SPECIFIC DNA BINDING,0.00079435,0.20901,0.18734,1,1
1,IMMUNE RESPONSE,0.0010528,0.20898,0.21578,1,1
1,PID VEGFR1 PATHWAY,0.014841,0.20893,0.1751,1,1
1,REACTOME CELL CYCLE CHECKPOINTS,0.00026903,0.20861,0.18759,1,1
1,KEGG CYSTEINE AND METHIONINE METABOLISM,0.00052342,0.20854,0.20553,1,1
1,WOUND HEALING,1.5201e-05,0.20843,0.33457,1,1
1,REACTOME RNA POL I TRANSCRIPTION INITIATION,0.0023671,0.20835,0.1589,1,1
1,CARBOHYDRATE BIOSYNTHETIC PROCESS,0.0053338,0.20787,0.15703,1,1
1,REACTOME HOMOLOGOUS RECOMBINATION REPAIR OF REPLICATION INDEPENDENT DOUBLE STRAND BREAKS,0.041093,0.20779,0.14668,1,1
1,PID RHOA PATHWAY,1.5201e-05,0.20762,0.25769,1,1
1,ORGAN MORPHOGENESIS,0.00029782,0.20761,0.20444,1,1
1,DOUBLE STRAND BREAK REPAIR,0.0021062,0.20722,0.23175,1,1
1,PATTERN BINDING,0.026586,0.20678,0.15384,1,1
1,ST MYOCYTE AD PATHWAY,0.0010859,0.20541,0.25849,1,1
1,MITOCHONDRIAL ENVELOPE,0.011326,0.205,0.14923,1,1
1,GROWTH FACTOR BINDING,2.9532e-05,0.20494,0.25871,1,1
1,KEGG TIGHT JUNCTION,0.015953,0.20414,0.11464,1,1
1,REACTOME NEGATIVE REGULATION OF FGFR SIGNALING,0.00025131,0.20307,0.18518,1,1
1,SPINDLE POLE,0.0046564,0.20154,0.23809,1,1
1,RESPONSE TO OTHER ORGANISM,0.019283,0.20128,0.11491,1,1
1,ST GA13 PATHWAY,5.7413e-06,0.20045,0.26389,1,1
1,REGULATION OF JNK ACTIVITY,0.0071468,0.20034,0.1744,1,1
1,CYSTEINE TYPE PEPTIDASE ACTIVITY,0.0067808,0.19987,0.15803,1,1
1,REGULATION OF T CELL PROLIFERATION,0.00038934,0.19917,0.2839,1,1
1,HEMATOPOIETIN INTERFERON CLASSD200 DOMAIN CYTOKINE RECEPTOR BINDING,0.00044439,0.19883,0.29989,1,1
1,MITOCHONDRIAL TRANSPORT,0.0031536,0.19857,0.18125,1,1
1,CYTOKINE PRODUCTION,0.0050528,0.19781,0.21741,1,1
1,REACTOME MITOTIC G1 G1 S PHASES,0.00023468,0.19765,0.17445,1,1
1,NITROGEN COMPOUND METABOLIC PROCESS,0.00012964,0.197,0.17872,1,1
1,PID TCRRASPATHWAY,0.0029794,0.19686,0.2683,1,1
1,ORGANELLE MEMBRANE,9.0179e-06,0.19587,0.16415,1,1
1,TRANSFERASE ACTIVITY TRANSFERRING GROUPS OTHER THAN AMINO ACYL GROUPS,0.00041602,0.19585,0.21298,1,1
1,LIGASE ACTIVITY,0.00040247,0.1955,0.15228,1,1
1,REACTOME SIGNALING BY ERBB4,1.0311e-06,0.19536,0.19174,1,1
1,REACTOME TCR SIGNALING,0.014138,0.19512,0.11181,1,1
1,TISSUE DEVELOPMENT,0.0059384,0.19467,0.24369,1,1
1,ACTIVATION OF JNK ACTIVITY,0.014138,0.19464,0.1557,1,1
1,PEROXISOMAL MEMBRANE,0.011612,0.19424,0.14795,1,1
1,MICROBODY MEMBRANE,0.011612,0.19424,0.14795,1,1
1,REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION,0.011047,0.19419,0.15096,1,1
1,DEACETYLASE ACTIVITY,0.0085714,0.19397,0.17938,1,1
1,DNA POLYMERASE ACTIVITY,0.0036303,0.19381,0.18852,1,1
1,PROTEIN UBIQUITINATION,0.019283,0.19353,0.1165,1,1
1,REACTOME MRNA DECAY BY 3 TO 5 EXORIBONUCLEASE,0.036164,0.19315,0.155,1,1
1,CELL CYCLE ARREST GO 0007050,0.00012964,0.19297,0.22315,1,1
1,ANATOMICAL STRUCTURE FORMATION,0.00047456,0.1926,0.25553,1,1
1,REACTOME NFKB AND MAP KINASES ACTIVATION MEDIATED BY TLR4 SIGNALING REPERTOIRE,0.00063551,0.19203,0.18596,1,1
1,REGULATION OF TRANSCRIPTION FACTOR ACTIVITY,0.00014935,0.19162,0.1894,1,1
1,REACTOME HEMOSTASIS,3.8583e-05,0.19099,0.17992,1,1
1,REACTOME SYNTHESIS AND INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES,0.0066042,0.19086,0.26187,1,1
1,POSITIVE REGULATION OF TRANSCRIPTIONDNA DEPENDENT,1.6455e-05,0.19077,0.21217,1,1
1,PROTEIN LOCALIZATION,4.1112e-06,0.19068,0.16918,1,1
1,REACTOME TOLL RECEPTOR CASCADES,0.00084609,0.19064,0.16943,1,1
1,PID ERBB1 RECEPTOR PROXIMAL PATHWAY,0.00057693,0.19041,0.2274,1,1
1,TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY,0.031059,0.19009,0.15205,1,1
1,NUCLEOTIDYLTRANSFERASE ACTIVITY,0.00072223,0.18992,0.16671,1,1
1,REACTOME APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B,0.0029794,0.1895,0.17604,1,1
1,METHYLTRANSFERASE ACTIVITY,0.018398,0.18948,0.1258,1,1
1,GENERATION OF PRECURSOR METABOLITES AND ENERGY,0.0040578,0.1893,0.1318,1,1
1,REACTOME DESTABILIZATION OF MRNA BY TRISTETRAPROLIN TTP,0.014841,0.18908,0.14922,1,1
1,LYTIC VACUOLE,0.0010859,0.18902,0.18474,1,1
1,LYSOSOME,0.0010859,0.18902,0.18474,1,1
1,HEMOSTASIS,0.00031859,0.1889,0.26846,1,1
1,PHAGOCYTOSIS,0.0014299,0.18837,0.24044,1,1
1,BIOCARTA MAPK PATHWAY,2.0833e-05,0.18794,0.19758,1,1
1,GOLGI APPARATUS,5.2837e-06,0.18685,0.16909,1,1
1,TRANSFERASE ACTIVITY TRANSFERRING ACYL GROUPS,9.7346e-05,0.18675,0.19863,1,1
1,REACTOME METABOLISM OF VITAMINS AND COFACTORS,0.014841,0.18656,0.13052,1,1
1,KEGG COLORECTAL CANCER,0.0028957,0.18573,0.15214,1,1
1,CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY,0.0054795,0.18561,0.1771,1,1
1,HOMEOSTASIS OF NUMBER OF CELLS,0.0011549,0.1856,0.24073,1,1
1,BIOCARTA PPARA PATHWAY,0.0017123,0.18555,0.16168,1,1
1,PID INSULIN PATHWAY,0.00050664,0.18479,0.19379,1,1
1,REACTOME APC CDC20 MEDIATED DEGRADATION OF NEK2A,0.0020453,0.18474,0.16335,1,1
1,GLYCOSAMINOGLYCAN BINDING,0.035393,0.18437,0.17106,1,1
1,KEGG N GLYCAN BIOSYNTHESIS,0.0057817,0.18429,0.1367,1,1
1,NUCLEOLUS,0.014841,0.18427,0.12214,1,1
1,PID ECADHERIN NASCENTAJ PATHWAY,0.031748,0.18359,0.15298,1,1
1,PID CIRCADIANPATHWAY,0.0053338,0.1834,0.21667,1,1
1,RIBONUCLEOPROTEIN COMPLEX BIOGENESIS AND ASSEMBLY,0.015953,0.18307,0.12395,1,1
1,INTRACELLULAR TRANSPORT,2.6307e-05,0.18295,0.16957,1,1
1,REGULATION OF GTPASE ACTIVITY,0.035393,0.18242,0.21179,1,1
1,REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY,0.00047456,0.18201,0.18461,1,1
1,REACTOME MTORC1 MEDIATED SIGNALLING,0.03939,0.18168,0.18841,1,1
1,KEGG NON SMALL CELL LUNG CANCER,6.7596e-05,0.18146,0.17493,1,1
1,MYOSIN COMPLEX,0.0013872,0.1809,0.23164,1,1
1,REACTOME DNA REPLICATION,0.0016129,0.18061,0.14485,1,1
1,ENDONUCLEASE ACTIVITY,0.0041716,0.18028,0.12941,1,1
1,DNA DIRECTED DNA POLYMERASE ACTIVITY,0.0059384,0.18014,0.16297,1,1
1,POSITIVE REGULATION OF RNA METABOLIC PROCESS,2.6307e-05,0.17979,0.20447,1,1
1,PID S1P META PATHWAY,0.0094949,0.17972,0.20989,1,1
1,BIOCARTA HCMV PATHWAY,0.0099891,0.1797,0.17368,1,1
1,REACTOME ACTIVATED AMPK STIMULATES FATTY ACID OXIDATION IN MUSCLE,0.0045306,0.17946,0.21541,1,1
1,REACTOME SIGNALING BY RHO GTPASES,0.0066042,0.17929,0.131,1,1
1,PHOSPHOLIPID BIOSYNTHETIC PROCESS,0.045624,0.17917,0.10521,1,1
1,ACTIVATION OF MAPK ACTIVITY,0.00059588,0.17913,0.14915,1,1
1,ORGANELLE OUTER MEMBRANE,0.0017641,0.1788,0.12315,1,1
1,GOLGI APPARATUS PART,6.2786e-05,0.17874,0.16999,1,1
1,AMINO ACID METABOLIC PROCESS,0.0025083,0.17772,0.14324,1,1
1,IMMUNE SYSTEM PROCESS,0.010773,0.17771,0.15108,1,1
1,PROTEIN HETERODIMERIZATION ACTIVITY,0.001228,0.17762,0.14689,1,1
1,PHOSPHOINOSITIDE BIOSYNTHETIC PROCESS,0.014138,0.1776,0.14091,1,1
1,PROTEIN DIMERIZATION ACTIVITY,0.00026903,0.17758,0.13382,1,1
1,BIOCARTA AKT PATHWAY,0.0020453,0.17738,0.19475,1,1
1,KEGG ENDOMETRIAL CANCER,0.00040247,0.17717,0.19367,1,1
1,PID CD8TCRPATHWAY,0.013798,0.17713,0.11721,1,1
1,PID TXA2PATHWAY,0.0060989,0.17707,0.14558,1,1
1,REACTOME EICOSANOID LIGAND BINDING RECEPTORS,0.0053338,0.17706,0.18747,1,1
1,MITOSIS,0.00079435,0.17699,0.16599,1,1
1,REACTOME HIV INFECTION,0.00026903,0.17589,0.16915,1,1
1,REACTOME METABOLISM OF NON CODING RNA,0.024846,0.17404,0.13447,1,1
1,POSITIVE REGULATION OF TRANSCRIPTION,1.0184e-05,0.17396,0.19507,1,1
1,BIOCARTA MEF2D PATHWAY,0.0014738,0.17367,0.23155,1,1
1,POSITIVE REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,8.6584e-06,0.17351,0.18317,1,1
1,PORE COMPLEX,0.00087311,0.17249,0.20024,1,1
1,BIOCARTA PDGF PATHWAY,0.00087311,0.1724,0.2367,1,1
1,REACTOME ACTIVATED TLR4 SIGNALLING,0.010506,0.17236,0.14291,1,1
1,MULTI ORGANISM PROCESS,0.037747,0.17222,0.087976,1,1
1,RNA HELICASE ACTIVITY,0.044685,0.17196,0.14937,1,1
1,RNA BINDING,0.0015653,0.17186,0.16248,1,1
1,KINETOCHORE,0.019739,0.1715,0.15313,1,1
1,CIRCADIAN RHYTHM,0.015574,0.17117,0.13327,1,1
1,LIPID TRANSPORTER ACTIVITY,0.020205,0.17105,0.21682,1,1
1,ST G ALPHA I PATHWAY,0.041093,0.1709,0.14305,1,1
1,MACROMOLECULE LOCALIZATION,1.6455e-05,0.17021,0.14618,1,1
1,BIOCARTA GATA3 PATHWAY,0.024846,0.17018,0.14967,1,1
1,ENDONUCLEASE ACTIVITY GO 0016893,0.047551,0.16935,0.066057,1,1
1,REACTOME SIGNALING BY ILS,0.00036427,0.16861,0.2329,1,1
1,PID PLK1 PATHWAY,0.0025817,0.16842,0.20765,1,1
1,KEGG NON HOMOLOGOUS END JOINING,0.0014738,0.16838,0.2121,1,1
1,PROTEIN AMINO ACID ADP RIBOSYLATION,0.00025131,0.16835,0.21235,1,1
1,LEADING EDGE,0.0071468,0.16765,0.21207,1,1
1,RESPONSE TO BIOTIC STIMULUS,0.00092958,0.16722,0.16622,1,1
1,ENVELOPE,0.0038387,0.16714,0.1184,1,1
1,ORGANELLE ENVELOPE,0.0038387,0.16714,0.1184,1,1
1,PID HDAC CLASSI PATHWAY,7.547e-05,0.16636,0.15589,1,1
1,PID HIF1 TFPATHWAY,0.03939,0.16615,0.27053,1,1
1,KEGG BASE EXCISION REPAIR,0.015574,0.16551,0.11354,1,1
1,REACTOME RNA POL II TRANSCRIPTION PRE INITIATION AND PROMOTER OPENING,0.00035231,0.16544,0.15632,1,1
1,KEGG RENAL CELL CARCINOMA,0.041093,0.16426,0.10266,1,1
1,SPINDLE,0.0064317,0.16407,0.20126,1,1
1,M PHASE OF MITOTIC CELL CYCLE,0.0013457,0.16406,0.15943,1,1
1,ACTIN BINDING,0.025994,0.16287,0.11811,1,1
1,PID FCER1PATHWAY,0.0057817,0.1624,0.15536,1,1
1,PROTEIN METABOLIC PROCESS,1.1267e-06,0.16211,0.15753,1,1
1,PROTEIN RNA COMPLEX ASSEMBLY,0.030383,0.16173,0.11255,1,1
1,RIBONUCLEASE ACTIVITY,0.0060989,0.16108,0.14809,1,1
1,REACTOME MHC CLASS II ANTIGEN PRESENTATION,0.00021909,0.16094,0.16742,1,1
1,PID INSULIN GLUCOSE PATHWAY,0.0097392,0.16041,0.14661,1,1
1,PEPTIDASE ACTIVITY,0.0013872,0.16033,0.13716,1,1
1,ENZYME INHIBITOR ACTIVITY,0.046579,0.16019,0.12854,1,1
1,REACTOME GLUCOSE METABOLISM,0.018836,0.16003,0.12546,1,1
1,REGULATION OF BODY FLUID LEVELS,0.0019282,0.15945,0.23132,1,1
1,BIOCARTA CARM1 PATHWAY,0.013465,0.15943,0.20414,1,1
1,CELLULAR PROTEIN CATABOLIC PROCESS,0.00026003,0.15926,0.18113,1,1
1,POSITIVE REGULATION OF CATALYTIC ACTIVITY,0.00034072,0.15902,0.14485,1,1
1,REACTOME DOUBLE STRAND BREAK REPAIR,0.036948,0.159,0.15439,1,1
1,REACTOME METABOLISM OF AMINO ACIDS AND DERIVATIVES,0.004408,0.15868,0.10666,1,1
1,REGULATION OF MAP KINASE ACTIVITY,0.0034322,0.15853,0.15477,1,1
1,PID BETACATENIN NUC PATHWAY,0.017969,0.15851,0.15503,1,1
1,SPHINGOLIPID METABOLIC PROCESS,0.036164,0.15784,0.11156,1,1
1,POLYSACCHARIDE BINDING,0.044685,0.15738,0.15219,1,1
1,HORMONE RECEPTOR BINDING,0.0079323,0.15664,0.17886,1,1
1,ONE CARBON COMPOUND METABOLIC PROCESS,0.035393,0.15622,0.1082,1,1
1,PID EPHA2 FWDPATHWAY,0.004408,0.15584,0.21606,1,1
1,RECEPTOR BINDING,0.0037331,0.15479,0.12052,1,1
1,DNA REPLICATION,0.019283,0.15399,0.10031,1,1
1,NUCLEAR PORE,0.0027346,0.15379,0.19377,1,1
1,REGULATION OF DEFENSE RESPONSE,0.023205,0.15352,0.14289,1,1
1,KEGG PYRIMIDINE METABOLISM,6.5149e-05,0.15307,0.19532,1,1
1,PID IGF1 PATHWAY,0.0045306,0.15244,0.13961,1,1
1,PID CD8TCRDOWNSTREAMPATHWAY,0.00021909,0.15237,0.22194,1,1
1,REACTOME NUCLEOTIDE EXCISION REPAIR,0.019283,0.15212,0.11438,1,1
1,REACTOME FORMATION OF TRANSCRIPTION COUPLED NER TC NER REPAIR COMPLEX,0.00079435,0.15198,0.15594,1,1
1,CELLULAR PROTEIN METABOLIC PROCESS,2.2658e-06,0.15197,0.14751,1,1
1,CELL DEVELOPMENT,9.7346e-05,0.15177,0.13802,1,1
1,MACROMOLECULE BIOSYNTHETIC PROCESS,0.00092958,0.15116,0.14307,1,1
1,CELLULAR MACROMOLECULE CATABOLIC PROCESS,8.4205e-05,0.15101,0.16331,1,1
1,PID P75NTRPATHWAY,0.0040578,0.15047,0.15013,1,1
1,CELLULAR MACROMOLECULE METABOLIC PROCESS,2.6902e-06,0.15015,0.14347,1,1
1,UBIQUITIN CYCLE,0.0073363,0.14994,0.13734,1,1
1,PID RB 1PATHWAY,0.0051916,0.14989,0.14407,1,1
1,CHROMOSOMEPERICENTRIC REGION,0.031748,0.14966,0.13003,1,1
1,CELL CYCLE GO 0007049,0.001191,0.14918,0.11983,1,1
1,PID DNAPK PATHWAY,0.00014418,0.14893,0.20213,1,1
1,REACTOME MITOTIC PROMETAPHASE,0.022165,0.14875,0.11978,1,1
1,REACTOME SYNTHESIS OF PA,0.042857,0.14835,0.13987,1,1
1,REGULATION OF CELLULAR METABOLIC PROCESS,0.00010092,0.14808,0.12777,1,1
1,REACTOME CELL CYCLE MITOTIC,0.0027346,0.14806,0.11833,1,1
1,MACROMOLECULAR COMPLEX ASSEMBLY,4.3218e-05,0.14764,0.13984,1,1
1,PID IL2 PI3KPATHWAY,0.034637,0.1469,0.12988,1,1
1,PID TCR PATHWAY,0.017137,0.14626,0.10166,1,1
1,POSITIVE REGULATION OF HYDROLASE ACTIVITY,0.0017641,0.14618,0.16504,1,1
1,DNA HELICASE ACTIVITY,0.0056288,0.14546,0.16692,1,1
1,REGULATION OF METABOLIC PROCESS,0.00010845,0.14533,0.12653,1,1
1,ENDOPEPTIDASE ACTIVITY,0.0012662,0.14529,0.15313,1,1
1,BIOCARTA PTEN PATHWAY,0.00092958,0.1452,0.27605,1,1
1,EXTRACELLULAR SPACE,0.029068,0.14519,0.14961,1,1
1,MITOCHONDRION,0.0039469,0.14493,0.13268,1,1
1,ST T CELL SIGNAL TRANSDUCTION,0.0017641,0.14491,0.14594,1,1
1,LIPID BINDING,0.0067808,0.14488,0.13244,1,1
1,DNA DEPENDENT DNA REPLICATION,0.036164,0.14433,0.10582,1,1
1,INTRACELLULAR SIGNALING CASCADE,0.00059588,0.14363,0.13103,1,1
1,SULFOTRANSFERASE ACTIVITY,0.0083534,0.14316,0.187,1,1
1,PID MTOR 4PATHWAY,0.00014935,0.1427,0.14777,1,1
1,REACTOME METABOLISM OF POLYAMINES,0.010245,0.14252,0.20097,1,1
1,REACTOME DESTABILIZATION OF MRNA BY KSRP,0.011612,0.14186,0.15234,1,1
1,NUCLEAR HORMONE RECEPTOR BINDING,0.015203,0.14173,0.15981,1,1
1,REACTOME FRS2 MEDIATED CASCADE,0.0097392,0.14098,0.13534,1,1
1,REACTOME NEP NS2 INTERACTS WITH THE CELLULAR EXPORT MACHINERY,0.046579,0.14085,0.13995,1,1
1,NEGATIVE REGULATION OF TRANSCRIPTION,0.026586,0.1404,0.091344,1,1
1,KEGG HUNTINGTONS DISEASE,0.0045306,0.14006,0.090454,1,1
1,EMBRYO IMPLANTATION,0.033166,0.14003,0.15724,1,1
1,RESPONSE TO CHEMICAL STIMULUS,0.022165,0.13989,0.11388,1,1
1,REACTOME TRIF MEDIATED TLR3 SIGNALING,0.00026003,0.13931,0.18629,1,1
1,KEGG GLIOMA,0.0011199,0.13876,0.13671,1,1
1,GTPASE BINDING,0.02843,0.13862,0.10106,1,1
1,KINASE BINDING,0.0071468,0.13805,0.10096,1,1
1,TRANSFERASE ACTIVITY TRANSFERRING SULFUR CONTAINING GROUPS,0.0039469,0.13804,0.2006,1,1
1,REACTOME GLOBAL GENOMIC NER GG NER,0.0059384,0.13798,0.14738,1,1
1,REACTOME G1 PHASE,0.0085714,0.13772,0.1351,1,1
1,PROTEIN KINASE ACTIVITY,0.0017641,0.13658,0.11963,1,1
1,KEGG UBIQUITIN MEDIATED PROTEOLYSIS,0.00095906,0.1353,0.11803,1,1
1,CYTOPLASMIC PART,1.7806e-05,0.13496,0.1306,1,1
1,ENZYME BINDING,0.0014738,0.13491,0.090601,1,1
1,RHYTHMIC PROCESS,0.010245,0.1347,0.10915,1,1
1,ENZYME ACTIVATOR ACTIVITY,0.0013054,0.13442,0.14212,1,1
1,KEGG CELL CYCLE,0.033894,0.13423,0.096678,1,1
1,NF KAPPAB BINDING,0.019283,0.13411,0.15275,1,1
1,KEGG NUCLEOTIDE EXCISION REPAIR,0.0097392,0.13347,0.12491,1,1
1,NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,0.0034322,0.13209,0.12169,1,1
1,REGULATION OF MOLECULAR FUNCTION,6.5149e-05,0.13091,0.13264,1,1
1,PROTEIN AMINO ACID O LINKED GLYCOSYLATION,0.036948,0.13022,0.16734,1,1
1,REACTOME RNA POL II PRE TRANSCRIPTION EVENTS,0.0033369,0.13003,0.12476,1,1
1,PROTEIN AMINO ACID PHOSPHORYLATION,0.00022676,0.13001,0.13035,1,1
1,CELLULAR COMPONENT ASSEMBLY,0.00012074,0.12972,0.12734,1,1
1,BIOSYNTHETIC PROCESS,0.00095906,0.12943,0.13393,1,1
1,MITOCHONDRION ORGANIZATION AND BIOGENESIS,0.02166,0.12892,0.10145,1,1
1,RNA CATABOLIC PROCESS,0.033166,0.12874,0.11935,1,1
1,RESPONSE TO BACTERIUM,0.0021689,0.12874,0.097785,1,1
1,REACTOME DEADENYLATION DEPENDENT MRNA DECAY,0.015203,0.12872,0.10831,1,1
1,REGULATION OF CELLULAR COMPONENT ORGANIZATION AND BIOGENESIS,0.00074557,0.12814,0.14807,1,1
1,TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS,0.00041602,0.12799,0.10807,1,1
1,CATION BINDING,4.1617e-05,0.12645,0.16261,1,1
1,REGULATION OF HYDROLASE ACTIVITY,0.00054072,0.12633,0.15267,1,1
1,ST ADRENERGIC,0.017969,0.1262,0.16911,1,1
1,ACTIVATION OF NF KAPPAB TRANSCRIPTION FACTOR,0.00019079,0.12535,0.22184,1,1
1,RIBONUCLEOPROTEIN COMPLEX,0.020205,0.12488,0.098443,1,1
1,REACTOME CONVERSION FROM APC C CDC20 TO APC C CDH1 IN LATE ANAPHASE,0.0041716,0.12461,0.16406,1,1
1,PID FGF PATHWAY,0.02166,0.1237,0.13077,1,1
1,M PHASE,0.02268,0.12364,0.1091,1,1
1,IDENTICAL PROTEIN BINDING,0.0069616,0.12323,0.098631,1,1
1,GTPASE ACTIVITY,0.018836,0.12259,0.11202,1,1
1,REACTOME TRANSCRIPTION COUPLED NER TC NER,0.038561,0.12179,0.094874,1,1
1,CYTOSOL,9.0551e-05,0.12148,0.14886,1,1
1,NUCLEOTIDE EXCISION REPAIR,0.015953,0.12132,0.15028,1,1
1,ST GA12 PATHWAY,0.027188,0.12091,0.11064,1,1
1,SOLUBLE FRACTION,0.00353,0.12042,0.14267,1,1
1,PHOSPHOTRANSFERASE ACTIVITY ALCOHOL GROUP AS ACCEPTOR,0.001662,0.11979,0.10764,1,1
1,PHOSPHORYLATION,0.00021909,0.1195,0.12431,1,1
1,CYTOPLASM,3.8583e-05,0.11925,0.11673,1,1
1,RESPONSE TO UV,0.044685,0.11919,0.088596,1,1
1,PROTEIN CATABOLIC PROCESS,0.00021167,0.11917,0.15462,1,1
1,REGULATION OF GENE EXPRESSION,0.0010859,0.11879,0.1058,1,1
1,POSITIVE REGULATION OF CASPASE ACTIVITY,0.0045306,0.11875,0.17779,1,1
1,DNA DIRECTED RNA POLYMERASE COMPLEX,0.013139,0.11841,0.10826,1,1
1,NUCLEAR DNA DIRECTED RNA POLYMERASE COMPLEX,0.013139,0.11841,0.10826,1,1
1,RNA POLYMERASE COMPLEX,0.013139,0.11841,0.10826,1,1
1,NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,0.00035231,0.1177,0.092111,1,1
1,REACTOME LATE PHASE OF HIV LIFE CYCLE,0.0022992,0.11746,0.1368,1,1
1,REGULATION OF TRANSFERASE ACTIVITY,0.00014935,0.11681,0.14141,1,1
1,BIOCARTA VIP PATHWAY,0.011326,0.11672,0.17548,1,1
1,SMALL GTPASE BINDING,0.033166,0.11671,0.090183,1,1
1,TRANSCRIPTION REPRESSOR ACTIVITY,0.0047853,0.11657,0.11663,1,1
1,NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION AND BIOGENESIS,0.045624,0.11525,0.13732,1,1
1,ACTIN FILAMENT BASED PROCESS,0.027188,0.1151,0.096349,1,1
1,REGULATION OF KINASE ACTIVITY,7.2754e-05,0.11468,0.1448,1,1
1,MITOTIC CELL CYCLE,0.00353,0.11456,0.12904,1,1
1,ACTIN CYTOSKELETON ORGANIZATION AND BIOGENESIS,0.0085714,0.11396,0.12074,1,1
1,BIOCARTA LECTIN PATHWAY,0.0025817,0.11376,0.24009,1,1
1,REGULATION OF LYMPHOCYTE ACTIVATION,0.010773,0.11355,0.20902,1,1
1,REACTOME DNA REPAIR,0.036164,0.11339,0.079963,1,1
1,REPRODUCTIVE PROCESS,0.029719,0.11262,0.08758,1,1
1,ORGANELLE LUMEN,0.00353,0.11219,0.092308,1,1
1,MEMBRANE ENCLOSED LUMEN,0.00353,0.11219,0.092308,1,1
1,TRANSCRIPTION FACTOR TFIID COMPLEX,0.013139,0.11215,0.12109,1,1
1,REACTOME FORMATION OF RNA POL II ELONGATION COMPLEX ,0.0056288,0.11074,0.12788,1,1
1,BIOCARTA RAS PATHWAY,0.021165,0.11004,0.10995,1,1
1,DNA METABOLIC PROCESS,0.014138,0.10845,0.089089,1,1
1,KINASE ACTIVITY,0.0034322,0.10824,0.093293,1,1
1,REACTOME FORMATION OF THE HIV1 EARLY ELONGATION COMPLEX,0.0051916,0.10772,0.13948,1,1
1,REGULATION OF PROTEIN KINASE ACTIVITY,0.00012074,0.10743,0.14368,1,1
1,NEGATIVE REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,0.023205,0.10683,0.079002,1,1
1,BIOPOLYMER METABOLIC PROCESS,0.00072223,0.10609,0.08211,1,1
1,REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES,0.036948,0.10541,0.24432,1,1
1,BIOPOLYMER MODIFICATION,0.0022332,0.10519,0.086948,1,1
1,RNA METABOLIC PROCESS,0.0026572,0.10504,0.09053,1,1
1,REACTOME FACTORS INVOLVED IN MEGAKARYOCYTE DEVELOPMENT AND PLATELET PRODUCTION,0.0033369,0.10496,0.10794,1,1
1,REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,0.0087944,0.10439,0.08995,1,1
1,PID CXCR4 PATHWAY,0.018398,0.10323,0.10656,1,1
1,REACTOME MRNA CAPPING,0.0099891,0.10293,0.12454,1,1
1,ESTABLISHMENT OF CELLULAR LOCALIZATION,0.011612,0.10172,0.071154,1,1
1,REACTOME SPRY REGULATION OF FGF SIGNALING,0.0025083,0.10117,0.14803,1,1
1,REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,0.0023671,0.10115,0.095099,1,1
1,RESPONSE TO RADIATION,0.019283,0.10097,0.069434,1,1
1,SIGNAL TRANSDUCTION,0.013798,0.10073,0.087488,1,1
1,POST TRANSLATIONAL PROTEIN MODIFICATION,0.0013457,0.098816,0.098725,1,1
1,GTP BINDING,0.0071468,0.097823,0.14457,1,1
1,INTRACELLULAR ORGANELLE PART,0.00098941,0.097804,0.084222,1,1
1,REGULATION OF RNA METABOLIC PROCESS,0.013465,0.095558,0.085342,1,1
1,REGULATION OF TRANSCRIPTION,0.0025817,0.095065,0.097148,1,1
1,ORGANELLE PART,0.0010859,0.094643,0.084181,1,1
1,ION BINDING,0.00031859,0.094344,0.11819,1,1
1,KEGG VIBRIO CHOLERAE INFECTION,0.041093,0.093613,0.091499,1,1
1,REGULATION OF BIOLOGICAL QUALITY,0.037747,0.093589,0.079796,1,1
1,REGULATION OF TRANSCRIPTIONDNA DEPENDENT,0.0085714,0.093118,0.089608,1,1
1,CELLULAR LOCALIZATION,0.0071468,0.092437,0.069559,1,1
1,REACTOME PI3K EVENTS IN ERBB2 SIGNALING,0.0011549,0.092329,0.12302,1,1
1,TRANSCRIPTION,0.0025817,0.091685,0.091098,1,1
1,NEGATIVE REGULATION OF CELLULAR METABOLIC PROCESS,0.012508,0.091644,0.083571,1,1
1,NEGATIVE REGULATION OF METABOLIC PROCESS,0.011612,0.091129,0.084264,1,1
1,PROTEIN MODIFICATION PROCESS,0.0045306,0.090591,0.08199,1,1
1,TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,0.019283,0.090556,0.07258,1,1
1,MACROMOLECULE CATABOLIC PROCESS,7.547e-05,0.089364,0.12136,1,1
1,REGULATION OF CATALYTIC ACTIVITY,0.00092958,0.087454,0.10527,1,1
1,NON MEMBRANE BOUND ORGANELLE,0.036164,0.087302,0.061469,1,1
1,INTRACELLULAR NON MEMBRANE BOUND ORGANELLE,0.036164,0.087302,0.061469,1,1
1,KEGG FC GAMMA R MEDIATED PHAGOCYTOSIS,0.014138,0.085721,0.10055,1,1
1,RNA BIOSYNTHETIC PROCESS,0.0064317,0.084363,0.08341,1,1
1,TRANSCRIPTION DNA DEPENDENT,0.0062634,0.084003,0.08388,1,1
1,KEGG MAPK SIGNALING PATHWAY,0.014841,0.082956,0.098315,1,1
1,ENZYME REGULATOR ACTIVITY,0.017137,0.082388,0.093537,1,1
1,POSITIVE REGULATION OF BINDING,0.009256,0.08227,0.13333,1,1
1,NUCLEUS,0.0022992,0.082181,0.067283,1,1
1,POSITIVE REGULATION OF DNA BINDING,0.021165,0.080879,0.1174,1,1
1,BIOPOLYMER CATABOLIC PROCESS,0.00074557,0.08038,0.1086,1,1
1,MACROMOLECULAR COMPLEX,0.0041716,0.076263,0.071012,1,1
1,TRANSCRIPTION COREPRESSOR ACTIVITY,0.031748,0.071828,0.099965,1,1
1,MEMBRANE,0.045624,0.068962,0.050361,1,1
1,GUANYL NUCLEOTIDE BINDING,0.015574,0.068399,0.13971,1,1
1,PURINE NUCLEOTIDE BINDING,0.027188,0.068074,0.067931,1,1
1,PROTEIN COMPLEX,0.0071468,0.062374,0.066329,1,1
1,NUCLEOTIDE BINDING,0.034637,0.058946,0.063171,1,1
2,REACTOME APOPTOTIC CLEAVAGE OF CELL ADHESION PROTEINS,3.4421e-05,0.81064,0.86255,1,1
2,PID INTEGRIN4 PATHWAY,0.0006154,0.74435,0.68278,1,1
2,VESICLE LOCALIZATION,1.4039e-05,0.73002,0.70196,1,1
2,OXIDOREDUCTASE ACTIVITY ACTING ON THE ALDEHYDE OR OXO GROUP OF DONORSNAD OR NADP AS ACCEPTOR,0.0006154,0.67269,0.57188,1,1
2,REACTOME ACYL CHAIN REMODELLING OF PI,1.6729e-06,0.65639,0.5735,1,1
2,POSITIVE REGULATION OF PROTEIN AMINO ACID PHOSPHORYLATION,2.3418e-05,0.65201,0.51126,1,1
2,KEGG ALLOGRAFT REJECTION,0.0028141,0.6126,0.44071,1,1
2,MESODERM DEVELOPMENT,0.00054072,0.61159,0.47098,1,1
2,REACTOME APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS,1.6455e-05,0.611,0.51181,1,1
2,GLAND DEVELOPMENT,0.0030654,0.6,0.44663,1,1
2,OXIDOREDUCTASE ACTIVITY ACTING ON SULFUR GROUP OF DONORS,0.00040247,0.58906,0.38235,1,1
2,MORPHOGENESIS OF AN EPITHELIUM,0.00017186,0.58826,0.52381,1,1
2,G1 PHASE OF MITOTIC CELL CYCLE,1.8251e-06,0.56644,0.53778,1,1
2,INTERCELLULAR JUNCTION ASSEMBLY,0.00050664,0.5497,0.49676,1,1
2,POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS,6.5149e-05,0.54276,0.41615,1,1
2,TRANSITION METAL ION TRANSMEMBRANE TRANSPORTER ACTIVITY,2.0033e-05,0.53113,0.43289,1,1
2,ICOSANOID METABOLIC PROCESS,0.0050528,0.52983,0.37542,1,1
2,COENZYME BIOSYNTHETIC PROCESS,0.00025131,0.5276,0.48531,1,1
2,REACTOME ACYL CHAIN REMODELLING OF PS,1.1267e-06,0.52368,0.52828,1,1
2,OXIDOREDUCTASE ACTIVITY ACTING ON THE ALDEHYDE OR OXO GROUP OF DONORS,0.00047456,0.52161,0.46654,1,1
2,POSITIVE REGULATION OF PHOSPHORYLATION,5.4121e-05,0.51163,0.41533,1,1
2,SA MMP CYTOKINE CONNECTION,3.5759e-05,0.51158,0.43959,1,1
2,TYROSINE PHOSPHORYLATION OF STAT PROTEIN,0.00012964,0.50994,0.47221,1,1
2,REACTOME METABOLISM OF PORPHYRINS,0.0027346,0.50668,0.34176,1,1
2,ESTABLISHMENT OF ORGANELLE LOCALIZATION,0.00013917,0.50596,0.39757,1,1
2,COENZYME METABOLIC PROCESS,2.1663e-05,0.48368,0.37322,1,1
2,REACTOME YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION,0.00021167,0.46957,0.41693,1,1
2,CORNIFIED ENVELOPE,0.00024286,0.46667,0.41795,1,1
2,POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS,6.7596e-05,0.46495,0.34305,1,1
2,COFACTOR METABOLIC PROCESS,4.1617e-05,0.46412,0.34052,1,1
2,DEAMINASE ACTIVITY,0.00040247,0.46345,0.39382,1,1
2,REACTOME PLATELET SENSITIZATION BY LDL,1.0207e-07,0.46097,0.47143,1,1
2,N TERMINAL PROTEIN AMINO ACID MODIFICATION,3.1904e-06,0.45144,0.39812,1,1
2,SMOOTH MUSCLE CONTRACTION GO 0006939,1.8251e-06,0.45092,0.43943,1,1
2,REACTOME BRANCHED CHAIN AMINO ACID CATABOLISM,1.6455e-05,0.44385,0.4343,1,1
2,BIOCARTA AHSP PATHWAY,0.0059384,0.44291,0.39643,1,1
2,REACTOME GLUTATHIONE CONJUGATION,0.00026903,0.43775,0.47973,1,1
2,CELLULAR MONOVALENT INORGANIC CATION HOMEOSTASIS,0.0069616,0.4334,0.34514,1,1
2,COFACTOR BIOSYNTHETIC PROCESS,4.6597e-05,0.43142,0.38949,1,1
2,POSITIVE REGULATION OF CELL ADHESION,2.4346e-05,0.43141,0.3868,1,1
2,CYTOPLASM ORGANIZATION AND BIOGENESIS,0.00049035,0.42987,0.4204,1,1
2,BIOCARTA SPPA PATHWAY,4.6623e-06,0.42816,0.37701,1,1
2,PID ERBB NETWORK PATHWAY,0.00038934,0.42501,0.37707,1,1
2,BIOCARTA DEATH PATHWAY,0.013139,0.42174,0.27782,1,1
2,REACTOME APOPTOTIC EXECUTION PHASE,4.2876e-06,0.4175,0.38349,1,1
2,BIOCARTA ARF PATHWAY,0.0014738,0.41487,0.29805,1,1
2,PID RHOA REG PATHWAY,0.00047456,0.41345,0.3063,1,1
2,ISOPRENOID METABOLIC PROCESS,0.00021167,0.40532,0.34594,1,1
2,KEGG ETHER LIPID METABOLISM,3.6228e-06,0.40396,0.40327,1,1
2,REACTOME SIGNAL REGULATORY PROTEIN SIRP FAMILY INTERACTIONS,0.0036303,0.40276,0.36538,1,1
2,REACTOME ACYL CHAIN REMODELLING OF PG,0.00032948,0.40115,0.34311,1,1
2,REGULATION OF PROTEIN IMPORT INTO NUCLEUS,0.00090094,0.39792,0.32481,1,1
2,GLIOGENESIS,0.0053338,0.39738,0.29791,1,1
2,KERATINOCYTE DIFFERENTIATION,0.00032948,0.39661,0.41266,1,1
2,BIOCARTA IL4 PATHWAY,0.00025131,0.39501,0.36466,1,1
2,PID IL2 STAT5PATHWAY,0.00013917,0.39283,0.30867,1,1
2,INTERCELLULAR JUNCTION ASSEMBLY AND MAINTENANCE,0.001872,0.39267,0.35436,1,1
2,REGULATION OF CELL SHAPE,0.00079435,0.39255,0.29386,1,1
2,KEGG VIRAL MYOCARDITIS,0.0013054,0.39016,0.26859,1,1
2,REACTOME PRE NOTCH PROCESSING IN GOLGI,0.0045306,0.38476,0.29051,1,1
2,HORMONE BINDING,0.011612,0.38316,0.33101,1,1
2,ENDOPLASMIC RETICULUM LUMEN,0.0018173,0.38107,0.32236,1,1
2,BIOCARTA TH1TH2 PATHWAY,0.0015653,0.37978,0.28172,1,1
2,ANTIOXIDANT ACTIVITY,0.016734,0.37913,0.22151,1,1
2,ORGANELLE LOCALIZATION,3.4421e-05,0.37011,0.29714,1,1
2,REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION,0.00032948,0.36798,0.35894,1,1
2,MONOVALENT INORGANIC CATION HOMEOSTASIS,0.0046564,0.36637,0.30058,1,1
2,RESPONSE TO HEAT,0.00019753,0.36357,0.29002,1,1
2,BIOCARTA TEL PATHWAY,0.0025083,0.3633,0.3094,1,1
2,KEGG LINOLEIC ACID METABOLISM,0.00021909,0.36216,0.27167,1,1
2,PROTEIN BINDING BRIDGING,5.2837e-06,0.36206,0.32363,1,1
2,REACTOME ACYL CHAIN REMODELLING OF PE,2.6307e-05,0.36124,0.35791,1,1
2,REGULATION OF CELL MORPHOGENESIS,0.0012662,0.36009,0.26217,1,1
2,RRNA PROCESSING,0.0016129,0.35701,0.301,1,1
2,BIOCARTA MITOCHONDRIA PATHWAY,0.022165,0.35674,0.22474,1,1
2,TRANSLATION FACTOR ACTIVITY NUCLEIC ACID BINDING,0.00081984,0.35543,0.28191,1,1
2,BIOCARTA RHO PATHWAY,0.00069957,0.35488,0.27883,1,1
2,REACTOME CELL EXTRACELLULAR MATRIX INTERACTIONS,0.0081404,0.34931,0.24321,1,1
2,REACTOME CALNEXIN CALRETICULIN CYCLE,0.0031536,0.34831,0.263,1,1
2,RIBOSOME BIOGENESIS AND ASSEMBLY,0.0011549,0.34774,0.31214,1,1
2,KEGG PROPANOATE METABOLISM,0.0067808,0.34727,0.27099,1,1
2,REACTOME ADVANCED GLYCOSYLATION ENDPRODUCT RECEPTOR SIGNALING,0.00049035,0.3465,0.29814,1,1
2,SINGLE STRANDED RNA BINDING,0.00028792,0.34455,0.30099,1,1
2,RIBONUCLEOPROTEIN BINDING,0.00037661,0.34077,0.27696,1,1
2,FATTY ACID METABOLIC PROCESS,0.00012512,0.33916,0.29627,1,1
2,KEGG PROTEASOME,0.001986,0.33841,0.26367,1,1
2,KEGG PYRUVATE METABOLISM,0.033894,0.33821,0.27223,1,1
2,BIOCARTA VDR PATHWAY,1.5201e-05,0.33705,0.34864,1,1
2,TRANSLATION REGULATOR ACTIVITY,0.001228,0.33547,0.25921,1,1
2,PERIPHERAL NERVOUS SYSTEM DEVELOPMENT,0.007729,0.33465,0.27504,1,1
2,PID EPHA FWDPATHWAY,3.3132e-05,0.33445,0.30143,1,1
2,RAS GTPASE ACTIVATOR ACTIVITY,0.0037331,0.33216,0.26339,1,1
2,MEIOTIC RECOMBINATION,0.0047853,0.3302,0.24069,1,1
2,REACTOME VIF MEDIATED DEGRADATION OF APOBEC3G,0.0020453,0.32896,0.23627,1,1
2,DNA DAMAGE RESPONSESIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR,0.0019282,0.32722,0.32223,1,1
2,REACTOME P53 INDEPENDENT G1 S DNA DAMAGE CHECKPOINT,0.00063551,0.32538,0.25609,1,1
2,REACTOME CDK MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6,0.0022332,0.32456,0.23369,1,1
2,RRNA METABOLIC PROCESS,0.001986,0.32163,0.27785,1,1
2,REACTOME SMAD2 SMAD3 SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION,0.0014299,0.32133,0.27393,1,1
2,ADHERENS JUNCTION,0.00022676,0.32086,0.32902,1,1
2,REACTOME APOPTOSIS,0.00035231,0.31738,0.21675,1,1
2,REGULATION OF PROTEIN AMINO ACID PHOSPHORYLATION,0.00050664,0.31616,0.30182,1,1
2,BIOCARTA PITX2 PATHWAY,0.0053338,0.31562,0.24453,1,1
2,KEGG VALINE LEUCINE AND ISOLEUCINE DEGRADATION,0.0073363,0.31461,0.22907,1,1
2,REACTOME NOTCH HLH TRANSCRIPTION PATHWAY,0.00067758,0.31311,0.32503,1,1
2,KEGG GLUTATHIONE METABOLISM,0.00057693,0.31282,0.26863,1,1
2,REACTOME AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1,0.001191,0.31272,0.24733,1,1
2,MEIOSIS I,0.0060989,0.31236,0.21924,1,1
2,BIOCARTA WNT PATHWAY,0.00041602,0.31198,0.28682,1,1
2,KEGG ALPHA LINOLENIC ACID METABOLISM,0.00012512,0.31192,0.33956,1,1
2,PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION,0.038561,0.31008,0.20198,1,1
2,REACTOME N GLYCAN TRIMMING IN THE ER AND CALNEXIN CALRETICULIN CYCLE,0.0057817,0.30758,0.23958,1,1
2,REACTOME REGULATION OF ORNITHINE DECARBOXYLASE ODC,0.0039469,0.30749,0.2261,1,1
2,EMBRYONIC MORPHOGENESIS,0.0094949,0.30617,0.23216,1,1
2,REACTOME DESTABILIZATION OF MRNA BY AUF1 HNRNP D0,0.0038387,0.30568,0.20214,1,1
2,ORGANELLE OUTER MEMBRANE,9.7801e-06,0.30513,0.26564,1,1
2,TISSUE DEVELOPMENT,0.00069957,0.30195,0.2401,1,1
2,REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EMI1,0.001986,0.30194,0.21928,1,1
2,SPECIFIC RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY,0.00092958,0.30058,0.25512,1,1
2,REACTOME PRE NOTCH EXPRESSION AND PROCESSING,8.4205e-05,0.29718,0.2452,1,1
2,REACTOME CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES,0.0040578,0.29707,0.2064,1,1
2,CELL PROJECTION BIOGENESIS,2.9532e-05,0.29701,0.26794,1,1
2,REGULATION OF PROTEIN MODIFICATION PROCESS,0.0021689,0.29605,0.22925,1,1
2,SPHINGOID METABOLIC PROCESS,0.0028141,0.29537,0.20375,1,1
2,KEGG PORPHYRIN AND CHLOROPHYLL METABOLISM,0.0033369,0.29489,0.20423,1,1
2,PROTEIN IMPORT INTO NUCLEUS,0.00057693,0.29428,0.24091,1,1
2,CASPASE REGULATOR ACTIVITY,0.047551,0.29397,0.1609,1,1
2,REACTOME SULFUR AMINO ACID METABOLISM,3.7145e-05,0.29238,0.32667,1,1
2,NEGATIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,0.025994,0.29237,0.1877,1,1
2,REACTOME SYNTHESIS OF PA,0.00013917,0.29234,0.28945,1,1
2,KEGG LYSINE DEGRADATION,0.00045924,0.29164,0.24117,1,1
2,REACTOME PRE NOTCH TRANSCRIPTION AND TRANSLATION,0.00010462,0.29133,0.2889,1,1
2,REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL,0.013798,0.29108,0.18975,1,1
2,PID HIF2PATHWAY,0.0010859,0.28814,0.24422,1,1
2,KEGG GLYCOLYSIS GLUCONEOGENESIS,0.0062634,0.2881,0.22783,1,1
2,BIOCARTA PROTEASOME PATHWAY,0.0054795,0.2872,0.22927,1,1
2,TRANSLATION INITIATION FACTOR ACTIVITY,0.0014299,0.28668,0.28205,1,1
2,SECONDARY METABOLIC PROCESS,4.3218e-05,0.28646,0.29595,1,1
2,PIGMENT METABOLIC PROCESS,0.00019079,0.28492,0.29085,1,1
2,POSITIVE REGULATION OF ANGIOGENESIS,0.011326,0.28444,0.31977,1,1
2,REACTOME CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX,0.0022992,0.2839,0.209,1,1
2,REACTOME ACTIVATED AMPK STIMULATES FATTY ACID OXIDATION IN MUSCLE,0.001662,0.28372,0.24097,1,1
2,RESPONSE TO CARBOHYDRATE STIMULUS,0.024288,0.28347,0.17153,1,1
2,MONOCARBOXYLIC ACID METABOLIC PROCESS,0.00020448,0.28197,0.2362,1,1
2,REACTOME APC C CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS,0.0017123,0.28108,0.2062,1,1
2,KEGG METABOLISM OF XENOBIOTICS BY CYTOCHROME P450,0.001228,0.28074,0.32527,1,1
2,NUCLEOTIDE SUGAR METABOLIC PROCESS,0.0030654,0.2793,0.35984,1,1
2,KEGG THYROID CANCER,0.00012964,0.27783,0.30122,1,1
2,SERINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY,0.016734,0.27674,0.20924,1,1
2,REACTOME SIGNALING BY HIPPO,0.011612,0.27654,0.38977,1,1
2,FOCAL ADHESION,0.0036303,0.27509,0.29807,1,1
2,NEGATIVE REGULATION OF ANGIOGENESIS,0.025414,0.27383,0.25808,1,1
2,OUTER MEMBRANE,3.7145e-05,0.27348,0.23076,1,1
2,SIG PIP3 SIGNALING IN B LYMPHOCYTES,0.00047456,0.27312,0.22887,1,1
2,REACTOME ACYL CHAIN REMODELLING OF PC,5.2139e-05,0.27288,0.27751,1,1
2,ADP BINDING,0.0031536,0.27262,0.27238,1,1
2,REACTOME SYNTHESIS AND INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES,0.011047,0.27123,0.26388,1,1
2,SA CASPASE CASCADE,0.031748,0.27058,0.21481,1,1
2,KEGG RETINOL METABOLISM,0.00067758,0.2704,0.2686,1,1
2,MITOCHONDRIAL MATRIX,0.0015653,0.26892,0.23325,1,1
2,MITOCHONDRIAL LUMEN,0.0015653,0.26892,0.23325,1,1
2,REACTOME ACTIVATION OF NF KAPPAB IN B CELLS,0.0027346,0.26793,0.18039,1,1
2,CYTOKINE BIOSYNTHETIC PROCESS,0.0027346,0.26698,0.16453,1,1
2,BIOCARTA RARRXR PATHWAY,0.00016595,0.2653,0.24807,1,1
2,REACTOME REGULATION OF APOPTOSIS,0.0079323,0.26518,0.15337,1,1
2,MITOCHONDRIAL TRANSPORT,0.00037661,0.26499,0.26491,1,1
2,RESPONSE TO OXIDATIVE STRESS,0.00018427,0.26465,0.24959,1,1
2,HEPARIN BINDING,0.0097392,0.26445,0.21787,1,1
2,REACTOME SYNTHESIS OF PE,0.0010859,0.2642,0.2486,1,1
2,DRUG BINDING,4.8379e-05,0.26408,0.28585,1,1
2,REACTOME AUTODEGRADATION OF CDH1 BY CDH1 APC C,0.0015189,0.26389,0.21251,1,1
2,BIOCARTA EIF PATHWAY,0.00010092,0.26369,0.30757,1,1
2,MITOCHONDRIAL OUTER MEMBRANE,0.00031859,0.26324,0.25163,1,1
2,POSITIVE REGULATION OF CELL CYCLE,0.0041716,0.26309,0.29027,1,1
2,FATTY ACID BIOSYNTHETIC PROCESS,0.0075304,0.2629,0.3088,1,1
2,BIOCARTA PML PATHWAY,0.03939,0.26195,0.16034,1,1
2,PID IL2 PI3KPATHWAY,0.00014935,0.26134,0.26253,1,1
2,REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,0.0038387,0.25972,0.15103,1,1
2,PID INTEGRIN CS PATHWAY,0.041093,0.25967,0.22855,1,1
2,REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION,0.00063551,0.25859,0.22796,1,1
2,PEPTIDYL TYROSINE PHOSPHORYLATION,0.00067758,0.25842,0.25173,1,1
2,REGULATION OF MUSCLE CONTRACTION,0.0017123,0.25794,0.20346,1,1
2,REACTOME LYSOSOME VESICLE BIOGENESIS,0.013798,0.25758,0.2076,1,1
2,REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT,0.0083534,0.25758,0.21326,1,1
2,REGULATION OF CELL ADHESION,4.3218e-05,0.25708,0.27106,1,1
2,G1 PHASE,0.00021167,0.25675,0.33841,1,1
2,REACTOME APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1,0.00095906,0.25631,0.21317,1,1
2,BIOCARTA CYTOKINE PATHWAY,7.3528e-06,0.25574,0.21687,1,1
2,PID MYC PATHWAY,0.00024286,0.25559,0.26602,1,1
2,BIOCARTA LONGEVITY PATHWAY,0.00017796,0.25441,0.31687,1,1
2,REACTOME P53 DEPENDENT G1 DNA DAMAGE RESPONSE,0.011612,0.25306,0.17323,1,1
2,AMINOPEPTIDASE ACTIVITY,0.021165,0.25262,0.18974,1,1
2,OXYGEN BINDING,0.0038387,0.24996,0.21595,1,1
2,RNA HELICASE ACTIVITY,8.1192e-05,0.24958,0.23833,1,1
2,BIOCARTA PS1 PATHWAY,0.001662,0.24946,0.21291,1,1
2,STEROID BINDING,0.00036427,0.24945,0.31964,1,1
2,CYTOKINE METABOLIC PROCESS,0.0069616,0.24907,0.14622,1,1
2,PROTEIN IMPORT,7.547e-05,0.24894,0.22135,1,1
2,RNA 3END PROCESSING,0.0033369,0.2486,0.19853,1,1
2,BIOCARTA PAR1 PATHWAY,0.0013457,0.2482,0.19615,1,1
2,PID EPOPATHWAY,0.00029782,0.2477,0.25129,1,1
2,CELL CYCLE ARREST GO 0007050,1.1964e-05,0.2469,0.21736,1,1
2,REACTOME SIGNALING BY WNT,0.00353,0.24685,0.17083,1,1
2,BIOCARTA CARM1 PATHWAY,0.013798,0.24629,0.20293,1,1
2,REACTOME PEROXISOMAL LIPID METABOLISM,0.001228,0.24551,0.23882,1,1
2,REACTOME CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION ,0.0079323,0.24546,0.1663,1,1
2,U12 DEPENDENT SPLICEOSOME,3.8583e-05,0.24515,0.24852,1,1
2,REACTOME TRANS GOLGI NETWORK VESICLE BUDDING,0.00040247,0.24503,0.22557,1,1
2,KEGG INOSITOL PHOSPHATE METABOLISM,1.4674e-06,0.24502,0.23435,1,1
2,PHOSPHOLIPASE C ACTIVITY,0.0042883,0.24471,0.19739,1,1
2,KEGG FC GAMMA R MEDIATED PHAGOCYTOSIS,0.00030804,0.24446,0.25118,1,1
2,REACTOME SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE,0.00057693,0.24439,0.2187,1,1
2,BIOCARTA EIF2 PATHWAY,0.00072223,0.24437,0.24312,1,1
2,ACTIN FILAMENT POLYMERIZATION,0.0069616,0.24352,0.2874,1,1
2,KEGG DRUG METABOLISM CYTOCHROME P450,0.00016595,0.24244,0.28039,1,1
2,PIGMENT BIOSYNTHETIC PROCESS,0.00023468,0.24217,0.27214,1,1
2,OXIDOREDUCTASE ACTIVITY,0.00026903,0.24169,0.22072,1,1
2,NUCLEAR MEMBRANE,4.1112e-06,0.24157,0.24979,1,1
2,BIOCARTA RANMS PATHWAY,0.027803,0.2412,0.15568,1,1
2,PEPTIDYL TYROSINE MODIFICATION,0.0010859,0.24015,0.22718,1,1
2,BIOCARTA ARAP PATHWAY,0.0083534,0.23979,0.13342,1,1
2,REACTOME PHASE1 FUNCTIONALIZATION OF COMPOUNDS,0.00050664,0.23588,0.23453,1,1
2,KEGG PENTOSE AND GLUCURONATE INTERCONVERSIONS,0.030383,0.23563,0.17268,1,1
2,BIOCARTA CHEMICAL PATHWAY,0.012203,0.23497,0.15777,1,1
2,SH3 SH2 ADAPTOR ACTIVITY,0.00065623,0.23435,0.21517,1,1
2,PID ECADHERIN STABILIZATION PATHWAY,0.0041716,0.23418,0.20918,1,1
2,REACTOME METABOLISM OF VITAMINS AND COFACTORS,0.00067758,0.23401,0.19835,1,1
2,REACTOME SMOOTH MUSCLE CONTRACTION,0.023205,0.23336,0.25288,1,1
2,REACTOME ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GENERATION OF SECOND MESSENGERS,0.00084609,0.23255,0.25687,1,1
2,BIOCARTA RAC1 PATHWAY,0.017969,0.23225,0.17483,1,1
2,ENDORIBONUCLEASE ACTIVITY,0.00055855,0.23125,0.26151,1,1
2,NUCLEAR IMPORT,0.00059588,0.23047,0.21702,1,1
2,RIBONUCLEOPROTEIN COMPLEX BIOGENESIS AND ASSEMBLY,0.001191,0.22897,0.19926,1,1
2,REACTOME PROCESSIVE SYNTHESIS ON THE LAGGING STRAND,0.0090226,0.2283,0.16518,1,1
2,REACTOME INFLUENZA LIFE CYCLE,0.033894,0.22763,0.19273,1,1
2,REACTOME GRB2 EVENTS IN ERBB2 SIGNALING,0.0034322,0.22736,0.15999,1,1
2,REACTOME PURINE CATABOLISM,0.042857,0.2266,0.11961,1,1
2,INTEGRATOR COMPLEX,0.0001165,0.22647,0.2018,1,1
2,TRANSFERASE ACTIVITY TRANSFERRING GROUPS OTHER THAN AMINO ACYL GROUPS,3.4421e-05,0.226,0.23418,1,1
2,SIG BCR SIGNALING PATHWAY,0.0037331,0.22563,0.19298,1,1
2,REGULATION OF TRANSLATION,0.00013917,0.22494,0.19913,1,1
2,REGULATION OF ENDOCYTOSIS,0.029719,0.2246,0.14574,1,1
2,REACTOME GOLGI ASSOCIATED VESICLE BIOGENESIS,0.00041602,0.22448,0.20211,1,1
2,REACTOME TRANSPORT OF VITAMINS NUCLEOSIDES AND RELATED MOLECULES,0.00031859,0.22384,0.25486,1,1
2,INTERFERON GAMMA PRODUCTION,0.0037331,0.22382,0.18147,1,1
2,REACTOME RNA POL I TRANSCRIPTION INITIATION,7.8282e-05,0.22349,0.23866,1,1
2,NUCLEOTIDE KINASE ACTIVITY,0.042857,0.22136,0.23562,1,1
2,ST T CELL SIGNAL TRANSDUCTION,0.0013054,0.22132,0.17622,1,1
2,TRANSITION METAL ION TRANSPORT,0.0087944,0.22096,0.16755,1,1
2,RESPONSE TO HORMONE STIMULUS,0.00050664,0.22019,0.31197,1,1
2,NEGATIVE REGULATION OF CELL CYCLE,2.5308e-05,0.21919,0.21156,1,1
2,PID WNT CANONICAL PATHWAY,5.2139e-05,0.21835,0.21502,1,1
2,REACTOME APC CDC20 MEDIATED DEGRADATION OF NEK2A,0.00025131,0.21743,0.17703,1,1
2,HISTONE DEACETYLASE BINDING,0.0094949,0.21691,0.20696,1,1
2,HELICASE ACTIVITY,8.7323e-05,0.21687,0.18543,1,1
2,KEGG APOPTOSIS,0.041967,0.21642,0.14276,1,1
2,PID IL8CXCR2 PATHWAY,0.0064317,0.21622,0.24991,1,1
2,REACTOME GLYCEROPHOSPHOLIPID BIOSYNTHESIS,0.00047456,0.21592,0.17231,1,1
2,KEGG GLYOXYLATE AND DICARBOXYLATE METABOLISM,0.007729,0.21483,0.22418,1,1
2,CELL CORTEX,0.0013054,0.21465,0.16267,1,1
2,OVULATION CYCLE,0.0016129,0.21388,0.18393,1,1
2,BIOCARTA DC PATHWAY,0.0056288,0.21376,0.14896,1,1
2,OXIDOREDUCTASE ACTIVITY GO 0016616,0.0024367,0.21246,0.21611,1,1
2,REACTOME BIOLOGICAL OXIDATIONS,0.00014418,0.2121,0.24578,1,1
2,REACTOME MEMBRANE TRAFFICKING,0.00024286,0.21197,0.18147,1,1
2,REACTOME TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD3 SMAD4 HETEROTRIMER,0.0013457,0.21177,0.22117,1,1
2,BIOCARTA FCER1 PATHWAY,0.0029794,0.21142,0.18779,1,1
2,PID P38ALPHABETADOWNSTREAMPATHWAY,0.00067758,0.21106,0.18123,1,1
2,NUCLEOBASENUCLEOSIDENUCLEOTIDE KINASE ACTIVITY,0.0045306,0.21013,0.19455,1,1
2,REACTOME REGULATION OF MITOTIC CELL CYCLE,0.0031536,0.20985,0.17639,1,1
2,PID S1P S1P1 PATHWAY,0.013139,0.20932,0.16908,1,1
2,REACTOME SCFSKP2 MEDIATED DEGRADATION OF P27 P21,0.041967,0.20929,0.11959,1,1
2,TRANSCRIPTION ELONGATION REGULATOR ACTIVITY,0.00057693,0.20925,0.18831,1,1
2,REACTOME SYNTHESIS OF PC,0.01282,0.20919,0.17045,1,1
2,CHAPERONE BINDING,0.012508,0.20814,0.18393,1,1
2,BIOCARTA CTCF PATHWAY,0.0085714,0.20795,0.21175,1,1
2,PEROXISOMAL MEMBRANE,0.0097392,0.20742,0.15449,1,1
2,MICROBODY MEMBRANE,0.0097392,0.20742,0.15449,1,1
2,KEGG ENDOCYTOSIS,0.00084609,0.20704,0.16164,1,1
2,BIOCARTA P38MAPK PATHWAY,0.001986,0.20639,0.18657,1,1
2,KEGG ARACHIDONIC ACID METABOLISM,0.001662,0.20617,0.22261,1,1
2,OXIDOREDUCTASE ACTIVITY ACTING ON CH OH GROUP OF DONORS,0.0022332,0.20604,0.21007,1,1
2,HYDROLASE ACTIVITY ACTING ON CARBON NITROGEN NOT PEPTIDEBONDSIN LINEAR AMIDES,0.0046564,0.20578,0.16682,1,1
2,BIOCARTA GCR PATHWAY,0.024288,0.20423,0.1623,1,1
2,INTERACTION WITH HOST,0.02268,0.20363,0.15784,1,1
2,REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS,0.00036427,0.20215,0.16034,1,1
2,REACTOME DOWNREGULATION OF SMAD2 3 SMAD4 TRANSCRIPTIONAL ACTIVITY,0.0021689,0.20205,0.23314,1,1
2,PID FAK PATHWAY,0.0059384,0.20197,0.1497,1,1
2,REACTOME APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B,0.0010859,0.20173,0.17001,1,1
2,REACTOME DEADENYLATION DEPENDENT MRNA DECAY,5.7413e-06,0.2011,0.21534,1,1
2,PEROXISOMAL PART,0.0013872,0.20028,0.20451,1,1
2,MICROBODY PART,0.0013872,0.20028,0.20451,1,1
2,REACTOME DEADENYLATION OF MRNA,4.8612e-06,0.20017,0.24319,1,1
2,SENSORY PERCEPTION OF CHEMICAL STIMULUS,0.046579,0.19991,0.26097,1,1
2,REACTOME PPARA ACTIVATES GENE EXPRESSION,0.00049035,0.19968,0.18128,1,1
2,REACTOME ANTIVIRAL MECHANISM BY IFN STIMULATED GENES,0.0040578,0.1992,0.14214,1,1
2,CARBOXYLIC ACID METABOLIC PROCESS,0.00019753,0.199,0.21249,1,1
2,REACTOME PHOSPHORYLATION OF THE APC C,0.0017641,0.19895,0.1648,1,1
2,REGULATION OF RAS GTPASE ACTIVITY,0.00059588,0.19873,0.16779,1,1
2,BIOCARTA UCALPAIN PATHWAY,0.012508,0.1981,0.14773,1,1
2,PEPTIDYL AMINO ACID MODIFICATION,6.0504e-05,0.19739,0.17354,1,1
2,KEGG NON SMALL CELL LUNG CANCER,0.00050664,0.1972,0.16552,1,1
2,ANTI APOPTOSIS,0.00050664,0.19633,0.18405,1,1
2,PROTEASOME COMPLEX,0.011047,0.19628,0.20668,1,1
2,NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID TRANSPORT,3.1888e-05,0.19576,0.17701,1,1
2,LIGASE ACTIVITY,1.1493e-05,0.1956,0.19763,1,1
2,NUCLEAR MEMBRANE PART,5.7413e-06,0.19457,0.23794,1,1
2,POSITIVE REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS,0.00019753,0.19456,0.18446,1,1
2,KEGG SMALL CELL LUNG CANCER,0.0051916,0.19402,0.2135,1,1
2,VIRAL GENOME REPLICATION,0.046579,0.19335,0.1134,1,1
2,REACTOME MRNA SPLICING MINOR PATHWAY,0.0013054,0.19334,0.16229,1,1
2,ORGANIC ACID METABOLIC PROCESS,0.0001547,0.19318,0.21662,1,1
2,PID KITPATHWAY,0.0075304,0.19227,0.15692,1,1
2,REACTOME PKB MEDIATED EVENTS,0.00057693,0.19214,0.18177,1,1
2,MAINTENANCE OF CELLULAR LOCALIZATION,0.027188,0.19207,0.15405,1,1
2,PID CD8TCRPATHWAY,0.02068,0.19202,0.13999,1,1
2,REACTOME METABOLISM OF RNA,0.0017123,0.19168,0.19289,1,1
2,KEGG PRIMARY IMMUNODEFICIENCY,0.02268,0.19105,0.1337,1,1
2,NUCLEAR TRANSPORT,0.00017186,0.18982,0.19257,1,1
2,BIOCARTA CELL2CELL PATHWAY,0.011904,0.18948,0.20118,1,1
2,RNA SPLICING FACTOR ACTIVITYTRANSESTERIFICATION MECHANISM,0.0036303,0.18938,0.16613,1,1
2,PHOSPHOTRANSFERASE ACTIVITY PHOSPHATE GROUP AS ACCEPTOR,0.015203,0.18905,0.25004,1,1
2,REACTOME SIGNALING BY RHO GTPASES,0.0053338,0.18867,0.13198,1,1
2,KEGG CYSTEINE AND METHIONINE METABOLISM,0.0027346,0.18821,0.18968,1,1
2,PID CERAMIDE PATHWAY,0.0047853,0.18814,0.15566,1,1
2,BIOCARTA CERAMIDE PATHWAY,0.046579,0.18813,0.15919,1,1
2,POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS,0.0001547,0.18759,0.18055,1,1
2,REACTOME DESTABILIZATION OF MRNA BY BRF1,0.0037331,0.18717,0.19839,1,1
2,NUCLEAR PORE,1.0184e-05,0.18715,0.24693,1,1
2,MEMBRANE FUSION,0.0012662,0.18672,0.22856,1,1
2,VITAMIN METABOLIC PROCESS,0.0020453,0.18657,0.25272,1,1
2,VESICLE MEMBRANE,0.0031536,0.18549,0.14508,1,1
2,SOLUTE SODIUM SYMPORTER ACTIVITY,0.015203,0.18537,0.22894,1,1
2,REACTOME RNA POL III TRANSCRIPTION INITIATION FROM TYPE 2 PROMOTER,0.004408,0.18536,0.14068,1,1
2,DNA HELICASE ACTIVITY,0.00012512,0.18526,0.19151,1,1
2,REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION,0.0031536,0.18483,0.13907,1,1
2,MOLECULAR ADAPTOR ACTIVITY,0.0023671,0.18481,0.18904,1,1
2,REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM,0.00030804,0.1842,0.14805,1,1
2,REGULATION OF PROTEIN METABOLIC PROCESS,0.00038934,0.18315,0.14969,1,1
2,REACTOME TCR SIGNALING,0.00092958,0.18311,0.14337,1,1
2,DNA POLYMERASE ACTIVITY,0.00041602,0.18306,0.1767,1,1
2,PID RXR VDR PATHWAY,0.017969,0.18303,0.153,1,1
2,INTERPHASE OF MITOTIC CELL CYCLE,0.0010206,0.18285,0.14823,1,1
2,JAK STAT CASCADE,0.0085714,0.1826,0.17906,1,1
2,PORE COMPLEX,2.1663e-05,0.18253,0.23159,1,1
2,REACTOME IL1 SIGNALING,0.00045924,0.18251,0.19359,1,1
2,CELL SUBSTRATE ADHERENS JUNCTION,0.015203,0.18234,0.22489,1,1
2,BIOCARTA SARS PATHWAY,0.02166,0.18193,0.17807,1,1
2,ORGANELLE MEMBRANE,0.0001165,0.18176,0.13941,1,1
2,NUCLEOCYTOPLASMIC TRANSPORT,0.00018427,0.18058,0.19175,1,1
2,REACTOME HOST INTERACTIONS OF HIV FACTORS,0.00026003,0.18004,0.1729,1,1
2,PID AR PATHWAY,0.00353,0.17984,0.20705,1,1
2,KEGG PHOSPHATIDYLINOSITOL SIGNALING SYSTEM,0.00028792,0.17928,0.17508,1,1
2,DNA REPLICATION INITIATION,0.00067758,0.17879,0.19419,1,1
2,ENDOPLASMIC RETICULUM PART,0.001872,0.17879,0.15127,1,1
2,REGULATION OF PH,0.036164,0.17681,0.15229,1,1
2,REACTOME OXYGEN DEPENDENT PROLINE HYDROXYLATION OF HYPOXIA INDUCIBLE FACTOR ALPHA,0.010773,0.17593,0.18124,1,1
2,BIOCARTA VIP PATHWAY,0.017549,0.17564,0.13834,1,1
2,BIOCARTA GH PATHWAY,0.0046564,0.17468,0.15816,1,1
2,POSITIVE REGULATION OF TRANSLATION,0.0015653,0.17451,0.14131,1,1
2,PROTEIN AMINO ACID ADP RIBOSYLATION,0.00018427,0.17441,0.25788,1,1
2,NUCLEAR ENVELOPE,2.4346e-05,0.17334,0.17088,1,1
2,VIRAL REPRODUCTIVE PROCESS,0.0064317,0.17302,0.13208,1,1
2,PROTEIN TARGETING,0.0017641,0.17273,0.14382,1,1
2,ORGANELLE ENVELOPE,4.4878e-05,0.17253,0.16437,1,1
2,ENVELOPE,4.4878e-05,0.17253,0.16437,1,1
2,KEGG NON HOMOLOGOUS END JOINING,0.03939,0.17196,0.13246,1,1
2,DOUBLE STRANDED RNA BINDING,0.00028792,0.17185,0.19646,1,1
2,DEFENSE RESPONSE TO BACTERIUM,0.00020448,0.17154,0.18756,1,1
2,REACTOME RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES,0.017137,0.17117,0.10973,1,1
2,LIGASE ACTIVITY FORMING CARBON NITROGEN BONDS,2.7343e-05,0.17059,0.14933,1,1
2,AROMATIC COMPOUND METABOLIC PROCESS,0.010245,0.16998,0.14484,1,1
2,BASAL LAMINA,0.02843,0.16967,0.24547,1,1
2,REACTOME TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX,0.0099891,0.16937,0.11606,1,1
2,PROTEIN RNA COMPLEX ASSEMBLY,0.0049174,0.16907,0.16927,1,1
2,TRANSFERASE ACTIVITY TRANSFERRING ACYL GROUPS,0.00026903,0.16905,0.20177,1,1
2,REACTOME INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS,0.00031859,0.1687,0.16984,1,1
2,REACTOME RAF MAP KINASE CASCADE,0.012508,0.16828,0.11525,1,1
2,PID VEGFR1 2 PATHWAY,0.004408,0.16779,0.12543,1,1
2,POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,0.0013054,0.16756,0.21103,1,1
2,ACTIVATION OF NF KAPPAB TRANSCRIPTION FACTOR,0.0045306,0.16724,0.15435,1,1
2,REACTOME MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE,0.00040247,0.16687,0.18479,1,1
2,KEGG FC EPSILON RI SIGNALING PATHWAY,0.0038387,0.16683,0.19673,1,1
2,PID ECADHERIN NASCENTAJ PATHWAY,0.043763,0.16662,0.14384,1,1
2,RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY,0.0016129,0.16586,0.13231,1,1
2,NUCLEAR HORMONE RECEPTOR BINDING,0.0010859,0.16526,0.12471,1,1
2,REACTOME INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS,0.00074557,0.16426,0.17159,1,1
2,AMINO ACID CATABOLIC PROCESS,0.040234,0.16414,0.12557,1,1
2,REACTOME FATTY ACYL COA BIOSYNTHESIS,0.024846,0.16398,0.1927,1,1
2,ENDOMEMBRANE SYSTEM,0.00021167,0.16397,0.13467,1,1
2,ER TO GOLGI VESICLE MEDIATED TRANSPORT,0.02268,0.16314,0.10313,1,1
2,REACTOME SIGNALING BY THE B CELL RECEPTOR BCR,0.0033369,0.16306,0.13085,1,1
2,REACTOME HIV LIFE CYCLE,0.00095906,0.16281,0.12612,1,1
2,ANDROGEN RECEPTOR SIGNALING PATHWAY,0.0010528,0.16264,0.19283,1,1
2,NEGATIVE REGULATION OF CELL ADHESION,0.012203,0.16236,0.22667,1,1
2,SPLICEOSOME,0.00019079,0.16207,0.19016,1,1
2,REACTOME SIGNALING BY TGF BETA RECEPTOR COMPLEX,0.00044439,0.16197,0.18902,1,1
2,NITROGEN COMPOUND CATABOLIC PROCESS,0.026586,0.16183,0.14776,1,1
2,REACTOME S PHASE,0.0053338,0.16181,0.14456,1,1
2,KEGG PEROXISOME,0.0017123,0.16172,0.16545,1,1
2,KEGG B CELL RECEPTOR SIGNALING PATHWAY,0.00087311,0.16125,0.18043,1,1
2,KEGG HOMOLOGOUS RECOMBINATION,0.0010528,0.16058,0.16149,1,1
2,REACTOME METABOLISM OF AMINO ACIDS AND DERIVATIVES,0.00026003,0.15989,0.15989,1,1
2,REACTOME M G1 TRANSITION,0.0071468,0.15952,0.14605,1,1
2,REACTOME TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM,0.00031859,0.15929,0.18729,1,1
2,KEGG BASE EXCISION REPAIR,0.0053338,0.15868,0.14592,1,1
2,TRANSFERASE ACTIVITY TRANSFERRING ONE CARBON GROUPS,0.00069957,0.15845,0.15416,1,1
2,RNA SPLICINGVIA TRANSESTERIFICATION REACTIONS,0.0087944,0.15787,0.11265,1,1
2,BIOCARTA ATRBRCA PATHWAY,0.031059,0.15784,0.13918,1,1
2,RAS GTPASE BINDING,0.00074557,0.15734,0.16124,1,1
2,KEGG PPAR SIGNALING PATHWAY,0.018836,0.15726,0.12106,1,1
2,REACTOME DESTABILIZATION OF MRNA BY TRISTETRAPROLIN TTP,0.0025817,0.15684,0.17958,1,1
2,KEGG VEGF SIGNALING PATHWAY,0.00081984,0.15668,0.15616,1,1
2,INDUCTION OF APOPTOSIS BY EXTRACELLULAR SIGNALS,0.017549,0.15638,0.093829,1,1
2,ANTIGEN BINDING,0.010245,0.15585,0.14159,1,1
2,CYTOKINE AND CHEMOKINE MEDIATED SIGNALING PATHWAY,0.041967,0.15581,0.12807,1,1
2,BIOCARTA INTEGRIN PATHWAY,0.009256,0.15576,0.10565,1,1
2,REACTOME FORMATION OF RNA POL II ELONGATION COMPLEX ,0.0022992,0.1553,0.099335,1,1
2,PID RAC1 PATHWAY,0.0047853,0.15503,0.15006,1,1
2,SMALL GTPASE BINDING,0.0014299,0.1545,0.14107,1,1
2,KEGG GLYCEROPHOSPHOLIPID METABOLISM,0.00084609,0.15441,0.15119,1,1
2,POSITIVE REGULATION OF TRANSCRIPTIONDNA DEPENDENT,0.00069957,0.15414,0.17348,1,1
2,REACTOME LATE PHASE OF HIV LIFE CYCLE,5.6174e-05,0.15374,0.15247,1,1
2,REACTOME RNA POL II TRANSCRIPTION PRE INITIATION AND PROMOTER OPENING,0.00095906,0.15359,0.13413,1,1
2,REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS,0.00087311,0.15353,0.12772,1,1
2,HORMONE RECEPTOR BINDING,0.00090094,0.15344,0.13272,1,1
2,REACTOME ADAPTIVE IMMUNE SYSTEM,0.0039469,0.15317,0.10185,1,1
2,DNA DIRECTED DNA POLYMERASE ACTIVITY,0.00074557,0.15285,0.1614,1,1
2,REACTOME TRANSPORT OF RIBONUCLEOPROTEINS INTO THE HOST NUCLEUS,0.00018427,0.15164,0.21464,1,1
2,PID TELOMERASEPATHWAY,0.00035231,0.1516,0.15966,1,1
2,BIOCARTA AKAP95 PATHWAY,0.038561,0.15157,0.16002,1,1
2,KEGG SPLICEOSOME,0.001662,0.15144,0.15182,1,1
2,REGULATION OF CELL MIGRATION,0.038561,0.15062,0.2021,1,1
2,PID NFKAPPABCANONICALPATHWAY,0.0066042,0.15022,0.17105,1,1
2,BIOCARTA BARRESTIN SRC PATHWAY,0.00098941,0.14999,0.25427,1,1
2,REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION,0.0079323,0.1497,0.14384,1,1
2,GLUCOSAMINE METABOLIC PROCESS,0.044685,0.1494,0.10262,1,1
2,TRANSCRIPTION FACTOR COMPLEX,0.00095906,0.14931,0.12428,1,1
2,ENDOPLASMIC RETICULUM MEMBRANE,0.011612,0.14864,0.11856,1,1
2,KEGG ADHERENS JUNCTION,0.017969,0.14773,0.14494,1,1
2,LIPID METABOLIC PROCESS,0.0046564,0.14744,0.12198,1,1
2,ACID AMINO ACID LIGASE ACTIVITY,0.00090094,0.14736,0.1271,1,1
2,REACTOME REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN,0.001191,0.14734,0.16698,1,1
2,PROTEIN N TERMINUS BINDING,6.4994e-06,0.14732,0.19807,1,1
2,RESPONSE TO BACTERIUM,0.00010092,0.14725,0.15497,1,1
2,REACTOME MRNA PROCESSING,0.00010462,0.14693,0.17065,1,1
2,REACTOME GLUCOSE TRANSPORT,0.0022992,0.14685,0.13429,1,1
2,STEROID HORMONE RECEPTOR BINDING,0.045624,0.14661,0.14492,1,1
2,REGULATION OF RHO GTPASE ACTIVITY,0.004408,0.14578,0.13786,1,1
2,POSITIVE REGULATION OF RNA METABOLIC PROCESS,0.00079435,0.14574,0.17003,1,1
2,CYTOPLASMIC VESICLE MEMBRANE,0.0099891,0.1457,0.11751,1,1
2,CYTOPLASMIC VESICLE PART,0.0099891,0.1457,0.11751,1,1
2,NUCLEAR ENVELOPE ENDOPLASMIC RETICULUM NETWORK,0.0036303,0.1453,0.1298,1,1
2,BIOCARTA MAL PATHWAY,0.014486,0.14472,0.086584,1,1
2,INTRACELLULAR PROTEIN TRANSPORT,0.0022332,0.14417,0.12432,1,1
2,REACTOME IMMUNE SYSTEM,0.0087944,0.14367,0.094159,1,1
2,DNA RECOMBINATION,0.00055855,0.14362,0.17207,1,1
2,RNA BINDING,0.0015189,0.1436,0.14562,1,1
2,PROTEIN HETERODIMERIZATION ACTIVITY,0.0020453,0.1433,0.1305,1,1
2,HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN COMPLEX,0.041093,0.1431,0.1241,1,1
2,POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,0.0094949,0.14259,0.11725,1,1
2,REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA,0.00054072,0.14257,0.16241,1,1
2,REACTOME TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRONLESS TRANSCRIPT,0.00021909,0.14189,0.20037,1,1
2,ST B CELL ANTIGEN RECEPTOR,0.0036303,0.14146,0.17204,1,1
2,REACTOME SHC1 EVENTS IN ERBB4 SIGNALING,0.0045306,0.14087,0.14656,1,1
2,MEDIATOR COMPLEX,0.0029794,0.14043,0.13167,1,1
2,NUCLEOTIDE EXCISION REPAIR,0.0050528,0.1385,0.1191,1,1
2,REACTOME FORMATION OF TRANSCRIPTION COUPLED NER TC NER REPAIR COMPLEX,0.001872,0.13819,0.13481,1,1
2,REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION,0.0030654,0.1381,0.12474,1,1
2,REACTOME RNA POL II PRE TRANSCRIPTION EVENTS,0.001662,0.1379,0.11382,1,1
2,GTPASE BINDING,0.0018173,0.13728,0.1357,1,1
2,REACTOME P75 NTR RECEPTOR MEDIATED SIGNALLING,0.0079323,0.13614,0.10945,1,1
2,RNA EXPORT FROM NUCLEUS,0.00050664,0.1357,0.14342,1,1
2,BIOCARTA EDG1 PATHWAY,0.0067808,0.13538,0.14188,1,1
2,REGULATION OF GENE EXPRESSION,0.00098941,0.13525,0.10438,1,1
2,REACTOME CONVERSION FROM APC C CDC20 TO APC C CDH1 IN LATE ANAPHASE,0.00098941,0.13524,0.16227,1,1
2,REACTOME MRNA 3 END PROCESSING,0.0079323,0.13471,0.15027,1,1
2,RNA POLYMERASE II TRANSCRIPTION MEDIATOR ACTIVITY,0.001872,0.13399,0.16961,1,1
2,BIOCARTA BARR MAPK PATHWAY,0.014841,0.13391,0.16677,1,1
2,REACTOME PROCESSING OF INTRONLESS PRE MRNAS,0.024288,0.13368,0.12166,1,1
2,PID FOXM1PATHWAY,0.024846,0.13368,0.14169,1,1
2,GOLGI VESICLE TRANSPORT,0.0041716,0.13302,0.1411,1,1
2,SUGAR BINDING,0.00090094,0.13186,0.1737,1,1
2,REGULATION OF RNA METABOLIC PROCESS,0.00040247,0.13133,0.11698,1,1
2,BIOCARTA EIF4 PATHWAY,0.015574,0.1313,0.11032,1,1
2,REACTOME PHOSPHOLIPID METABOLISM,0.0047853,0.13127,0.10117,1,1
2,HOMEOSTASIS OF NUMBER OF CELLS,0.015574,0.13114,0.14436,1,1
2,SMALL PROTEIN CONJUGATING ENZYME ACTIVITY,0.0099891,0.13086,0.093407,1,1
2,BIOCARTA HCMV PATHWAY,0.0064317,0.1307,0.14859,1,1
2,DNA DIRECTED RNA POLYMERASEII HOLOENZYME,1.7474e-06,0.13053,0.14891,1,1
2,POSITIVE REGULATION OF CELLULAR METABOLIC PROCESS,0.00095906,0.12956,0.13135,1,1
2,METHYLTRANSFERASE ACTIVITY,0.00084609,0.12934,0.13562,1,1
2,REACTOME HIV INFECTION,0.00026903,0.12877,0.14318,1,1
2,REACTOME NOD1 2 SIGNALING PATHWAY,0.016339,0.12861,0.14029,1,1
2,REACTOME DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BCR,0.029068,0.12853,0.091126,1,1
2,REACTOME SOS MEDIATED SIGNALLING,0.012508,0.12784,0.10933,1,1
2,REGULATION OF TRANSCRIPTIONDNA DEPENDENT,0.00044439,0.12769,0.11465,1,1
2,POSITIVE REGULATION OF METABOLIC PROCESS,0.00087311,0.12759,0.12825,1,1
2,REACTOME ENDOSOMAL SORTING COMPLEX REQUIRED FOR TRANSPORT ESCRT,0.026586,0.1274,0.12462,1,1
2,RIBONUCLEOPROTEIN COMPLEX,0.00021167,0.12717,0.15342,1,1
2,REACTOME TRANSCRIPTION COUPLED NER TC NER,0.0056288,0.12663,0.098781,1,1
2,PID DNAPK PATHWAY,0.030383,0.12557,0.1047,1,1
2,REGULATION OF LYMPHOCYTE ACTIVATION,0.017969,0.12539,0.098861,1,1
2,KEGG RNA DEGRADATION,0.00026003,0.12527,0.165,1,1
2,REACTOME MRNA CAPPING,0.0062634,0.12525,0.10077,1,1
2,PID HIF1APATHWAY,0.02166,0.12304,0.16822,1,1
2,REGULATION OF CATABOLIC PROCESS,0.0051916,0.12266,0.13013,1,1
2,BIOCARTA FMLP PATHWAY,0.0022992,0.12241,0.119,1,1
2,REACTOME PI METABOLISM,0.0019282,0.12239,0.13697,1,1
2,GENERAL RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY,0.0021062,0.12236,0.12091,1,1
2,REGULATION OF CELLULAR METABOLIC PROCESS,0.0011199,0.12148,0.099162,1,1
2,KEGG ENDOMETRIAL CANCER,0.037747,0.12143,0.11791,1,1
2,REACTOME RNA POL II TRANSCRIPTION,0.0011199,0.1211,0.12797,1,1
2,REACTOME NEGATIVE REGULATION OF FGFR SIGNALING,0.014486,0.12074,0.1277,1,1
2,DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS,0.02268,0.12003,0.15266,1,1
2,REACTOME REMOVAL OF THE FLAP INTERMEDIATE FROM THE C STRAND,0.0040578,0.11987,0.18598,1,1
2,REACTOME PROCESSING OF CAPPED INTRONLESS PRE MRNA,0.0090226,0.11976,0.11592,1,1
2,REACTOME MRNA SPLICING,0.0012662,0.11909,0.14722,1,1
2,REGULATION OF METABOLIC PROCESS,0.0015189,0.11853,0.097151,1,1
2,RNA PROCESSING,0.0013457,0.11838,0.13548,1,1
2,KEGG RNA POLYMERASE,0.045624,0.11792,0.10898,1,1
2,ENDOPLASMIC RETICULUM,0.034637,0.11771,0.073261,1,1
2,ORGANELLE LUMEN,4.1617e-05,0.11697,0.12473,1,1
2,MEMBRANE ENCLOSED LUMEN,4.1617e-05,0.11697,0.12473,1,1
2,SMALL CONJUGATING PROTEIN LIGASE ACTIVITY,0.02166,0.11693,0.081768,1,1
2,PROTEIN TRANSPORT,0.0042883,0.11543,0.10749,1,1
2,MITOTIC CELL CYCLE,0.012203,0.11506,0.10056,1,1
2,RNA SPLICING,0.00041602,0.11498,0.14775,1,1
2,MUSCLE DEVELOPMENT,0.026586,0.11475,0.10827,1,1
2,UBIQUITIN PROTEIN LIGASE ACTIVITY,0.023205,0.11342,0.07781,1,1
2,MACROMOLECULAR COMPLEX ASSEMBLY,0.0029794,0.11229,0.091149,1,1
2,PID P53REGULATIONPATHWAY,0.0011199,0.10907,0.11676,1,1
2,PERINUCLEAR REGION OF CYTOPLASM,0.0056288,0.10901,0.12948,1,1
2,PID FCER1PATHWAY,0.011612,0.10843,0.12558,1,1
2,CYTOSOL,0.012508,0.10662,0.093441,1,1
2,RECEPTOR MEDIATED ENDOCYTOSIS,0.027803,0.10606,0.098466,1,1
2,ENZYME ACTIVATOR ACTIVITY,0.001986,0.10576,0.14379,1,1
2,HISTONE DEACETYLASE COMPLEX,0.016734,0.10441,0.11934,1,1
2,REACTOME GLOBAL GENOMIC NER GG NER,0.011904,0.10438,0.086063,1,1
2,NUCLEAR EXPORT,0.0051916,0.10403,0.11312,1,1
2,GOLGI ASSOCIATED VESICLE,0.027188,0.10388,0.12081,1,1
2,REGULATION OF TRANSCRIPTION,0.0069616,0.10351,0.093351,1,1
2,ADENYL NUCLEOTIDE BINDING,0.0081404,0.10347,0.081501,1,1
2,PID HDAC CLASSI PATHWAY,0.0025083,0.10282,0.09425,1,1
2,REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,0.011612,0.10263,0.089164,1,1
2,INTRACELLULAR TRANSPORT,0.00022676,0.1026,0.12038,1,1
2,THYROID HORMONE RECEPTOR BINDING,0.018398,0.10178,0.12617,1,1
2,DNA INTEGRITY CHECKPOINT,0.016339,0.10171,0.11639,1,1
2,CELL CYCLE GO 0007049,0.0014738,0.10148,0.10071,1,1
2,PROTEIN METABOLIC PROCESS,0.010506,0.10133,0.076096,1,1
2,POSITIVE REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,0.024288,0.10124,0.11199,1,1
2,INTERPHASE,0.0073363,0.10101,0.11517,1,1
2,NUCLEAR PART,0.00013433,0.099583,0.10998,1,1
2,PID RB 1PATHWAY,0.041093,0.099448,0.089133,1,1
2,REGULATION OF CELL CYCLE,0.00012964,0.09932,0.13521,1,1
2,RNA METABOLIC PROCESS,9.7346e-05,0.099311,0.10902,1,1
2,ST GA12 PATHWAY,0.03939,0.09929,0.11885,1,1
2,CELLULAR PROTEIN CATABOLIC PROCESS,0.0097392,0.099242,0.10889,1,1
2,REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,0.0045306,0.099194,0.090505,1,1
2,ACETYLTRANSFERASE ACTIVITY,0.0045306,0.098967,0.14673,1,1
2,PID PDGFRBPATHWAY,0.015953,0.098628,0.092868,1,1
2,RNA BIOSYNTHETIC PROCESS,0.0021062,0.098513,0.098984,1,1
2,REACTOME SIGNALING BY FGFR MUTANTS,0.015953,0.09794,0.14814,1,1
2,POSITIVE REGULATION OF DNA BINDING,0.045624,0.097578,0.089378,1,1
2,CERAMIDE METABOLIC PROCESS,0.010773,0.097341,0.1409,1,1
2,TRANSCRIPTION DNA DEPENDENT,0.0021689,0.097251,0.09864,1,1
2,CARBOHYDRATE BINDING,0.027188,0.097181,0.10667,1,1
2,REACTOME FORMATION OF INCISION COMPLEX IN GG NER,0.014138,0.096754,0.10857,1,1
2,CELLULAR COMPONENT ASSEMBLY,0.00353,0.096455,0.09067,1,1
2,DI   TRI VALENT INORGANIC CATION TRANSMEMBRANE TRANSPORTER ACTIVITY,0.03939,0.096429,0.11512,1,1
2,CELLULAR PROTEIN METABOLIC PROCESS,0.009256,0.095363,0.074585,1,1
2,REACTOME CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION ,0.0039469,0.095095,0.141,1,1
2,REACTOME SPRY REGULATION OF FGF SIGNALING,0.0025083,0.094391,0.18044,1,1
2,NUCLEOPLASM PART,0.0001547,0.093239,0.10152,1,1
2,REACTOME INSULIN RECEPTOR SIGNALLING CASCADE,0.0099891,0.092307,0.083177,1,1
2,KEGG NUCLEOTIDE EXCISION REPAIR,0.027803,0.089399,0.075197,1,1
2,ORGANELLE PART,0.00030804,0.08887,0.084322,1,1
2,INTRACELLULAR ORGANELLE PART,0.00027832,0.088842,0.084986,1,1
2,ADENYL RIBONUCLEOTIDE BINDING,0.0099891,0.08835,0.080798,1,1
2,CELLULAR MACROMOLECULE METABOLIC PROCESS,0.010506,0.088236,0.071742,1,1
2,ATP BINDING,0.03939,0.087686,0.060607,1,1
2,KEGG ERBB SIGNALING PATHWAY,0.0083534,0.086588,0.10574,1,1
2,KEGG BASAL TRANSCRIPTION FACTORS,0.0024367,0.086511,0.13709,1,1
2,PID PS1PATHWAY,0.022165,0.086444,0.095573,1,1
2,REACTOME ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION,0.0053338,0.085481,0.090614,1,1
2,MACROMOLECULE LOCALIZATION,0.033166,0.085243,0.071843,1,1
2,TRANSCRIPTION,0.010773,0.084646,0.083103,1,1
2,MRNA METABOLIC PROCESS,0.017137,0.083271,0.098341,1,1
2,RHYTHMIC PROCESS,0.043763,0.081643,0.066124,1,1
2,CHROMATIN REMODELING,0.025994,0.08123,0.13708,1,1
2,NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS,0.00057693,0.080344,0.08839,1,1
2,PROTEIN CATABOLIC PROCESS,0.0029794,0.079992,0.11056,1,1
2,TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER,0.018836,0.078898,0.077769,1,1
2,BIOPOLYMER METABOLIC PROCESS,0.0007696,0.077304,0.079824,1,1
2,INTRACELLULAR RECEPTOR MEDIATED SIGNALING PATHWAY,0.0017641,0.076867,0.14051,1,1
2,CELL CYCLE PHASE,0.02843,0.075843,0.080156,1,1
2,STEROID HORMONE RECEPTOR SIGNALING PATHWAY,0.0014738,0.071676,0.14984,1,1
2,NUCLEOPLASM,0.00095906,0.071336,0.091347,1,1
2,PID ANGIOPOIETINRECEPTOR PATHWAY,0.022165,0.069294,0.13162,1,1
2,PURINE RIBONUCLEOTIDE BINDING,0.044685,0.068427,0.058098,1,1
2,ESTABLISHMENT AND OR MAINTENANCE OF CHROMATIN ARCHITECTURE,0.043763,0.067487,0.074667,1,1
2,NUCLEUS,0.00090094,0.067417,0.078782,1,1
2,ORGANELLE ORGANIZATION AND BIOGENESIS,0.017549,0.067029,0.061768,1,1
2,PURINE NUCLEOTIDE BINDING,0.042857,0.063343,0.059351,1,1
2,PID MET PATHWAY,0.03939,0.061223,0.090812,1,1
2,CHROMATIN MODIFICATION,0.036164,0.061223,0.064436,1,1
2,RESPONSE TO ENDOGENOUS STIMULUS,0.024846,0.051901,0.079415,1,1
3,INWARD RECTIFIER POTASSIUM CHANNEL ACTIVITY,5.1671e-08,1.1507,1.1105,1,1
3,REACTOME GABA A RECEPTOR ACTIVATION,3.1904e-06,1.0322,0.91935,1,1
3,NICOTINIC ACETYLCHOLINE GATED RECEPTOR CHANNEL COMPLEX,3.9418e-06,0.8507,0.83133,1,1
3,NICOTINIC ACETYLCHOLINE ACTIVATED CATION SELECTIVE CHANNEL ACTIVITY,3.9418e-06,0.8507,0.83133,1,1
3,REACTOME PRESYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS,2.1663e-05,0.83024,0.76691,1,1
3,ANCHORED TO MEMBRANE,4.1112e-06,0.75566,0.65851,1,1
3,ANCHORED TO PLASMA MEMBRANE,4.1112e-06,0.75566,0.65851,1,1
3,3 5 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY,2.0833e-05,0.7335,0.67739,1,1
3,REACTOME HIGHLY CALCIUM PERMEABLE POSTSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS,8.3127e-06,0.72903,0.74257,1,1
3,GABA RECEPTOR ACTIVITY,7.5427e-07,0.72894,0.70688,1,1
3,REACTOME PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS,7.013e-05,0.68154,0.52636,1,1
3,CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY,2.0033e-05,0.6678,0.62209,1,1
3,REACTOME ACETYLCHOLINE BINDING AND DOWNSTREAM EVENTS,1.2962e-05,0.65925,0.65732,1,1
3,SIALYLTRANSFERASE ACTIVITY,0.0010859,0.62299,0.54314,1,1
3,EXCITATORY EXTRACELLULAR LIGAND GATED ION CHANNEL ACTIVITY,2.8418e-05,0.5475,0.50622,1,1
3,GLUTAMATE SIGNALING PATHWAY,1.349e-05,0.51275,0.50403,1,1
3,REACTOME LIGAND GATED ION CHANNEL TRANSPORT,0.00010092,0.51129,0.46348,1,1
3,REACTOME PEPTIDE CHAIN ELONGATION,0.0041716,0.49802,0.46591,1,1
3,KEGG RIBOSOME,0.0039469,0.49602,0.45458,1,1
3,INORGANIC ANION TRANSMEMBRANE TRANSPORTER ACTIVITY,7.3528e-06,0.49102,0.38655,1,1
3,STRUCTURAL CONSTITUENT OF RIBOSOME,0.0034322,0.48081,0.44148,1,1
3,REACTOME INHIBITION OF VOLTAGE GATED CA2 CHANNELS VIA GBETA GAMMA SUBUNITS,1.9263e-05,0.48053,0.49694,1,1
3,REACTOME INWARDLY RECTIFYING K CHANNELS,3.5759e-05,0.47661,0.43879,1,1
3,MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION,4.2876e-06,0.47541,0.4858,1,1
3,BIOCARTA NO1 PATHWAY,9.0179e-06,0.46034,0.39123,1,1
3,REACTOME ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S,0.0033369,0.45444,0.39615,1,1
3,REACTOME INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION,0.00353,0.44972,0.40435,1,1
3,REACTOME FORMATION OF THE TERNARY COMPLEX AND SUBSEQUENTLY THE 43S COMPLEX,0.0028141,0.44779,0.41784,1,1
3,REACTOME 3 UTR MEDIATED TRANSLATIONAL REGULATION,0.0045306,0.44187,0.43022,1,1
3,COFACTOR TRANSPORTER ACTIVITY,0.0075304,0.43796,0.34399,1,1
3,EXTRACELLULAR LIGAND GATED ION CHANNEL ACTIVITY,0.00016023,0.42832,0.42653,1,1
3,REACTOME GABA RECEPTOR ACTIVATION,1.4674e-06,0.40825,0.40776,1,1
3,RHO GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY,2.5308e-05,0.40663,0.42283,1,1
3,VOLTAGE GATED POTASSIUM CHANNEL ACTIVITY,3.4421e-05,0.40076,0.46851,1,1
3,POSITIVE REGULATION OF CYTOSKELETON ORGANIZATION AND BIOGENESIS,0.00037661,0.38614,0.32668,1,1
3,CARBOHYDRATE KINASE ACTIVITY,0.00013917,0.38317,0.32561,1,1
3,REACTOME GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE,0.00012964,0.37875,0.44895,1,1
3,REACTOME REGULATION OF GENE EXPRESSION IN BETA CELLS,0.00038934,0.37345,0.42166,1,1
3,PROTEOGLYCAN BIOSYNTHETIC PROCESS,0.0001547,0.36786,0.3513,1,1
3,REACTOME FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC,2.6307e-05,0.36769,0.3805,1,1
3,REACTOME SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE,0.01282,0.36751,0.32406,1,1
3,REACTOME INFLUENZA LIFE CYCLE,0.0022992,0.36743,0.32939,1,1
3,PROTEIN TARGETING TO MITOCHONDRION,0.00057693,0.36671,0.32632,1,1
3,NEUROTRANSMITTER RECEPTOR ACTIVITY,8.4205e-05,0.3621,0.29515,1,1
3,PROTEIN POLYMERIZATION,5.0683e-06,0.35716,0.36378,1,1
3,NEUROTRANSMITTER BINDING,5.6174e-05,0.35595,0.29214,1,1
3,DEVELOPMENTAL GROWTH,0.00018427,0.35272,0.35889,1,1
3,GENERATION OF NEURONS,1.6455e-05,0.3517,0.3352,1,1
3,TRANSLATION INITIATION FACTOR ACTIVITY,0.00030804,0.34795,0.323,1,1
3,LIGASE ACTIVITY FORMING CARBON OXYGEN BONDS,0.0027346,0.34666,0.33277,1,1
3,CYTOCHROME C OXIDASE ACTIVITY,0.0017641,0.34272,0.25505,1,1
3,REACTOME TRANSLATION,0.0073363,0.34223,0.32018,1,1
3,REACTOME ASSOCIATION OF LICENSING FACTORS WITH THE PRE REPLICATIVE COMPLEX,9.0179e-06,0.34134,0.32816,1,1
3,REACTOME PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC,4.6597e-05,0.33966,0.31472,1,1
3,REACTOME NONSENSE MEDIATED DECAY ENHANCED BY THE EXON JUNCTION COMPLEX,0.0056288,0.33655,0.35678,1,1
3,RESPONSE TO TEMPERATURE STIMULUS,0.0014299,0.33387,0.23909,1,1
3,PID MYC PATHWAY,0.0083534,0.33355,0.21495,1,1
3,SYNAPSE ORGANIZATION AND BIOGENESIS,0.0028957,0.33198,0.28951,1,1
3,REACTOME RAS ACTIVATION UOPN CA2 INFUX THROUGH NMDA RECEPTOR,0.0033369,0.32779,0.24599,1,1
3,RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY,0.00016023,0.32773,0.2963,1,1
3,REGULATION OF PROTEIN POLYMERIZATION,0.0013872,0.32487,0.27997,1,1
3,NUCLEOTIDE BIOSYNTHETIC PROCESS,0.0010206,0.32366,0.26602,1,1
3,REACTOME CLASS C 3 METABOTROPIC GLUTAMATE PHEROMONE RECEPTORS,0.0041716,0.32359,0.28908,1,1
3,RESPONSE TO HEAT,0.001191,0.32214,0.23138,1,1
3,RESPIRATORY GASEOUS EXCHANGE,0.042857,0.32128,0.17104,1,1
3,NEUROGENESIS,3.0576e-06,0.32,0.33964,1,1
3,EXTRINSIC TO PLASMA MEMBRANE,0.0034322,0.31926,0.27882,1,1
3,GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY,6.0198e-07,0.30899,0.28139,1,1
3,BIOCARTA EIF PATHWAY,0.00026903,0.30654,0.29039,1,1
3,REACTOME PURINE METABOLISM,0.00057693,0.30427,0.27299,1,1
3,LIGAND GATED CHANNEL ACTIVITY,0.0025083,0.30233,0.26844,1,1
3,PID MYC ACTIVPATHWAY,0.001228,0.30193,0.24805,1,1
3,REACTOME PURINE SALVAGE,0.0085714,0.30131,0.26272,1,1
3,ACTIN FILAMENT POLYMERIZATION,0.00079435,0.29981,0.27528,1,1
3,REACTOME GLYCOLYSIS,0.0050528,0.29967,0.29578,1,1
3,BIOCARTA NDKDYNAMIN PATHWAY,0.001191,0.29855,0.25058,1,1
3,PURINE NUCLEOTIDE METABOLIC PROCESS,0.00042998,0.29402,0.31848,1,1
3,POTASSIUM ION TRANSPORT,0.0015189,0.28899,0.27497,1,1
3,REACTOME CREB PHOSPHORYLATION THROUGH THE ACTIVATION OF CAMKII,0.0028141,0.2881,0.23216,1,1
3,INTRAMOLECULAR OXIDOREDUCTASE ACTIVITY,0.0016129,0.28716,0.19925,1,1
3,GLIOGENESIS,0.00098941,0.2855,0.29977,1,1
3,ACTIN POLYMERIZATION AND OR DEPOLYMERIZATION,0.0023671,0.28489,0.24078,1,1
3,RRNA PROCESSING,0.0012662,0.28459,0.36143,1,1
3,EXOCYTOSIS,0.011904,0.28376,0.29208,1,1
3,FOCAL ADHESION,0.043763,0.28313,0.20255,1,1
3,CELLULAR PROTEIN COMPLEX DISASSEMBLY,0.0029794,0.28176,0.23817,1,1
3,BIOCARTA RANMS PATHWAY,0.0057817,0.2807,0.2078,1,1
3,RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITYENHANCER BINDING,0.0026572,0.28009,0.20554,1,1
3,PEPTIDE RECEPTOR ACTIVITY,0.0007696,0.27831,0.2176,1,1
3,REGULATION OF TRANSLATIONAL INITIATION,0.0036303,0.27519,0.20725,1,1
3,REACTOME CITRIC ACID CYCLE TCA CYCLE,0.001191,0.27197,0.24785,1,1
3,RIBOSOME BIOGENESIS AND ASSEMBLY,0.00079435,0.27074,0.35811,1,1
3,PID P38GAMMADELTAPATHWAY,0.013465,0.26913,0.26855,1,1
3,REACTOME POST CHAPERONIN TUBULIN FOLDING PATHWAY,0.00072223,0.26909,0.32266,1,1
3,MAINTENANCE OF PROTEIN LOCALIZATION,0.00084609,0.26829,0.28041,1,1
3,NEURON PROJECTION,0.0049174,0.2674,0.26602,1,1
3,NEUROPEPTIDE RECEPTOR ACTIVITY,0.0032441,0.26722,0.21849,1,1
3,NEUROPEPTIDE BINDING,0.0032441,0.26722,0.21849,1,1
3,AMINO ACID TRANSPORT,0.00092958,0.26682,0.24662,1,1
3,INTEGRIN BINDING,0.0034322,0.26568,0.2369,1,1
3,NLS BEARING SUBSTRATE IMPORT INTO NUCLEUS,0.00026003,0.26567,0.25081,1,1
3,REACTOME SYNTHESIS AND INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES,0.001191,0.26153,0.24932,1,1
3,EXTRINSIC TO MEMBRANE,0.0012662,0.26099,0.28647,1,1
3,SYNAPSE PART,7.547e-05,0.25804,0.28851,1,1
3,KEGG GLYCOLYSIS GLUCONEOGENESIS,0.0059384,0.25456,0.21043,1,1
3,TRANSLATIONAL INITIATION,0.00092958,0.25454,0.22768,1,1
3,ISOMERASE ACTIVITY,0.00019079,0.25242,0.20856,1,1
3,REACTOME ROLE OF DCC IN REGULATING APOPTOSIS,0.0067808,0.25237,0.2683,1,1
3,RRNA METABOLIC PROCESS,0.0017123,0.25226,0.3346,1,1
3,KEGG PYRUVATE METABOLISM,0.011326,0.25177,0.21236,1,1
3,PIGMENT METABOLIC PROCESS,0.0010859,0.25125,0.21734,1,1
3,REACTOME EFFECTS OF PIP2 HYDROLYSIS,0.0010528,0.25101,0.20992,1,1
3,CHAPERONE BINDING,0.0030654,0.24689,0.21419,1,1
3,CYCLIC NUCLEOTIDE MEDIATED SIGNALING,4.1617e-05,0.24645,0.22401,1,1
3,MITOCHONDRIAL MEMBRANE PART,0.00084609,0.24455,0.19703,1,1
3,HEME METABOLIC PROCESS,0.0069616,0.23953,0.2599,1,1
3,RESPONSE TO CARBOHYDRATE STIMULUS,0.011612,0.2393,0.21521,1,1
3,G PROTEIN SIGNALING COUPLED TO CYCLIC NUCLEOTIDE SECOND MESSENGER,3.8583e-05,0.23902,0.22685,1,1
3,REACTOME PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE,0.0054795,0.23834,0.17695,1,1
3,KEGG CITRATE CYCLE TCA CYCLE,0.0013872,0.23808,0.24182,1,1
3,RIBOSOMAL SUBUNIT,0.0083534,0.2359,0.19554,1,1
3,MITOCHONDRIAL INNER MEMBRANE,0.00016023,0.23474,0.23434,1,1
3,KEGG ARGININE AND PROLINE METABOLISM,0.0046564,0.23331,0.22027,1,1
3,CYTOSOLIC PART,0.0011199,0.22759,0.21628,1,1
3,RIBONUCLEOPROTEIN COMPLEX BIOGENESIS AND ASSEMBLY,0.00021167,0.22696,0.21666,1,1
3,REACTOME GLUCONEOGENESIS,0.013139,0.22654,0.17754,1,1
3,PROTEIN RNA COMPLEX ASSEMBLY,0.00026003,0.22566,0.19189,1,1
3,TRANSFERASE ACTIVITY TRANSFERRING ONE CARBON GROUPS,0.00010462,0.22474,0.25213,1,1
3,SMALL NUCLEAR RIBONUCLEOPROTEIN COMPLEX,0.00049035,0.21999,0.29871,1,1
3,MAINTENANCE OF CELLULAR LOCALIZATION,0.0066042,0.21874,0.25002,1,1
3,SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES,0.00010092,0.21701,0.23755,1,1
3,REACTOME METABOLISM OF NUCLEOTIDES,0.00047456,0.2142,0.21232,1,1
3,TRANSLATION FACTOR ACTIVITY NUCLEIC ACID BINDING,0.0032441,0.21187,0.20304,1,1
3,CAMP MEDIATED SIGNALING,0.001191,0.21078,0.17296,1,1
3,KEGG NEUROACTIVE LIGAND RECEPTOR INTERACTION,1.0184e-05,0.20941,0.20932,1,1
3,REACTOME L1CAM INTERACTIONS,0.00013917,0.20931,0.23215,1,1
3,CELL MATRIX ADHESION,0.019739,0.20758,0.14045,1,1
3,REACTOME MITOCHONDRIAL PROTEIN IMPORT,0.0032441,0.20664,0.1982,1,1
3,REACTOME METABOLISM OF RNA,0.0057817,0.20511,0.18374,1,1
3,TRANSLATION REGULATOR ACTIVITY,0.0049174,0.20447,0.1918,1,1
3,RIBONUCLEOPROTEIN BINDING,0.0073363,0.20418,0.18252,1,1
3,ACTIVATION OF PROTEIN KINASE ACTIVITY,0.0019282,0.20385,0.18464,1,1
3,RESPONSE TO ORGANIC SUBSTANCE,0.018398,0.20381,0.12395,1,1
3,PID REELINPATHWAY,0.022165,0.20374,0.18477,1,1
3,ATP DEPENDENT DNA HELICASE ACTIVITY,0.0047853,0.20369,0.17699,1,1
3,REACTOME RNA POL III CHAIN ELONGATION,0.00022676,0.20329,0.22049,1,1
3,AMINO SUGAR METABOLIC PROCESS,0.00030804,0.20308,0.21027,1,1
3,DYSTROPHIN ASSOCIATED GLYCOPROTEIN COMPLEX,0.00026003,0.20296,0.37269,1,1
3,PID S1P S1P4 PATHWAY,0.027803,0.20277,0.17845,1,1
3,BIOCARTA CHREBP2 PATHWAY,0.0049174,0.20168,0.16137,1,1
3,REACTOME CDC6 ASSOCIATION WITH THE ORC ORIGIN COMPLEX,0.00010845,0.20028,0.29298,1,1
3,CELL SUBSTRATE ADHESION,0.018836,0.19956,0.13469,1,1
3,CARBOHYDRATE BIOSYNTHETIC PROCESS,0.00090094,0.19818,0.1822,1,1
3,REGULATION OF CELL MIGRATION,0.033166,0.19755,0.13984,1,1
3,ORGANIC ACID TRANSMEMBRANE TRANSPORTER ACTIVITY,0.00079435,0.197,0.23102,1,1
3,CARBOXYLIC ACID TRANSMEMBRANE TRANSPORTER ACTIVITY,0.00079435,0.197,0.23102,1,1
3,REACTOME INTRINSIC PATHWAY,0.0083534,0.19634,0.15922,1,1
3,REACTOME RNA POL III TRANSCRIPTION TERMINATION,0.00016023,0.19619,0.21065,1,1
3,ORGANELLE INNER MEMBRANE,0.00019079,0.19559,0.18358,1,1
3,REACTOME NRAGE SIGNALS DEATH THROUGH JNK,0.00012512,0.19535,0.24895,1,1
3,G PROTEIN SIGNALING COUPLED TO CAMP NUCLEOTIDE SECOND MESSENGER,0.0016129,0.19485,0.17083,1,1
3,NADH DEHYDROGENASE COMPLEX,0.0056288,0.19471,0.19709,1,1
3,MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX I,0.0056288,0.19471,0.19709,1,1
3,RESPIRATORY CHAIN COMPLEX I,0.0056288,0.19471,0.19709,1,1
3,REACTOME AMINE COMPOUND SLC TRANSPORTERS,0.023205,0.19324,0.14752,1,1
3,BIOCARTA SARS PATHWAY,0.019283,0.19188,0.17857,1,1
3,MAINTENANCE OF CELLULAR PROTEIN LOCALIZATION,0.0050528,0.19171,0.27568,1,1
3,REACTOME GLUCOSE TRANSPORT,0.011612,0.19036,0.13703,1,1
3,POSITIVE REGULATION OF TRANSCRIPTION FACTOR ACTIVITY,0.00010845,0.19024,0.17829,1,1
3,REACTOME RNA POL III TRANSCRIPTION INITIATION FROM TYPE 3 PROMOTER,0.00035231,0.19017,0.15439,1,1
3,POSITIVE REGULATION OF DNA BINDING,1.4609e-05,0.19009,0.20014,1,1
3,ORGANIC ACID TRANSPORT,0.00059588,0.18963,0.21541,1,1
3,CARBOXYLIC ACID TRANSPORT,0.00059588,0.18963,0.21541,1,1
3,HETEROCYCLE METABOLIC PROCESS,0.0046564,0.1872,0.19957,1,1
3,MITOCHONDRIAL RESPIRATORY CHAIN,0.00052342,0.18606,0.22219,1,1
3,MICROTUBULE BINDING,0.00016023,0.18089,0.21891,1,1
3,AMINE TRANSPORT,0.001872,0.18071,0.18085,1,1
3,REACTOME METABOLISM OF MRNA,0.014486,0.18049,0.17881,1,1
3,REACTOME INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS,0.0015189,0.17978,0.15623,1,1
3,REACTOME ACTIVATION OF THE PRE REPLICATIVE COMPLEX,0.00063551,0.17895,0.19258,1,1
3,MITOCHONDRIAL PART,0.0087944,0.17656,0.14217,1,1
3,FEEDING BEHAVIOR,0.017137,0.17619,0.18047,1,1
3,REACTOME NITRIC OXIDE STIMULATES GUANYLATE CYCLASE,0.035393,0.17612,0.1231,1,1
3,REGULATION OF GTPASE ACTIVITY,0.03939,0.17542,0.13231,1,1
3,METHYLTRANSFERASE ACTIVITY,0.00041602,0.17525,0.19005,1,1
3,PID HDAC CLASSIII PATHWAY,0.0047853,0.17482,0.21313,1,1
3,PID CDC42 REG PATHWAY,0.0047853,0.17408,0.14081,1,1
3,MITOCHONDRIAL ENVELOPE,0.0031536,0.17307,0.1354,1,1
3,REACTOME MTORC1 MEDIATED SIGNALLING,0.022165,0.17189,0.20082,1,1
3,REACTOME PROTEIN FOLDING,0.0017123,0.16972,0.13379,1,1
3,NUCLEOLAR PART,0.02166,0.16646,0.17531,1,1
3,KEGG FRUCTOSE AND MANNOSE METABOLISM,0.018836,0.16435,0.16793,1,1
3,SPLICEOSOME,0.0015189,0.16395,0.16344,1,1
3,REACTOME E2F ENABLED INHIBITION OF PRE REPLICATION COMPLEX FORMATION,0.0083534,0.16322,0.19012,1,1
3,REACTOME TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT,0.0097392,0.16297,0.1368,1,1
3,TRANSLATION,0.043763,0.15937,0.14391,1,1
3,POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION AND BIOGENESIS,0.0087944,0.15911,0.13894,1,1
3,DNA HELICASE ACTIVITY,0.00052342,0.15905,0.15344,1,1
3,MITOCHONDRIAL MEMBRANE,0.0057817,0.15814,0.12644,1,1
3,PID TELOMERASEPATHWAY,0.00055855,0.15803,0.12908,1,1
3,REACTOME RECYCLING PATHWAY OF L1,0.014841,0.1568,0.13588,1,1
3,PHOSPHORIC DIESTER HYDROLASE ACTIVITY,0.0049174,0.15544,0.17337,1,1
3,PIGMENT BIOSYNTHETIC PROCESS,0.013139,0.15501,0.15128,1,1
3,REACTOME PROCESSING OF INTRONLESS PRE MRNAS,0.010773,0.15487,0.14427,1,1
3,REACTOME G1 PHASE,0.027188,0.15456,0.11653,1,1
3,DNA REPLICATION INITIATION,0.014486,0.15348,0.12082,1,1
3,REACTOME TRANSPORT OF INORGANIC CATIONS ANIONS AND AMINO ACIDS OLIGOPEPTIDES,0.00098941,0.15253,0.16152,1,1
3,REACTOME RNA POL I TRANSCRIPTION TERMINATION,0.043763,0.15175,0.12072,1,1
3,CATION TRANSMEMBRANE TRANSPORTER ACTIVITY,0.013465,0.15174,0.12027,1,1
3,BIOCARTA EIF2 PATHWAY,0.010506,0.15065,0.15832,1,1
3,KEGG PURINE METABOLISM,0.00065623,0.14872,0.14577,1,1
3,SMOOTH MUSCLE CONTRACTION GO 0006939,0.02068,0.14765,0.13791,1,1
3,SECONDARY METABOLIC PROCESS,0.02068,0.14749,0.12004,1,1
3,DNA INTEGRITY CHECKPOINT,0.019283,0.14739,0.1168,1,1
3,SECOND MESSENGER MEDIATED SIGNALING,0.0018173,0.14704,0.12562,1,1
3,REACTOME TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRONLESS TRANSCRIPT,0.011612,0.14596,0.13856,1,1
3,RNA SPLICINGVIA TRANSESTERIFICATION REACTIONS,0.0013872,0.14491,0.1241,1,1
3,METALLOENDOPEPTIDASE ACTIVITY,0.0069616,0.14461,0.14467,1,1
3,KEGG HOMOLOGOUS RECOMBINATION,0.0085714,0.14419,0.1362,1,1
3,HYDROGEN ION TRANSMEMBRANE TRANSPORTER ACTIVITY,0.024288,0.14377,0.089888,1,1
3,MAINTENANCE OF LOCALIZATION,0.0085714,0.14327,0.17029,1,1
3,REACTOME PROCESSING OF CAPPED INTRONLESS PRE MRNA,0.0010528,0.14308,0.13708,1,1
3,OVULATION CYCLE,0.0022332,0.14264,0.11042,1,1
3,REACTOME SLBP DEPENDENT PROCESSING OF REPLICATION DEPENDENT HISTONE PRE MRNAS,0.027803,0.13978,0.10157,1,1
3,POSITIVE REGULATION OF BINDING,6.0504e-05,0.13821,0.15286,1,1
3,HELICASE ACTIVITY,0.001872,0.13759,0.15474,1,1
3,SUBSTRATE SPECIFIC TRANSMEMBRANE TRANSPORTER ACTIVITY,0.0097392,0.13722,0.10661,1,1
3,KEGG RNA POLYMERASE,0.0040578,0.13655,0.14793,1,1
3,REACTOME PROTEOLYTIC CLEAVAGE OF SNARE COMPLEX PROTEINS,0.035393,0.13536,0.13081,1,1
3,KEGG GLYCEROLIPID METABOLISM,0.0039469,0.13433,0.14292,1,1
3,REACTOME NEP NS2 INTERACTS WITH THE CELLULAR EXPORT MACHINERY,0.018398,0.13384,0.12933,1,1
3,CHROMATIN ASSEMBLY OR DISASSEMBLY,0.015574,0.13036,0.13357,1,1
3,G PROTEIN COUPLED RECEPTOR PROTEIN SIGNALING PATHWAY,0.0069616,0.12991,0.091998,1,1
3,REACTOME FANCONI ANEMIA PATHWAY,0.00065623,0.1295,0.15476,1,1
3,REGULATION OF NEURON APOPTOSIS,0.037747,0.1284,0.1316,1,1
3,ENDONUCLEASE ACTIVITY GO 0016893,0.015953,0.12807,0.14854,1,1
3,ENDORIBONUCLEASE ACTIVITY,0.012203,0.12802,0.14377,1,1
3,REACTOME PKB MEDIATED EVENTS,0.015953,0.12292,0.11397,1,1
3,RNA POLYMERASE ACTIVITY,0.030383,0.12167,0.12141,1,1
3,DNA DEPENDENT DNA REPLICATION,0.0067808,0.12127,0.10415,1,1
3,REACTOME G2 M CHECKPOINTS,0.038561,0.12048,0.098967,1,1
3,CENTROSOME ORGANIZATION AND BIOGENESIS,0.02166,0.12035,0.12322,1,1
3,DNA DEPENDENT ATPASE ACTIVITY,0.0051916,0.11992,0.14091,1,1
3,PID LKB1 PATHWAY,0.0019282,0.11871,0.12951,1,1
3,MICROTUBULE CYTOSKELETON ORGANIZATION AND BIOGENESIS,0.02068,0.11773,0.11922,1,1
3,REACTOME TRANSPORT OF RIBONUCLEOPROTEINS INTO THE HOST NUCLEUS,0.014138,0.11421,0.13617,1,1
3,G PROTEIN COUPLED RECEPTOR ACTIVITY,0.0040578,0.11417,0.09858,1,1
3,REACTOME REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN,0.03939,0.11371,0.10542,1,1
3,REACTOME RAP1 SIGNALLING,0.033166,0.11223,0.19134,1,1
3,CARBOXYPEPTIDASE ACTIVITY,0.043763,0.11167,0.20908,1,1
3,ENVELOPE,0.0099891,0.11118,0.082787,1,1
3,ORGANELLE ENVELOPE,0.0099891,0.11118,0.082787,1,1
3,RNA BINDING,0.031059,0.10986,0.12396,1,1
3,ST INTEGRIN SIGNALING PATHWAY,0.033894,0.10917,0.089817,1,1
3,RIBONUCLEOPROTEIN COMPLEX,0.0066042,0.10531,0.12517,1,1
3,G1 S TRANSITION OF MITOTIC CELL CYCLE,0.019739,0.1046,0.12551,1,1
3,PID HDAC CLASSII PATHWAY,0.02843,0.10438,0.10439,1,1
3,REACTOME CELL DEATH SIGNALLING VIA NRAGE NRIF AND NADE,0.0013872,0.10374,0.1606,1,1
3,MICROTUBULE ORGANIZING CENTER ORGANIZATION AND BIOGENESIS,0.029719,0.1037,0.11108,1,1
3,REACTOME REGULATORY RNA PATHWAYS,0.019739,0.10341,0.10493,1,1
3,REACTOME FORMATION OF RNA POL II ELONGATION COMPLEX ,0.015203,0.10293,0.081846,1,1
3,REACTOME CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION ,0.013139,0.1028,0.10498,1,1
3,NUCLEAR ORGANIZATION AND BIOGENESIS,0.046579,0.1005,0.076104,1,1
3,REACTOME LATE PHASE OF HIV LIFE CYCLE,0.0025817,0.10025,0.09436,1,1
3,RIBONUCLEASE ACTIVITY,0.017549,0.10007,0.10056,1,1
3,REACTOME P75 NTR RECEPTOR MEDIATED SIGNALLING,0.0032441,0.097771,0.11304,1,1
3,REACTOME MRNA 3 END PROCESSING,0.041967,0.097387,0.099278,1,1
3,NUCLEOLUS,0.0062634,0.09717,0.12263,1,1
3,NUCLEAR PORE,0.012203,0.09359,0.12592,1,1
3,REACTOME HIV LIFE CYCLE,0.0054795,0.09225,0.086376,1,1
3,REACTOME MRNA PROCESSING,0.0030654,0.092083,0.11938,1,1
3,KEGG RNA DEGRADATION,0.0085714,0.091659,0.09447,1,1
3,REACTOME TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM,0.021165,0.09051,0.10281,1,1
3,REACTOME FORMATION OF TRANSCRIPTION COUPLED NER TC NER REPAIR COMPLEX,0.047551,0.089525,0.076333,1,1
3,PORE COMPLEX,0.03939,0.088225,0.094711,1,1
3,RNA PROCESSING,0.0013872,0.087119,0.12141,1,1
3,REACTOME RNA POL II TRANSCRIPTION,0.013465,0.083998,0.081794,1,1
3,RHODOPSIN LIKE RECEPTOR ACTIVITY,0.017549,0.083629,0.077614,1,1
3,KEGG SPLICEOSOME,0.029719,0.083362,0.0894,1,1
3,SMALL GTPASE BINDING,0.023205,0.080905,0.085477,1,1
3,MEDIATOR COMPLEX,0.036948,0.079462,0.092741,1,1
3,TRANSITION METAL ION BINDING,0.033894,0.079385,0.059175,1,1
3,DNA REPLICATION,0.023205,0.078142,0.063562,1,1
3,GTPASE REGULATOR ACTIVITY,0.018836,0.076419,0.094205,1,1
3,TRANSCRIPTION COREPRESSOR ACTIVITY,0.015574,0.072388,0.083118,1,1
3,REACTOME MRNA SPLICING,0.0087944,0.071026,0.11231,1,1
3,REACTOME DEADENYLATION DEPENDENT MRNA DECAY,0.02166,0.066236,0.076878,1,1
3,MRNA METABOLIC PROCESS,0.0064317,0.061385,0.082404,1,1
3,RESPONSE TO ABIOTIC STIMULUS,0.018398,0.058687,0.054211,1,1
3,REACTOME ELONGATION ARREST AND RECOVERY,0.025414,0.057685,0.093201,1,1
3,REACTOME RNA POL II PRE TRANSCRIPTION EVENTS,0.031748,0.055882,0.060233,1,1
4,ENDOTHELIAL CELL MIGRATION,3.4421e-05,1.1556,0.87186,1,1
4,REACTOME INTERFERON ALPHA BETA SIGNALING,7.6603e-06,0.91347,0.80993,1,1
4,ENDOTHELIAL CELL PROLIFERATION,4.1112e-06,0.89187,0.84176,1,1
4,BIOCARTA NKCELLS PATHWAY,9.0221e-07,0.70983,0.71846,1,1
4,ICOSANOID METABOLIC PROCESS,0.00016595,0.69921,0.69437,1,1
4,MYELOID LEUKOCYTE DIFFERENTIATION,0.00021167,0.6959,0.5384,1,1
4,REGULATION OF BLOOD PRESSURE,1.7474e-06,0.69276,0.59012,1,1
4,REACTOME SYNTHESIS SECRETION AND INACTIVATION OF GLP1,2.1663e-05,0.67203,0.645,1,1
4,REACTOME EXTRINSIC PATHWAY FOR APOPTOSIS,8.1192e-05,0.67029,0.55708,1,1
4,REACTOME APOPTOTIC CLEAVAGE OF CELL ADHESION PROTEINS,0.00030804,0.6534,0.72113,1,1
4,POSITIVE REGULATION OF CELL DIFFERENTIATION,2.8077e-06,0.63466,0.59181,1,1
4,ACETYLGLUCOSAMINYLTRANSFERASE ACTIVITY,9.8628e-07,0.62927,0.72256,1,1
4,PROTEIN AMINO ACID O LINKED GLYCOSYLATION,5.4977e-07,0.62878,0.5708,1,1
4,CALCIUM INDEPENDENT CELL CELL ADHESION,1.6455e-05,0.62573,0.62633,1,1
4,NEUROPEPTIDE HORMONE ACTIVITY,0.0007696,0.62079,0.64384,1,1
4,KEGG STEROID BIOSYNTHESIS,9.7346e-05,0.61737,0.53997,1,1
4,ALDO KETO REDUCTASE ACTIVITY,0.0013872,0.60421,0.80192,1,1
4,REGULATION OF MYELOID CELL DIFFERENTIATION,1.349e-05,0.59451,0.58207,1,1
4,REACTOME INTERFERON GAMMA SIGNALING,2.1663e-05,0.58904,0.53323,1,1
4,REACTOME TIGHT JUNCTION INTERACTIONS,4.6597e-05,0.5812,0.5406,1,1
4,POSITIVE REGULATION OF CYTOKINE PRODUCTION,4.1617e-05,0.57676,0.42831,1,1
4,REACTOME SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN,5.2837e-06,0.57478,0.69524,1,1
4,UDP GLYCOSYLTRANSFERASE ACTIVITY,2.8077e-06,0.5731,0.55917,1,1
4,REACTOME SIGNALING BY NOTCH2,1.0779e-06,0.55838,0.5487,1,1
4,BIOCARTA ARENRF2 PATHWAY,5.2837e-06,0.55298,0.58052,1,1
4,REGULATION OF HOMEOSTATIC PROCESS,0.00059588,0.54447,0.45559,1,1
4,REACTOME LYSOSOME VESICLE BIOGENESIS,3.9418e-06,0.53507,0.45371,1,1
4,BIOCARTA DEATH PATHWAY,7.547e-05,0.52196,0.41839,1,1
4,DEAMINASE ACTIVITY,2.8077e-06,0.52078,0.53105,1,1
4,REACTOME AMINE DERIVED HORMONES,0.00019079,0.513,0.5597,1,1
4,SECRETORY GRANULE,1.4674e-06,0.51024,0.51789,1,1
4,REACTOME SIGNALING BY NOTCH4,3.6414e-07,0.50283,0.52451,1,1
4,NEUTRAL AMINO ACID TRANSMEMBRANE TRANSPORTER ACTIVITY,0.0021689,0.50097,0.48235,1,1
4,KEGG ANTIGEN PROCESSING AND PRESENTATION,0.00016595,0.50095,0.41541,1,1
4,HORMONE BINDING,0.00013433,0.5002,0.44911,1,1
4,REACTOME SIGNALING BY NOTCH3,7.5427e-07,0.49614,0.48924,1,1
4,BIOCARTA IL22BP PATHWAY,0.00017796,0.48693,0.43217,1,1
4,REACTOME IKK COMPLEX RECRUITMENT MEDIATED BY RIP1,8.1192e-05,0.48683,0.46591,1,1
4,KEGG TYPE I DIABETES MELLITUS,0.00067758,0.48341,0.41519,1,1
4,ACETYLGALACTOSAMINYLTRANSFERASE ACTIVITY,0.0018173,0.48038,0.39886,1,1
4,REACTOME ACTIVATION OF IRF3 IRF7 MEDIATED BY TBK1 IKK EPSILON,7.3528e-06,0.47889,0.46641,1,1
4,GLYCOPROTEIN BIOSYNTHETIC PROCESS,2.9301e-06,0.4787,0.43832,1,1
4,BIOCARTA D4GDI PATHWAY,2.9532e-05,0.47404,0.35499,1,1
4,REACTOME REGULATION OF IFNA SIGNALING,9.8628e-07,0.4733,0.51243,1,1
4,ADENYLATE CYCLASE ACTIVATION,0.0032441,0.4717,0.31997,1,1
4,LIPID TRANSPORTER ACTIVITY,1.0604e-05,0.47076,0.38077,1,1
4,REACTOME O LINKED GLYCOSYLATION OF MUCINS,3.6228e-06,0.47,0.40776,1,1
4,KEGG MATURITY ONSET DIABETES OF THE YOUNG,3.8583e-05,0.46938,0.48005,1,1
4,GALACTOSYLTRANSFERASE ACTIVITY,2.0033e-05,0.46686,0.4611,1,1
4,TUBE MORPHOGENESIS,2.0833e-05,0.46644,0.47658,1,1
4,DIGESTION,1.7118e-05,0.46578,0.51462,1,1
4,VACUOLAR MEMBRANE,2.3418e-05,0.46447,0.43816,1,1
4,GLYCOPROTEIN METABOLIC PROCESS,1.3441e-06,0.46432,0.41883,1,1
4,STEROID BIOSYNTHETIC PROCESS,2.0784e-06,0.46278,0.50974,1,1
4,REACTOME REGULATION OF INSULIN SECRETION BY ACETYLCHOLINE,0.0051916,0.46219,0.31515,1,1
4,BIOCARTA RANKL PATHWAY,3.8583e-05,0.45994,0.46934,1,1
4,APICAL JUNCTION COMPLEX,1.2454e-05,0.45661,0.43781,1,1
4,APICOLATERAL PLASMA MEMBRANE,1.2454e-05,0.45661,0.43781,1,1
4,BIOCARTA SODD PATHWAY,0.00028792,0.45633,0.40511,1,1
4,SH2 DOMAIN BINDING,2.7343e-05,0.45601,0.41729,1,1
4,KEGG GLYCOSPHINGOLIPID BIOSYNTHESIS LACTO AND NEOLACTO SERIES,5.0683e-06,0.45427,0.46374,1,1
4,BIOCARTA MITOCHONDRIA PATHWAY,5.9841e-06,0.45401,0.46277,1,1
4,BIOCARTA IL2 PATHWAY,6.7728e-06,0.45016,0.42165,1,1
4,REACTOME ACTIVATION OF THE AP1 FAMILY OF TRANSCRIPTION FACTORS,8.7323e-05,0.44491,0.43006,1,1
4,TIGHT JUNCTION,5.6174e-05,0.43931,0.42966,1,1
4,MYELOID CELL DIFFERENTIATION,3.3132e-05,0.43897,0.3877,1,1
4,SA B CELL RECEPTOR COMPLEXES,1.6452e-07,0.43822,0.50184,1,1
4,APICAL PART OF CELL,1.0184e-05,0.43784,0.44914,1,1
4,APICAL PLASMA MEMBRANE,1.1493e-05,0.43738,0.44245,1,1
4,AMYLOID PRECURSOR PROTEIN METABOLIC PROCESS,4.6597e-05,0.43664,0.43243,1,1
4,LYSOSOMAL MEMBRANE,2.0033e-05,0.43554,0.42333,1,1
4,REACTOME CELL CELL JUNCTION ORGANIZATION,0.00026903,0.43542,0.37026,1,1
4,PROTEIN HOMOOLIGOMERIZATION,1.7118e-05,0.43236,0.4175,1,1
4,SERINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY,0.0017123,0.43224,0.44412,1,1
4,REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL,0.00047456,0.42978,0.30993,1,1
4,REACTOME METABOLISM OF POLYAMINES,6.7728e-06,0.42907,0.39127,1,1
4,SODIUM ION TRANSPORT,3.0689e-05,0.42842,0.4261,1,1
4,COENZYME BIOSYNTHETIC PROCESS,0.00065623,0.42554,0.4638,1,1
4,VACUOLAR PART,2.2524e-05,0.42019,0.40239,1,1
4,BIOCARTA CASPASE PATHWAY,0.00016023,0.41734,0.37375,1,1
4,REACTOME RECEPTOR LIGAND BINDING INITIATES THE SECOND PROTEOLYTIC CLEAVAGE OF NOTCH RECEPTOR,0.0001547,0.41558,0.43395,1,1
4,REACTOME PRE NOTCH PROCESSING IN GOLGI,0.001228,0.41505,0.39485,1,1
4,BIOCARTA TOLL PATHWAY,1.2308e-06,0.41491,0.37237,1,1
4,TUBE DEVELOPMENT,4.8379e-05,0.40795,0.41304,1,1
4,REACTOME INTERFERON SIGNALING,4.6597e-05,0.40456,0.35134,1,1
4,BIOCARTA IL3 PATHWAY,4.6597e-05,0.40253,0.37102,1,1
4,KEGG INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION,0.0001165,0.40086,0.28343,1,1
4,STEROID METABOLIC PROCESS,1.4674e-06,0.3973,0.47736,1,1
4,PID A6B1 A6B4 INTEGRIN PATHWAY,0.015203,0.39666,0.23148,1,1
4,BIOCARTA CTL PATHWAY,0.0034322,0.39632,0.29759,1,1
4,REACTOME REGULATION OF INSULIN LIKE GROWTH FACTOR IGF ACTIVITY BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS,0.013139,0.39625,0.31576,1,1
4,MORPHOGENESIS OF AN EPITHELIUM,0.0054795,0.38743,0.31245,1,1
4,REACTOME TRAF6 MEDIATED IRF7 ACTIVATION,1.0604e-05,0.38388,0.42065,1,1
4,VACUOLE,5.508e-06,0.38162,0.35315,1,1
4,KEGG O GLYCAN BIOSYNTHESIS,2.0033e-05,0.38143,0.41429,1,1
4,TRANSFERASE ACTIVITY TRANSFERRING HEXOSYL GROUPS,5.7413e-06,0.37963,0.38749,1,1
4,HYDROLASE ACTIVITY ACTING ON CARBON NITROGEN NOT PEPTIDEBONDSIN CYCLIC AMIDINES,2.0833e-05,0.37868,0.3431,1,1
4,BIOCARTA EPO PATHWAY,2.7343e-05,0.37863,0.31979,1,1
4,BIOCARTA NUCLEARRS PATHWAY,2.7343e-05,0.37817,0.47942,1,1
4,REACTOME NOD1 2 SIGNALING PATHWAY,1.7118e-05,0.37703,0.33425,1,1
4,REACTOME TANDEM PORE DOMAIN POTASSIUM CHANNELS,0.014841,0.37655,0.37181,1,1
4,BIOCARTA NFKB PATHWAY,0.00016023,0.37608,0.29269,1,1
4,REACTOME REGULATION OF BETA CELL DEVELOPMENT,0.00036427,0.37444,0.40324,1,1
4,GLAND DEVELOPMENT,0.014841,0.37409,0.33976,1,1
4,OXIDOREDUCTASE ACTIVITY ACTING ON THE CH CH GROUP OF DONORS,0.0081404,0.36953,0.37028,1,1
4,GLYCOPROTEIN CATABOLIC PROCESS,2.4346e-05,0.36893,0.3577,1,1
4,ST INTERLEUKIN 4 PATHWAY,6.5149e-05,0.36842,0.31361,1,1
4,I KAPPAB KINASE NF KAPPAB CASCADE,1.9263e-05,0.36493,0.33529,1,1
4,PROTEIN SECRETION,0.00025131,0.36469,0.3106,1,1
4,SA PROGRAMMED CELL DEATH,5.8301e-05,0.36414,0.38779,1,1
4,BIOCARTA IL7 PATHWAY,0.00012512,0.36153,0.42972,1,1
4,KEGG GLYCOSPHINGOLIPID BIOSYNTHESIS GLOBO SERIES,0.0099891,0.35971,0.25429,1,1
4,NUCLEOTIDE SUGAR METABOLIC PROCESS,0.0021689,0.35725,0.27277,1,1
4,REACTOME KERATAN SULFATE DEGRADATION,0.0029794,0.35593,0.28918,1,1
4,PROTEASE INHIBITOR ACTIVITY,0.0059384,0.35534,0.25917,1,1
4,BIOCARTA EPONFKB PATHWAY,0.0013054,0.35318,0.33936,1,1
4,LYTIC VACUOLE,6.7728e-06,0.35298,0.33958,1,1
4,LYSOSOME,6.7728e-06,0.35298,0.33958,1,1
4,REGULATION OF LIPID METABOLIC PROCESS,0.00041602,0.35114,0.31135,1,1
4,COENZYME BINDING,0.00026903,0.35075,0.34901,1,1
4,REACTOME REGULATION OF COMPLEMENT CASCADE,0.0011199,0.35061,0.37865,1,1
4,PHOSPHOLIPID TRANSPORTER ACTIVITY,0.00049035,0.35055,0.37025,1,1
4,OLIGOSACCHARYL TRANSFERASE COMPLEX,1.5201e-05,0.3504,0.41031,1,1
4,BIOCARTA BCELLSURVIVAL PATHWAY,0.00040247,0.34874,0.26059,1,1
4,REACTOME ACYL CHAIN REMODELLING OF PE,1.5816e-05,0.34768,0.35486,1,1
4,PID TOLL ENDOGENOUS PATHWAY,0.0001547,0.34724,0.29903,1,1
4,CELLULAR DEFENSE RESPONSE,0.00014935,0.34489,0.30641,1,1
4,COFACTOR BINDING,0.00014935,0.34435,0.32045,1,1
4,KEGG SPHINGOLIPID METABOLISM,5.7413e-06,0.34384,0.31611,1,1
4,REACTOME SYNTHESIS OF PC,0.00040247,0.34279,0.30591,1,1
4,KEGG RIBOFLAVIN METABOLISM,0.00049035,0.34251,0.38284,1,1
4,REACTOME N GLYCAN ANTENNAE ELONGATION,0.0038387,0.34214,0.33399,1,1
4,LIPID RAFT,6.2786e-05,0.34117,0.36591,1,1
4,NEGATIVE REGULATION OF PHOSPHORYLATION,0.015953,0.33886,0.30571,1,1
4,NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS,0.015953,0.33886,0.30571,1,1
4,NON MEMBRANE SPANNING PROTEIN TYROSINE KINASE ACTIVITY,0.00040247,0.33885,0.32533,1,1
4,REACTOME CHOLESTEROL BIOSYNTHESIS,0.0097392,0.3388,0.29774,1,1
4,HYDROLASE ACTIVITY HYDROLYZING O GLYCOSYL COMPOUNDS,3.8583e-05,0.33802,0.35365,1,1
4,NEGATIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,0.00013433,0.33786,0.35758,1,1
4,SODIUM CHANNEL ACTIVITY,0.00059588,0.33748,0.3175,1,1
4,REACTOME REGULATION OF KIT SIGNALING,0.030383,0.33744,0.2851,1,1
4,REACTOME INNATE IMMUNE SYSTEM,1.4039e-05,0.33677,0.27486,1,1
4,REGULATION OF CYTOKINE PRODUCTION,0.00054072,0.33631,0.23221,1,1
4,OXIDOREDUCTASE ACTIVITY ACTING ON PEROXIDE AS ACCEPTOR,0.0040578,0.33584,0.36717,1,1
4,REACTOME PEROXISOMAL LIPID METABOLISM,0.0033369,0.3354,0.28596,1,1
4,GOLGI STACK,0.00012964,0.33514,0.27648,1,1
4,PID ERB GENOMIC PATHWAY,5.2837e-06,0.33512,0.35701,1,1
4,CYTOKINE METABOLIC PROCESS,1.4609e-05,0.33504,0.28187,1,1
4,PID ALPHASYNUCLEIN PATHWAY,3.4421e-05,0.33399,0.31451,1,1
4,TISSUE REMODELING,0.0015653,0.33288,0.27679,1,1
4,PID HNF3APATHWAY,1.6455e-05,0.3327,0.37812,1,1
4,KINASE INHIBITOR ACTIVITY,0.0030654,0.33035,0.36921,1,1
4,INTERCELLULAR JUNCTION,6.7596e-05,0.3302,0.30856,1,1
4,LEUKOCYTE MIGRATION,0.00016595,0.32989,0.36847,1,1
4,STEROID BINDING,0.001986,0.32942,0.33407,1,1
4,KEGG ALDOSTERONE REGULATED SODIUM REABSORPTION,1.9263e-05,0.32838,0.30666,1,1
4,SIG PIP3 SIGNALING IN B LYMPHOCYTES,2.3654e-06,0.32435,0.34836,1,1
4,REACTOME NEF MEDIATES DOWN MODULATION OF CELL SURFACE RECEPTORS BY RECRUITING THEM TO CLATHRIN ADAPTERS,0.0017123,0.32263,0.26529,1,1
4,EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY,0.0036303,0.3221,0.27747,1,1
4,PID CASPASE PATHWAY,0.001872,0.32207,0.21324,1,1
4,BIOCARTA KERATINOCYTE PATHWAY,0.00010462,0.322,0.30745,1,1
4,REACTOME TOLL RECEPTOR CASCADES,3.7791e-06,0.32177,0.2919,1,1
4,KEGG NOTCH SIGNALING PATHWAY,0.0013457,0.32151,0.22186,1,1
4,EXCRETION,1.5816e-05,0.31891,0.30358,1,1
4,PID EPOPATHWAY,5.6174e-05,0.31846,0.33365,1,1
4,CALCIUM MEDIATED SIGNALING,0.0016129,0.31425,0.23778,1,1
4,INTEGRIN COMPLEX,0.00032948,0.31272,0.26475,1,1
4,PID HNF3BPATHWAY,1.906e-06,0.31241,0.43543,1,1
4,PML BODY,6.0504e-05,0.31208,0.2905,1,1
4,REACTOME GLUTATHIONE CONJUGATION,0.013798,0.31155,0.41843,1,1
4,PID IL1PATHWAY,4.1617e-05,0.31152,0.23937,1,1
4,REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM,4.4878e-05,0.31005,0.27438,1,1
4,FATTY ACID OXIDATION,0.0022992,0.30935,0.30064,1,1
4,BIOCARTA CERAMIDE PATHWAY,1.4039e-05,0.30875,0.32024,1,1
4,CYTOKINE BIOSYNTHETIC PROCESS,2.5308e-05,0.30847,0.2732,1,1
4,REACTOME CELL JUNCTION ORGANIZATION,0.00013917,0.30775,0.29809,1,1
4,REACTOME TRANS GOLGI NETWORK VESICLE BUDDING,2.0033e-05,0.30749,0.33843,1,1
4,PID AVB3 OPN PATHWAY,0.0022992,0.30736,0.26468,1,1
4,NEGATIVE REGULATION OF ANGIOGENESIS,0.0046564,0.30734,0.2077,1,1
4,REACTOME ACYL CHAIN REMODELLING OF PS,0.00013917,0.30633,0.35193,1,1
4,REACTOME SPHINGOLIPID METABOLISM,1.6455e-05,0.30606,0.29048,1,1
4,REACTOME HS GAG BIOSYNTHESIS,0.004408,0.30567,0.32009,1,1
4,HYDROLASE ACTIVITY ACTING ON GLYCOSYL BONDS,1.0604e-05,0.30496,0.31228,1,1
4,KEGG TOLL LIKE RECEPTOR SIGNALING PATHWAY,2.3654e-06,0.304,0.29697,1,1
4,POSITIVE REGULATION OF SIGNAL TRANSDUCTION,6.2786e-05,0.30394,0.26471,1,1
4,REACTOME GROWTH HORMONE RECEPTOR SIGNALING,0.00059588,0.30279,0.26925,1,1
4,TRANSFERASE ACTIVITY TRANSFERRING GLYCOSYL GROUPS,1.1493e-05,0.30215,0.2787,1,1
4,PROTEIN OLIGOMERIZATION,6.0504e-05,0.30176,0.28966,1,1
4,REACTOME P75NTR SIGNALS VIA NFKB,0.0015653,0.30131,0.21471,1,1
4,REACTOME RIG I MDA5 MEDIATED INDUCTION OF IFN ALPHA BETA PATHWAYS,0.00014935,0.30129,0.24964,1,1
4,REGULATION OF MEMBRANE POTENTIAL,0.0021062,0.30114,0.28104,1,1
4,PID NECTIN PATHWAY,0.00087311,0.30048,0.30636,1,1
4,REACTOME ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS,0.0071468,0.3002,0.2555,1,1
4,BIOCARTA ETS PATHWAY,0.00024286,0.30009,0.28147,1,1
4,ALCOHOL METABOLIC PROCESS,3.0264e-07,0.29867,0.32828,1,1
4,PROTEIN BINDING BRIDGING,0.00067758,0.29833,0.21439,1,1
4,TRANSPORT VESICLE,0.00010462,0.29595,0.26332,1,1
4,REACTOME APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS,0.0021689,0.29512,0.27663,1,1
4,REACTOME NFKB IS ACTIVATED AND SIGNALS SURVIVAL,0.00081984,0.29461,0.27359,1,1
4,G PROTEIN SIGNALING ADENYLATE CYCLASE ACTIVATING PATHWAY,0.012508,0.29373,0.19677,1,1
4,PID IL5 PATHWAY,0.0069616,0.29365,0.26886,1,1
4,REACTOME NRIF SIGNALS CELL DEATH FROM THE NUCLEUS,0.00090094,0.29309,0.23078,1,1
4,REACTOME NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR NLR SIGNALING PATHWAYS,5.4121e-05,0.29149,0.25186,1,1
4,SH3 SH2 ADAPTOR ACTIVITY,0.00092958,0.29098,0.23232,1,1
4,PROTEIN KINASE INHIBITOR ACTIVITY,0.0087944,0.29089,0.34762,1,1
4,PID TAP63PATHWAY,0.0071468,0.29031,0.23009,1,1
4,NEGATIVE REGULATION OF TRANSLATION,0.00012512,0.29008,0.24444,1,1
4,REACTOME TRANSPORT TO THE GOLGI AND SUBSEQUENT MODIFICATION,0.0067808,0.29005,0.21406,1,1
4,REACTOME N GLYCAN ANTENNAE ELONGATION IN THE MEDIAL TRANS GOLGI,0.02268,0.28923,0.22059,1,1
4,SEXUAL REPRODUCTION,3.6228e-06,0.28888,0.26292,1,1
4,BIOCARTA IL2RB PATHWAY,4.6597e-05,0.28849,0.2806,1,1
4,REACTOME LATENT INFECTION OF HOMO SAPIENS WITH MYCOBACTERIUM TUBERCULOSIS,5.4121e-05,0.28842,0.31544,1,1
4,REACTOME GOLGI ASSOCIATED VESICLE BIOGENESIS,1.349e-05,0.28729,0.30313,1,1
4,INFLAMMATORY RESPONSE,9.389e-05,0.28667,0.2269,1,1
4,REACTOME TRAF6 MEDIATED INDUCTION OF TAK1 COMPLEX,0.00057693,0.28562,0.29697,1,1
4,BIOCARTA STRESS PATHWAY,0.0001547,0.28459,0.25877,1,1
4,KEGG NATURAL KILLER CELL MEDIATED CYTOTOXICITY,0.00016595,0.2833,0.25192,1,1
4,INTRINSIC TO GOLGI MEMBRANE,0.0060989,0.28306,0.19511,1,1
4,REACTOME POST TRANSLATIONAL PROTEIN MODIFICATION,1.1493e-05,0.28289,0.27744,1,1
4,SIG BCR SIGNALING PATHWAY,2.9301e-06,0.28203,0.31814,1,1
4,PROTEIN SERINE THREONINE TYROSINE KINASE ACTIVITY,0.00067758,0.28164,0.26047,1,1
4,DI   TRI VALENT INORGANIC CATION TRANSPORT,0.0094949,0.28075,0.2118,1,1
4,CARBOXYLESTERASE ACTIVITY,0.00049035,0.28059,0.2495,1,1
4,EARLY ENDOSOME,0.022165,0.28057,0.16971,1,1
4,CELLULAR LIPID METABOLIC PROCESS,2.5774e-06,0.27992,0.30259,1,1
4,REACTOME ACTIVATION OF CHAPERONES BY ATF6 ALPHA,0.00059588,0.27962,0.28305,1,1
4,REACTOME TETRAHYDROBIOPTERIN BH4 SYNTHESIS RECYCLING SALVAGE AND REGULATION,0.00044439,0.27862,0.32688,1,1
4,REACTOME ACTIVATED TLR4 SIGNALLING,1.8251e-06,0.27762,0.27614,1,1
4,REACTOME ASPARAGINE N LINKED GLYCOSYLATION,0.00030804,0.27684,0.23877,1,1
4,REACTOME KERATAN SULFATE KERATIN METABOLISM,0.00024286,0.27677,0.23686,1,1
4,PID IL6 7PATHWAY,0.00067758,0.2763,0.26572,1,1
4,BIOCARTA TNFR2 PATHWAY,0.0028141,0.27585,0.19479,1,1
4,ENDOSOME,0.00012512,0.27565,0.21053,1,1
4,BIOCARTA IL6 PATHWAY,0.00032948,0.27516,0.24475,1,1
4,DNA DAMAGE RESPONSESIGNAL TRANSDUCTION RESULTING IN INDUCTION OF APOPTOSIS,0.030383,0.27395,0.25592,1,1
4,HORMONE ACTIVITY,0.0010859,0.27369,0.31364,1,1
4,DEFENSE RESPONSE,4.4878e-05,0.27272,0.23524,1,1
4,PID IL2 PI3KPATHWAY,0.011904,0.27234,0.18334,1,1
4,CELL MATURATION,0.0039469,0.27197,0.27664,1,1
4,ST WNT CA2 CYCLIC GMP PATHWAY,0.0021689,0.27187,0.20514,1,1
4,MOLECULAR ADAPTOR ACTIVITY,0.00054072,0.27186,0.23815,1,1
4,PID AP1 PATHWAY,0.011904,0.27054,0.19924,1,1
4,CARBON CARBON LYASE ACTIVITY,0.00013433,0.26919,0.29394,1,1
4,GLUCOSE METABOLIC PROCESS,2.5308e-05,0.26858,0.32522,1,1
4,REACTOME ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION,0.0054795,0.2681,0.19939,1,1
4,BILE ACID METABOLIC PROCESS,0.0021062,0.26758,0.36833,1,1
4,PROTEIN TYROSINE KINASE ACTIVITY,0.0057817,0.26716,0.20809,1,1
4,FATTY ACID METABOLIC PROCESS,0.00010845,0.26712,0.32201,1,1
4,CYTOKINE PRODUCTION,8.6584e-06,0.26656,0.25073,1,1
4,BIOCARTA IL1R PATHWAY,8.1192e-05,0.26647,0.21747,1,1
4,REACTOME MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES,0.00026903,0.26621,0.24937,1,1
4,REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS,3.8583e-05,0.26561,0.26235,1,1
4,BIOCARTA DC PATHWAY,0.0073363,0.26555,0.16543,1,1
4,CELLULAR LIPID CATABOLIC PROCESS,8.3127e-06,0.26501,0.30305,1,1
4,REACTOME TERMINATION OF O GLYCAN BIOSYNTHESIS,0.0017641,0.26501,0.26435,1,1
4,HYDROLASE ACTIVITY ACTING ON CARBON NITROGEN NOT PEPTIDEBONDSIN LINEAR AMIDES,0.00011241,0.26443,0.25683,1,1
4,LIPID METABOLIC PROCESS,8.6584e-06,0.26441,0.2604,1,1
4,EXOCYTOSIS,0.02068,0.26304,0.26402,1,1
4,PID HIVNEFPATHWAY,0.00016595,0.26256,0.29549,1,1
4,REACTOME REGULATION OF GENE EXPRESSION IN BETA CELLS,0.016339,0.26212,0.30361,1,1
4,PID TCRJNKPATHWAY,0.0024367,0.26181,0.22882,1,1
4,LEUKOCYTE DIFFERENTIATION,0.001191,0.26136,0.23117,1,1
4,SINGLE STRANDED RNA BINDING,0.0046564,0.26116,0.24829,1,1
4,REACTOME MITOCHONDRIAL FATTY ACID BETA OXIDATION,0.046579,0.26106,0.18293,1,1
4,ENDOSOME TRANSPORT,0.00017186,0.26082,0.24389,1,1
4,POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS,0.0001547,0.26077,0.19144,1,1
4,LIPID BIOSYNTHETIC PROCESS,1.8521e-05,0.26055,0.25507,1,1
4,GLYCEROPHOSPHOLIPID METABOLIC PROCESS,7.0571e-06,0.25995,0.24481,1,1
4,REACTOME MYD88 MAL CASCADE INITIATED ON PLASMA MEMBRANE,1.5331e-06,0.25934,0.26831,1,1
4,KEGG SULFUR METABOLISM,0.031059,0.25898,0.19384,1,1
4,LATE ENDOSOME,0.00059588,0.25882,0.26952,1,1
4,REACTOME CD28 CO STIMULATION,0.0010528,0.25846,0.24622,1,1
4,CYTOKINE ACTIVITY,4.6597e-05,0.25756,0.23,1,1
4,BIOCARTA 41BB PATHWAY,0.00021909,0.25734,0.25879,1,1
4,KEGG N GLYCAN BIOSYNTHESIS,4.1617e-05,0.25699,0.28712,1,1
4,BIOCARTA MTA3 PATHWAY,0.012203,0.25664,0.25407,1,1
4,KEGG CYTOSOLIC DNA SENSING PATHWAY,2.3418e-05,0.25583,0.22775,1,1
4,RESPONSE TO WOUNDING,0.00023468,0.2523,0.19184,1,1
4,REACTOME ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GENERATION OF SECOND MESSENGERS,4.6597e-05,0.25218,0.24832,1,1
4,GAMETE GENERATION,0.00028792,0.25194,0.22825,1,1
4,REACTOME OXYGEN DEPENDENT PROLINE HYDROXYLATION OF HYPOXIA INDUCIBLE FACTOR ALPHA,0.010245,0.25194,0.2306,1,1
4,REACTOME ABCA TRANSPORTERS IN LIPID HOMEOSTASIS,0.0001165,0.25169,0.26645,1,1
4,NEGATIVE REGULATION OF SECRETION,0.00014935,0.25115,0.30711,1,1
4,BIOCARTA HIVNEF PATHWAY,0.0010206,0.25081,0.23064,1,1
4,BIOCARTA GRANULOCYTES PATHWAY,0.0012662,0.25042,0.17255,1,1
4,KEGG STEROID HORMONE BIOSYNTHESIS,0.00095906,0.24931,0.40084,1,1
4,REACTOME MAP KINASE ACTIVATION IN TLR CASCADE,0.00029782,0.24904,0.21118,1,1
4,SECRETION,6.4994e-06,0.24736,0.23799,1,1
4,KEGG RENIN ANGIOTENSIN SYSTEM,0.014138,0.2467,0.26179,1,1
4,MONOCARBOXYLIC ACID METABOLIC PROCESS,0.00018427,0.24536,0.28795,1,1
4,MONOVALENT INORGANIC CATION TRANSPORT,0.00020448,0.24423,0.283,1,1
4,CYTOPLASMIC VESICLE MEMBRANE,0.00055855,0.24413,0.20716,1,1
4,CYTOPLASMIC VESICLE PART,0.00055855,0.24413,0.20716,1,1
4,CYSTEINE TYPE PEPTIDASE ACTIVITY,0.001228,0.2435,0.16756,1,1
4,NEGATIVE REGULATION OF HYDROLASE ACTIVITY,0.0031536,0.24313,0.31892,1,1
4,REACTOME REGULATION OF IFNG SIGNALING,0.00028792,0.24256,0.2863,1,1
4,BIOCARTA CTLA4 PATHWAY,0.0046564,0.2419,0.19486,1,1
4,KEGG CELL ADHESION MOLECULES CAMS,0.0029794,0.24079,0.21543,1,1
4,REACTOME CELL CELL COMMUNICATION,0.0028957,0.2406,0.18486,1,1
4,GLYCEROPHOSPHOLIPID BIOSYNTHETIC PROCESS,0.00022676,0.2404,0.22943,1,1
4,LIPID CATABOLIC PROCESS,1.0184e-05,0.23978,0.27819,1,1
4,HYDROLASE ACTIVITY ACTING ON CARBON NITROGEN NOT PEPTIDEBONDS,3.4421e-05,0.23909,0.22636,1,1
4,REACTOME NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY,0.00084609,0.23893,0.24442,1,1
4,KEGG LEUKOCYTE TRANSENDOTHELIAL MIGRATION,0.00074557,0.23813,0.18618,1,1
4,CELLULAR HOMEOSTASIS,0.00069957,0.23806,0.16515,1,1
4,IMMUNE RESPONSE,7.8282e-05,0.23786,0.19008,1,1
4,HYDROLASE ACTIVITY ACTING ON ACID ANHYDRIDESCATALYZING TRANSMEMBRANE MOVEMENT OF SUBSTANCES,0.00020448,0.23691,0.26084,1,1
4,ION HOMEOSTASIS,0.00036427,0.23634,0.17635,1,1
4,INSOLUBLE FRACTION,0.00025131,0.23609,0.28534,1,1
4,BIOCARTA BIOPEPTIDES PATHWAY,0.0094949,0.23605,0.156,1,1
4,PHOSPHOLIPID METABOLIC PROCESS,6.0198e-07,0.23579,0.23989,1,1
4,REACTOME PHASE1 FUNCTIONALIZATION OF COMPOUNDS,0.00019753,0.23472,0.29668,1,1
4,KEGG PROTEIN EXPORT,0.00016023,0.23451,0.22892,1,1
4,BIOCARTA GSK3 PATHWAY,0.004408,0.23412,0.17504,1,1
4,CELLULAR CATION HOMEOSTASIS,0.00030804,0.23399,0.18599,1,1
4,PRIMARY ACTIVE TRANSMEMBRANE TRANSPORTER ACTIVITY,0.00012512,0.23278,0.26402,1,1
4,KEGG TRYPTOPHAN METABOLISM,0.0013054,0.23243,0.22968,1,1
4,ACTIN FILAMENT BINDING,0.0034322,0.23201,0.20946,1,1
4,REACTOME IRON UPTAKE AND TRANSPORT,0.00010462,0.23192,0.2474,1,1
4,POTASSIUM CHANNEL REGULATOR ACTIVITY,0.013139,0.2318,0.27393,1,1
4,BIOCARTA EGF PATHWAY,0.00032948,0.23049,0.24339,1,1
4,CYTOKINE AND CHEMOKINE MEDIATED SIGNALING PATHWAY,6.7596e-05,0.23009,0.25167,1,1
4,REACTOME CHYLOMICRON MEDIATED LIPID TRANSPORT,0.007729,0.22959,0.27207,1,1
4,CATION HOMEOSTASIS,0.00021167,0.22865,0.18408,1,1
4,KEGG DRUG METABOLISM CYTOCHROME P450,0.024846,0.22845,0.20535,1,1
4,REACTOME BIOLOGICAL OXIDATIONS,0.00049035,0.22791,0.26039,1,1
4,PID P38 MKK3 6PATHWAY,0.00065623,0.22776,0.21116,1,1
4,PID CD40 PATHWAY,0.001191,0.22732,0.19747,1,1
4,ENDOCYTIC VESICLE,0.029068,0.22671,0.18114,1,1
4,KEGG ABC TRANSPORTERS,0.00035231,0.22644,0.26904,1,1
4,PID IL4 2PATHWAY,0.00072223,0.22636,0.23483,1,1
4,ATPASE ACTIVITY COUPLED TO MOVEMENT OF SUBSTANCES,0.00031859,0.22633,0.25372,1,1
4,REACTOME TRIF MEDIATED TLR3 SIGNALING,6.7596e-05,0.22543,0.22093,1,1
4,APOPTOTIC PROGRAM,0.00021909,0.22531,0.20174,1,1
4,KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION,0.00045924,0.22525,0.1683,1,1
4,BONE REMODELING,0.045624,0.22488,0.14234,1,1
4,KEGG RETINOL METABOLISM,0.0014299,0.22381,0.24201,1,1
4,REACTOME APOPTOSIS,0.00036427,0.2233,0.16469,1,1
4,REACTOME GLYCEROPHOSPHOLIPID BIOSYNTHESIS,1.349e-05,0.22317,0.23453,1,1
4,PHOSPHOLIPID BIOSYNTHETIC PROCESS,8.1192e-05,0.22308,0.21983,1,1
4,PID PTP1BPATHWAY,0.0085714,0.22204,0.16619,1,1
4,REACTOME SYNTHESIS OF PE,0.0026572,0.22191,0.20163,1,1
4,CATION TRANSPORT,9.7346e-05,0.22082,0.23198,1,1
4,KEGG HISTIDINE METABOLISM,0.00081984,0.22072,0.22853,1,1
4,REACTOME PURINE CATABOLISM,0.0081404,0.21977,0.16605,1,1
4,PID IL2 STAT5PATHWAY,0.046579,0.21971,0.15688,1,1
4,KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS HEPARAN SULFATE,0.024846,0.21959,0.1547,1,1
4,PROTEIN TRANSPORTER ACTIVITY,0.0051916,0.2195,0.219,1,1
4,DEVELOPMENTAL MATURATION,0.0021689,0.21845,0.26232,1,1
4,KEGG APOPTOSIS,0.00057693,0.21771,0.18724,1,1
4,PID AJDISS 2PATHWAY,0.0028957,0.21738,0.19761,1,1
4,BIOCARTA HSP27 PATHWAY,0.0062634,0.21728,0.16718,1,1
4,CELL CELL ADHESION,0.00029782,0.21663,0.21976,1,1
4,LOW DENSITY LIPOPROTEIN BINDING,0.0081404,0.21618,0.22742,1,1
4,CYTOPLASMIC MEMBRANE BOUND VESICLE,0.00028792,0.21601,0.16665,1,1
4,SERINE HYDROLASE ACTIVITY,0.0071468,0.21566,0.27341,1,1
4,RESPONSE TO VIRUS,0.0011199,0.21554,0.20055,1,1
4,PHOSPHOINOSITIDE BINDING,0.0012662,0.21501,0.20431,1,1
4,BIOCARTA P53HYPOXIA PATHWAY,0.0090226,0.21472,0.20112,1,1
4,REACTOME OTHER SEMAPHORIN INTERACTIONS,0.044685,0.21461,0.16768,1,1
4,REACTOME ION TRANSPORT BY P TYPE ATPASES,0.0025817,0.21403,0.18868,1,1
4,MEMBRANE BOUND VESICLE,0.00047456,0.214,0.15957,1,1
4,KEGG ARACHIDONIC ACID METABOLISM,0.00017796,0.21395,0.27795,1,1
4,CHEMICAL HOMEOSTASIS,7.2754e-05,0.21288,0.18904,1,1
4,POLYSACCHARIDE METABOLIC PROCESS,0.0028957,0.21285,0.21523,1,1
4,PID IL3 PATHWAY,0.010245,0.21215,0.18613,1,1
4,VESICLE MEMBRANE,0.0025083,0.21186,0.17671,1,1
4,KEGG DORSO VENTRAL AXIS FORMATION,0.0090226,0.2115,0.21539,1,1
4,RESPONSE TO OTHER ORGANISM,0.00040247,0.21141,0.16597,1,1
4,KEGG LINOLEIC ACID METABOLISM,5.8301e-05,0.21055,0.27707,1,1
4,NUCLEAR SPECK,0.042857,0.21025,0.15323,1,1
4,REACTOME IL1 SIGNALING,6.7596e-05,0.20987,0.2058,1,1
4,REACTOME AMINE COMPOUND SLC TRANSPORTERS,0.013798,0.20974,0.15559,1,1
4,EXONUCLEASE ACTIVITY,0.0029794,0.2092,0.17084,1,1
4,CARBOHYDRATE TRANSMEMBRANE TRANSPORTER ACTIVITY,0.031748,0.20918,0.14694,1,1
4,PID HIF2PATHWAY,0.018836,0.20895,0.1943,1,1
4,PID CERAMIDE PATHWAY,0.00069957,0.20862,0.16225,1,1
4,REACTOME SIGNALING BY ILS,0.00017186,0.20807,0.20442,1,1
4,REACTOME APOPTOTIC EXECUTION PHASE,0.012508,0.20798,0.15161,1,1
4,REACTOME SYNTHESIS OF VERY LONG CHAIN FATTY ACYL COAS,0.014486,0.20748,0.2029,1,1
4,KEGG GLYCOSYLPHOSPHATIDYLINOSITOL GPI ANCHOR BIOSYNTHESIS,0.00087311,0.20701,0.21065,1,1
4,REACTOME OLFACTORY SIGNALING PATHWAY,4.6597e-05,0.20623,0.23217,1,1
4,REACTOME ENDOSOMAL SORTING COMPLEX REQUIRED FOR TRANSPORT ESCRT,0.001662,0.20571,0.14063,1,1
4,PID NFKAPPABATYPICALPATHWAY,0.0075304,0.20564,0.2581,1,1
4,MONOOXYGENASE ACTIVITY,0.0039469,0.20544,0.32292,1,1
4,NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS,0.00079435,0.20483,0.19438,1,1
4,CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY,0.0015653,0.20436,0.153,1,1
4,PHOSPHOLIPASE ACTIVITY,0.0007696,0.20418,0.19717,1,1
4,BIOCARTA INSULIN PATHWAY,0.0007696,0.20387,0.19167,1,1
4,G PROTEIN COUPLED RECEPTOR BINDING,0.015203,0.20385,0.13129,1,1
4,PID IFNGPATHWAY,0.00019753,0.20332,0.22926,1,1
4,ANATOMICAL STRUCTURE FORMATION,0.0057817,0.20314,0.13882,1,1
4,REACTOME IL 2 SIGNALING,0.0018173,0.20171,0.23829,1,1
4,NEGATIVE REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS,0.00055855,0.20163,0.20596,1,1
4,METAL ION TRANSPORT,0.00049035,0.20148,0.22334,1,1
4,IMMUNE SYSTEM PROCESS,3.3132e-05,0.20101,0.19291,1,1
4,PID RAC1 PATHWAY,0.00047456,0.2009,0.20692,1,1
4,ANGIOGENESIS,0.011904,0.20085,0.14395,1,1
4,SIG IL4RECEPTOR IN B LYPHOCYTES,0.0024367,0.20053,0.1731,1,1
4,RESPONSE TO ORGANIC SUBSTANCE,0.0073363,0.20004,0.15335,1,1
4,PROTEIN KINASE CASCADE,9.0551e-05,0.2,0.19755,1,1
4,EXTRACELLULAR SPACE,0.00072223,0.19967,0.17648,1,1
4,ION TRANSPORT,9.389e-05,0.19962,0.19948,1,1
4,REACTOME TRANSPORT OF GLUCOSE AND OTHER SUGARS BILE SALTS AND ORGANIC ACIDS METAL IONS AND AMINE COMPOUNDS,0.00012964,0.19942,0.20849,1,1
4,BIOCARTA IGF1 PATHWAY,0.0094949,0.19936,0.14287,1,1
4,CARBOXYLIC ACID METABOLIC PROCESS,0.0032441,0.19934,0.19861,1,1
4,KEGG EPITHELIAL CELL SIGNALING IN HELICOBACTER PYLORI INFECTION,4.6597e-05,0.19928,0.20009,1,1
4,KEGG SNARE INTERACTIONS IN VESICULAR TRANSPORT,0.009256,0.19916,0.12625,1,1
4,BIOCARTA SPPA PATHWAY,0.025994,0.19846,0.14898,1,1
4,HOMEOSTATIC PROCESS,9.389e-05,0.19811,0.17065,1,1
4,RNA CATABOLIC PROCESS,0.0010206,0.19795,0.18241,1,1
4,BIOCARTA TALL1 PATHWAY,0.001986,0.1974,0.16272,1,1
4,TRANS GOLGI NETWORK TRANSPORT VESICLE,0.0069616,0.19731,0.1813,1,1
4,PHOSPHOINOSITIDE BIOSYNTHETIC PROCESS,0.0011549,0.19723,0.1896,1,1
4,KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY,0.0027346,0.19682,0.10715,1,1
4,MEMBRANE LIPID METABOLIC PROCESS,9.3916e-06,0.19552,0.20075,1,1
4,REACTOME KERATAN SULFATE BIOSYNTHESIS,0.0094949,0.19526,0.14237,1,1
4,PID GMCSF PATHWAY,0.00095906,0.19512,0.21351,1,1
4,CYTOPLASMIC VESICLE,0.00049035,0.19502,0.15267,1,1
4,REACTOME REGULATION OF INSULIN SECRETION,0.013465,0.19454,0.1815,1,1
4,PID IL2 1PATHWAY,0.0012662,0.19433,0.22601,1,1
4,NEGATIVE REGULATION OF PROGRAMMED CELL DEATH,0.0021689,0.19378,0.16057,1,1
4,REACTOME CYTOCHROME P450 ARRANGED BY SUBSTRATE TYPE,0.00069957,0.19328,0.25862,1,1
4,HEMATOPOIETIN INTERFERON CLASSD200 DOMAIN CYTOKINE RECEPTOR BINDING,0.0069616,0.1929,0.14777,1,1
4,PID P53DOWNSTREAMPATHWAY,0.0014299,0.19273,0.16936,1,1
4,CELL JUNCTION,0.0047853,0.19257,0.17513,1,1
4,PHOSPHOINOSITIDE MEDIATED SIGNALING,0.0023671,0.19221,0.15973,1,1
4,CELLULAR RESPIRATION,0.00081984,0.19215,0.22404,1,1
4,G PROTEIN SIGNALING COUPLED TO IP3 SECOND MESSENGERPHOSPHOLIPASE C ACTIVATING,0.0013457,0.19214,0.1791,1,1
4,PID BCR 5PATHWAY,0.00010845,0.19213,0.19321,1,1
4,REACTOME ACYL CHAIN REMODELLING OF PG,0.00081984,0.19192,0.26114,1,1
4,SOLUBLE FRACTION,1.1493e-05,0.19147,0.22353,1,1
4,CYTOKINE BINDING,0.0051916,0.19127,0.13583,1,1
4,REACTOME ION CHANNEL TRANSPORT,0.021165,0.19095,0.13686,1,1
4,GOLGI APPARATUS PART,0.00027832,0.19072,0.15984,1,1
4,HUMORAL IMMUNE RESPONSE,0.009256,0.1904,0.19334,1,1
4,PROTEOLYSIS,0.00010462,0.18994,0.17833,1,1
4,PID FASPATHWAY,0.0049174,0.18963,0.16152,1,1
4,REACTOME CD28 DEPENDENT PI3K AKT SIGNALING,0.014841,0.18925,0.17425,1,1
4,HEMOPOIESIS,0.00034072,0.1892,0.21071,1,1
4,KEGG ALANINE ASPARTATE AND GLUTAMATE METABOLISM,0.0067808,0.18813,0.17091,1,1
4,REGULATION OF PH,0.0073363,0.188,0.1772,1,1
4,POSITIVE REGULATION OF DEVELOPMENTAL PROCESS,8.4205e-05,0.18799,0.17715,1,1
4,PEROXISOMAL PART,0.016339,0.18779,0.14746,1,1
4,MICROBODY PART,0.016339,0.18779,0.14746,1,1
4,REACTOME DIABETES PATHWAYS,0.00081984,0.18769,0.19006,1,1
4,REACTOME HEPARAN SULFATE HEPARIN HS GAG METABOLISM,0.027188,0.18743,0.19833,1,1
4,VESICLE,0.00084609,0.18727,0.14116,1,1
4,AEROBIC RESPIRATION,0.0017123,0.18689,0.19923,1,1
4,PID CD8TCRPATHWAY,0.0057817,0.18676,0.15445,1,1
4,PID IL12 2PATHWAY,0.001228,0.18635,0.18238,1,1
4,KEGG ALZHEIMERS DISEASE,0.00040247,0.18615,0.14232,1,1
4,REACTOME IMMUNE SYSTEM,0.00013917,0.18612,0.16685,1,1
4,REPRODUCTION,9.3916e-06,0.18608,0.17894,1,1
4,AMINO ACID TRANSMEMBRANE TRANSPORTER ACTIVITY,0.031059,0.18594,0.1655,1,1
4,REGULATION OF BODY FLUID LEVELS,0.001191,0.18583,0.22796,1,1
4,REACTOME SPHINGOLIPID DE NOVO BIOSYNTHESIS,0.001662,0.18471,0.18077,1,1
4,BIOCARTA PDGF PATHWAY,0.00021909,0.18368,0.20746,1,1
4,AMINE TRANSMEMBRANE TRANSPORTER ACTIVITY,0.0053338,0.18337,0.19299,1,1
4,KEGG TYPE II DIABETES MELLITUS,0.0090226,0.18307,0.17921,1,1
4,MULTI ORGANISM PROCESS,0.00027832,0.1826,0.16607,1,1
4,SIG CD40PATHWAYMAP,0.0015653,0.18239,0.16538,1,1
4,MEMBRANE FRACTION,0.00036427,0.18225,0.17674,1,1
4,FEMALE GAMETE GENERATION,0.0073363,0.18196,0.17,1,1
4,ATPASE ACTIVITY COUPLED TO TRANSMEMBRANE MOVEMENT OF IONS,0.025414,0.18169,0.151,1,1
4,CASPASE ACTIVATION,0.011904,0.18156,0.13542,1,1
4,ANION TRANSPORT,0.0034322,0.18072,0.20624,1,1
4,PID HIF1 TFPATHWAY,0.0047853,0.18059,0.26673,1,1
4,EXTRACELLULAR REGION,0.0062634,0.18032,0.11636,1,1
4,PHOSPHOINOSITIDE METABOLIC PROCESS,0.00049035,0.17998,0.15392,1,1
4,KEGG PEROXISOME,0.0036303,0.17916,0.17532,1,1
4,GTPASE ACTIVATOR ACTIVITY,0.046579,0.17903,0.11604,1,1
4,PROTEIN TARGETING TO MEMBRANE,0.0027346,0.17872,0.21116,1,1
4,T CELL PROLIFERATION,0.0021062,0.17871,0.1828,1,1
4,ENDOPLASMIC RETICULUM PART,0.00023468,0.17837,0.22369,1,1
4,ST B CELL ANTIGEN RECEPTOR,0.0017123,0.1776,0.15058,1,1
4,LYASE ACTIVITY,0.0010859,0.17742,0.16836,1,1
4,ORGANIC ACID METABOLIC PROCESS,0.0027346,0.17741,0.19756,1,1
4,REACTOME TRAF6 MEDIATED INDUCTION OF NFKB AND MAP KINASES UPON TLR7 8 OR 9 ACTIVATION,0.00025131,0.17725,0.17753,1,1
4,REACTOME NFKB AND MAP KINASES ACTIVATION MEDIATED BY TLR4 SIGNALING REPERTOIRE,8.7323e-05,0.1772,0.20844,1,1
4,REACTOME COSTIMULATION BY THE CD28 FAMILY,0.0079323,0.17708,0.17656,1,1
4,PID IL23PATHWAY,0.00353,0.17708,0.13102,1,1
4,REACTOME ABC FAMILY PROTEINS MEDIATED TRANSPORT,0.0011199,0.17692,0.24496,1,1
4,CHLORIDE CHANNEL ACTIVITY,0.024846,0.1758,0.1356,1,1
4,ANION CHANNEL ACTIVITY,0.024846,0.1758,0.1356,1,1
4,IMMUNE SYSTEM DEVELOPMENT,0.0015189,0.17579,0.17545,1,1
4,OXIDOREDUCTASE ACTIVITY ACTING ON NADH OR NADPH,0.007729,0.17535,0.24181,1,1
4,UBIQUITIN BINDING,0.0045306,0.17499,0.19028,1,1
4,KEGG LEISHMANIA INFECTION,0.0011199,0.17456,0.18493,1,1
4,HYDROLASE ACTIVITY HYDROLYZING N GLYCOSYL COMPOUNDS,0.001872,0.17425,0.17163,1,1
4,REACTOME PD1 SIGNALING,0.042857,0.17406,0.23456,1,1
4,MICROSOME,0.00021909,0.1734,0.19525,1,1
4,REGULATION OF CELLULAR PH,0.0085714,0.17296,0.19227,1,1
4,CELLULAR CARBOHYDRATE METABOLIC PROCESS,5.0226e-05,0.17267,0.18225,1,1
4,REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS,0.00018427,0.17264,0.16421,1,1
4,PID P38ALPHABETADOWNSTREAMPATHWAY,0.0033369,0.17249,0.16304,1,1
4,PID NFAT TFPATHWAY,0.035393,0.17223,0.15206,1,1
4,REGULATION OF PROTEIN SECRETION,0.02068,0.17216,0.14704,1,1
4,BIOCARTA TPO PATHWAY,0.0024367,0.17211,0.21265,1,1
4,ENDOPLASMIC RETICULUM MEMBRANE,0.00020448,0.17193,0.21696,1,1
4,REACTOME ACTIVATED AMPK STIMULATES FATTY ACID OXIDATION IN MUSCLE,0.011326,0.17187,0.15703,1,1
4,REGULATION OF BIOLOGICAL QUALITY,4.4878e-05,0.17114,0.16542,1,1
4,SMALL CONJUGATING PROTEIN BINDING,0.0028141,0.17098,0.18099,1,1
4,REACTOME GPVI MEDIATED ACTIVATION CASCADE,0.0064317,0.1709,0.18508,1,1
4,REACTOME PHOSPHOLIPID METABOLISM,5.508e-06,0.17036,0.21354,1,1
4,REACTOME SIGNAL ATTENUATION,0.0069616,0.17005,0.19,1,1
4,MAGNESIUM ION BINDING,0.0028957,0.16984,0.13799,1,1
4,REACTOME PRE NOTCH EXPRESSION AND PROCESSING,0.027803,0.16982,0.12328,1,1
4,REPRODUCTIVE PROCESS,0.00020448,0.16974,0.14796,1,1
4,MONOSACCHARIDE BINDING,0.011904,0.16955,0.17646,1,1
4,PID DELTANP63PATHWAY,0.016339,0.16907,0.19174,1,1
4,RESPONSE TO EXTERNAL STIMULUS,0.0015653,0.16883,0.12548,1,1
4,METALLOEXOPEPTIDASE ACTIVITY,0.034637,0.16857,0.14809,1,1
4,MEMBRANE LIPID BIOSYNTHETIC PROCESS,0.0007696,0.16819,0.17985,1,1
4,PID INTEGRIN A4B1 PATHWAY,0.0062634,0.16799,0.19882,1,1
4,NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS,0.0075304,0.16684,0.1237,1,1
4,BIOCARTA GLEEVEC PATHWAY,0.0071468,0.16669,0.16291,1,1
4,LIPOPROTEIN METABOLIC PROCESS,0.0001547,0.16654,0.21186,1,1
4,LIPASE ACTIVITY,0.0014299,0.16644,0.16676,1,1
4,IMMUNE EFFECTOR PROCESS,0.022165,0.16507,0.12022,1,1
4,HEMOPOIETIC OR LYMPHOID ORGAN DEVELOPMENT,0.0017123,0.16485,0.1718,1,1
4,PID TXA2PATHWAY,0.025994,0.1647,0.17519,1,1
4,MITOCHONDRIAL MEMBRANE ORGANIZATION AND BIOGENESIS,0.024288,0.16461,0.16411,1,1
4,BIOCARTA BCR PATHWAY,0.0013872,0.16431,0.2116,1,1
4,REACTOME TRANSPORT OF VITAMINS NUCLEOSIDES AND RELATED MOLECULES,0.0014738,0.16385,0.22729,1,1
4,REGULATION OF CELL DIFFERENTIATION,0.0020453,0.16368,0.17747,1,1
4,BIOCARTA MAL PATHWAY,0.0090226,0.16356,0.12829,1,1
4,DOUBLE STRANDED RNA BINDING,0.014841,0.16211,0.14024,1,1
4,SUGAR BINDING,0.00092958,0.16176,0.14397,1,1
4,PID ATF2 PATHWAY,0.0081404,0.16165,0.17636,1,1
4,VESICULAR FRACTION,0.0010859,0.16133,0.1672,1,1
4,PID PI3KCIPATHWAY,0.0029794,0.16132,0.18992,1,1
4,KEGG FC EPSILON RI SIGNALING PATHWAY,0.00049035,0.15967,0.16068,1,1
4,CELL FRACTION,0.00010462,0.15927,0.17997,1,1
4,LIPID BINDING,0.0031536,0.15902,0.13298,1,1
4,ACID AMINO ACID LIGASE ACTIVITY,0.02268,0.15877,0.086607,1,1
4,FEMALE PREGNANCY,0.0067808,0.15785,0.13467,1,1
4,PID REG GR PATHWAY,0.014486,0.15781,0.13912,1,1
4,REGULATION OF PROGRAMMED CELL DEATH,0.00069957,0.15671,0.1414,1,1
4,PID S1P S1P2 PATHWAY,0.030383,0.15635,0.18535,1,1
4,MAPKKK CASCADE GO 0000165,0.041093,0.15604,0.10315,1,1
4,PEROXISOME,0.004408,0.15601,0.16599,1,1
4,MICROBODY,0.004408,0.15601,0.16599,1,1
4,INTEGRAL TO ORGANELLE MEMBRANE,0.00072223,0.15578,0.18248,1,1
4,PEPTIDE RECEPTOR ACTIVITY,0.013465,0.15575,0.11175,1,1
4,PID CD8TCRDOWNSTREAMPATHWAY,0.0054795,0.15486,0.14301,1,1
4,PHOSPHORIC MONOESTER HYDROLASE ACTIVITY,0.0025817,0.15458,0.12903,1,1
4,REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES,0.00055855,0.15429,0.18186,1,1
4,REACTOME STEROID HORMONES,0.0053338,0.15424,0.17818,1,1
4,REACTOME PEPTIDE LIGAND BINDING RECEPTORS,0.012508,0.154,0.090167,1,1
4,REACTOME JNK C JUN KINASES PHOSPHORYLATION AND ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1,0.0025817,0.15384,0.13637,1,1
4,REACTOME METABOLISM OF AMINO ACIDS AND DERIVATIVES,0.00069957,0.15362,0.16743,1,1
4,PEROXISOME ORGANIZATION AND BIOGENESIS,0.0037331,0.15349,0.19554,1,1
4,KEGG ADIPOCYTOKINE SIGNALING PATHWAY,0.0012662,0.15327,0.15703,1,1
4,PID FCER1PATHWAY,0.00022676,0.15218,0.16868,1,1
4,BIOCARTA FCER1 PATHWAY,0.0016129,0.15194,0.17897,1,1
4,INTRINSIC TO ORGANELLE MEMBRANE,0.0010859,0.15092,0.17482,1,1
4,ENZYME INHIBITOR ACTIVITY,0.011904,0.15089,0.11326,1,1
4,PID IL12 STAT4PATHWAY,0.030383,0.15018,0.11587,1,1
4,BIOCARTA MET PATHWAY,0.029068,0.1501,0.11628,1,1
4,EXTRACELLULAR REGION PART,0.033166,0.15008,0.07814,1,1
4,REGULATION OF APOPTOSIS,0.001228,0.1497,0.13327,1,1
4,RECEPTOR BINDING,0.0081404,0.14916,0.096094,1,1
4,ADAPTIVE IMMUNE RESPONSE,0.041967,0.14861,0.066993,1,1
4,PID ERBB1 DOWNSTREAM PATHWAY,0.0075304,0.14831,0.13249,1,1
4,DEFENSE RESPONSE TO BACTERIUM,0.0087944,0.14807,0.095422,1,1
4,INDUCTION OF APOPTOSIS BY EXTRACELLULAR SIGNALS,0.00084609,0.1478,0.2047,1,1
4,BIOSYNTHETIC PROCESS,0.00079435,0.14779,0.1511,1,1
4,RESPONSE TO CHEMICAL STIMULUS,0.00013433,0.14745,0.13748,1,1
4,REACTOME NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION,0.0090226,0.1474,0.14328,1,1
4,PID FGF PATHWAY,0.0097392,0.14689,0.13636,1,1
4,PROGRAMMED CELL DEATH,0.00092958,0.14663,0.12838,1,1
4,PID MAPKTRKPATHWAY,0.0081404,0.14562,0.1473,1,1
4,POST GOLGI VESICLE MEDIATED TRANSPORT,0.017549,0.14523,0.21783,1,1
4,REACTOME SIGNALING BY NOTCH,0.0069616,0.14363,0.13001,1,1
4,UBIQUITIN LIGASE COMPLEX,0.021165,0.14342,0.076308,1,1
4,REACTOME METAL ION SLC TRANSPORTERS,0.0049174,0.14341,0.20847,1,1
4,KEGG JAK STAT SIGNALING PATHWAY,0.004408,0.14319,0.13219,1,1
4,PID HES HEYPATHWAY,0.034637,0.14218,0.12818,1,1
4,SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION,0.015953,0.14169,0.10767,1,1
4,CARBOHYDRATE METABOLIC PROCESS,0.00084609,0.14026,0.14537,1,1
4,REACTOME SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE,0.013139,0.14019,0.15506,1,1
4,TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY,0.02843,0.14002,0.12165,1,1
4,PID MET PATHWAY,0.0060989,0.13987,0.12074,1,1
4,REACTOME ERK MAPK TARGETS,0.018836,0.13957,0.14777,1,1
4,APOPTOSIS GO,0.0013457,0.13955,0.1219,1,1
4,RECEPTOR COMPLEX,0.017549,0.13918,0.11817,1,1
4,REACTOME CLASS B 2 SECRETIN FAMILY RECEPTORS,0.02068,0.13754,0.10529,1,1
4,HYDROLASE ACTIVITY ACTING ON ESTER BONDS,0.0010528,0.13733,0.11328,1,1
4,PHOSPHOLIPID BINDING,0.0033369,0.13721,0.13404,1,1
4,BIOCARTA GH PATHWAY,0.007729,0.13698,0.15223,1,1
4,PID RHOA PATHWAY,0.011612,0.13672,0.14606,1,1
4,BIOCARTA ECM PATHWAY,0.042857,0.13633,0.12812,1,1
4,INTEGRAL TO PLASMA MEMBRANE,0.0015189,0.13583,0.12297,1,1
4,RESPONSE TO HYPOXIA,0.040234,0.13572,0.1548,1,1
4,KEGG ALPHA LINOLENIC ACID METABOLISM,0.0057817,0.13552,0.1732,1,1
4,BIOCARTA LECTIN PATHWAY,0.044685,0.13519,0.052751,1,1
4,KEGG GLYCEROPHOSPHOLIPID METABOLISM,0.00027832,0.13495,0.14883,1,1
4,REACTOME ENERGY DEPENDENT REGULATION OF MTOR BY LKB1 AMPK,0.022165,0.13481,0.14167,1,1
4,NUCLEAR ENVELOPE ENDOPLASMIC RETICULUM NETWORK,0.00081984,0.13452,0.18605,1,1
4,PEPTIDE BINDING,0.001872,0.1339,0.1444,1,1
4,KEGG B CELL RECEPTOR SIGNALING PATHWAY,0.0037331,0.13326,0.14953,1,1
4,KEGG OXIDATIVE PHOSPHORYLATION,0.012508,0.13298,0.12788,1,1
4,INTRINSIC TO PLASMA MEMBRANE,0.0028141,0.13262,0.11601,1,1
4,CALCIUM ION BINDING,0.013465,0.13222,0.10816,1,1
4,PLASMA MEMBRANE,0.00063551,0.13186,0.12799,1,1
4,COATED VESICLE,0.014841,0.1303,0.10404,1,1
4,POSITIVE REGULATION OF CELLULAR PROCESS,0.0012662,0.1296,0.11039,1,1
4,PLASMA MEMBRANE PART,0.001191,0.12954,0.12195,1,1
4,ACTIN BINDING,0.0030654,0.12921,0.14998,1,1
4,CHROMOSOME CONDENSATION,0.013465,0.12803,0.1842,1,1
4,BIOCARTA AT1R PATHWAY,0.037747,0.12792,0.14263,1,1
4,ACTIVE TRANSMEMBRANE TRANSPORTER ACTIVITY,0.00031859,0.12792,0.18248,1,1
4,REGULATION OF DEVELOPMENTAL PROCESS,0.0021689,0.12681,0.11587,1,1
4,REACTOME CLASS A1 RHODOPSIN LIKE RECEPTORS,0.02068,0.12664,0.070523,1,1
4,EXOPEPTIDASE ACTIVITY,0.031059,0.12592,0.16959,1,1
4,INTEGRAL TO MEMBRANE,0.0011549,0.1258,0.12435,1,1
4,TRANSMEMBRANE RECEPTOR ACTIVITY,0.024846,0.12512,0.081877,1,1
4,RESPONSE TO BACTERIUM,0.0050528,0.12489,0.094704,1,1
4,INTRACELLULAR SIGNALING CASCADE,0.00084609,0.12471,0.11806,1,1
4,PID ANGIOPOIETINRECEPTOR PATHWAY,0.015203,0.12432,0.13821,1,1
4,BIOPOLYMER MODIFICATION,0.0015653,0.12431,0.10623,1,1
4,REACTOME SIGNALLING TO RAS,0.012203,0.12391,0.11151,1,1
4,REACTOME BASE FREE SUGAR PHOSPHATE REMOVAL VIA THE SINGLE NUCLEOTIDE REPLACEMENT PATHWAY,0.0062634,0.12337,0.14427,1,1
4,SUBSTRATE SPECIFIC TRANSPORTER ACTIVITY,0.0020453,0.12316,0.12805,1,1
4,G PROTEIN COUPLED RECEPTOR PROTEIN SIGNALING PATHWAY,0.044685,0.12303,0.067569,1,1
4,RHODOPSIN LIKE RECEPTOR ACTIVITY,0.035393,0.1229,0.069123,1,1
4,INORGANIC CATION TRANSMEMBRANE TRANSPORTER ACTIVITY,0.0018173,0.12212,0.1283,1,1
4,BIOCARTA TNFR1 PATHWAY,0.024288,0.12199,0.10991,1,1
4,PID FOXOPATHWAY,0.03245,0.12119,0.10698,1,1
4,BIOCARTA NGF PATHWAY,0.0057817,0.12114,0.14517,1,1
4,MEMBRANE,0.00095906,0.12034,0.11981,1,1
4,INTRINSIC TO MEMBRANE,0.0015189,0.11988,0.1182,1,1
4,REGULATION OF MULTICELLULAR ORGANISMAL PROCESS,0.0071468,0.11987,0.091425,1,1
4,PROTEIN MODIFICATION PROCESS,0.001872,0.11872,0.10503,1,1
4,CELLULAR MACROMOLECULE CATABOLIC PROCESS,0.0031536,0.11809,0.10021,1,1
4,ENZYME ACTIVATOR ACTIVITY,0.017137,0.11809,0.11724,1,1
4,NEGATIVE REGULATION OF CELL PROLIFERATION,0.011047,0.11779,0.099349,1,1
4,HEMOSTASIS,0.0067808,0.11674,0.21115,1,1
4,KEGG INOSITOL PHOSPHATE METABOLISM,0.027188,0.11667,0.099984,1,1
4,BIOCARTA CXCR4 PATHWAY,0.025414,0.11657,0.13533,1,1
4,KEGG GNRH SIGNALING PATHWAY,0.0025817,0.11653,0.13596,1,1
4,KEGG VIBRIO CHOLERAE INFECTION,0.014486,0.11609,0.10206,1,1
4,PROTEIN KINASE ACTIVITY,0.0023671,0.11597,0.11339,1,1
4,LOCOMOTORY BEHAVIOR,0.001228,0.11562,0.10836,1,1
4,RESPONSE TO BIOTIC STIMULUS,0.0012662,0.11556,0.12099,1,1
4,PROTEIN HOMODIMERIZATION ACTIVITY,0.0071468,0.11513,0.10578,1,1
4,DEOXYRIBONUCLEASE ACTIVITY,0.0038387,0.11444,0.12655,1,1
4,RESPONSE TO STRESS,0.0029794,0.1136,0.096383,1,1
4,POSITIVE REGULATION OF BIOLOGICAL PROCESS,0.0010859,0.11355,0.10865,1,1
4,KEGG FC GAMMA R MEDIATED PHAGOCYTOSIS,0.02843,0.11337,0.11021,1,1
4,KEGG OLFACTORY TRANSDUCTION,0.0099891,0.11314,0.10439,1,1
4,PROTEIN AMINO ACID N LINKED GLYCOSYLATION,0.013798,0.11084,0.21392,1,1
4,REACTOME GPCR LIGAND BINDING,0.024846,0.11034,0.068945,1,1
4,PID SMAD2 3PATHWAY,0.012203,0.11027,0.15233,1,1
4,IDENTICAL PROTEIN BINDING,0.0011199,0.11012,0.11121,1,1
4,MEMBRANE PART,0.00063551,0.10957,0.12108,1,1
4,ENDOPEPTIDASE ACTIVITY,0.0073363,0.10929,0.12844,1,1
4,PID P73PATHWAY,0.043763,0.10913,0.10599,1,1
4,BIOCARTA TCR PATHWAY,0.0079323,0.10887,0.15574,1,1
4,REACTOME RESOLUTION OF AP SITES VIA THE SINGLE NUCLEOTIDE REPLACEMENT PATHWAY,0.014138,0.10863,0.096672,1,1
4,REGULATION OF HYDROLASE ACTIVITY,0.011904,0.10852,0.10472,1,1
4,CYTOPLASM,0.0013054,0.10788,0.094537,1,1
4,REACTOME GPCR DOWNSTREAM SIGNALING,0.035393,0.107,0.062799,1,1
4,PEPTIDASE ACTIVITY,0.0099891,0.10674,0.13218,1,1
4,ION TRANSMEMBRANE TRANSPORTER ACTIVITY,0.016339,0.10596,0.10111,1,1
4,CELL SURFACE RECEPTOR LINKED SIGNAL TRANSDUCTION GO 0007166,0.027803,0.10503,0.07391,1,1
4,REACTOME G ALPHA S SIGNALLING EVENTS,0.033894,0.10469,0.096923,1,1
4,KEGG PHOSPHATIDYLINOSITOL SIGNALING SYSTEM,0.018836,0.10436,0.1104,1,1
4,BIOCARTA ATM PATHWAY,0.011904,0.10389,0.17025,1,1
4,KEGG GLYCEROLIPID METABOLISM,0.031059,0.10381,0.17474,1,1
4,HISTONE DEACETYLASE BINDING,0.015953,0.10363,0.12921,1,1
4,TRANSMEMBRANE TRANSPORTER ACTIVITY,0.007729,0.10354,0.11891,1,1
4,LIPOPROTEIN BINDING,0.047551,0.10276,0.14451,1,1
4,ADENYL NUCLEOTIDE BINDING,0.025994,0.10183,0.079164,1,1
4,SIGNAL TRANSDUCTION,0.0039469,0.10178,0.096174,1,1
4,REACTOME TRANSMEMBRANE TRANSPORT OF SMALL MOLECULES,0.0014738,0.10161,0.11623,1,1
4,CELL PROJECTION,0.025414,0.10114,0.080577,1,1
4,NUCLEAR BODY,0.001662,0.098447,0.10489,1,1
4,CELL DEVELOPMENT,0.02268,0.096732,0.074917,1,1
4,TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS,0.011904,0.094772,0.078065,1,1
4,REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION,0.023205,0.093582,0.11611,1,1
4,PID ENDOTHELINPATHWAY,0.029719,0.093265,0.10595,1,1
4,PURINE NUCLEOTIDE BINDING,0.022165,0.092893,0.074657,1,1
4,PURINE RIBONUCLEOTIDE BINDING,0.031059,0.092783,0.065468,1,1
4,RECEPTOR ACTIVITY,0.038561,0.092187,0.074225,1,1
4,ESTABLISHMENT OF LOCALIZATION,0.00047456,0.092071,0.10794,1,1
4,TRANSFERASE ACTIVITY TRANSFERRING SULFUR CONTAINING GROUPS,0.043763,0.089436,0.11718,1,1
4,NEGATIVE REGULATION OF METABOLIC PROCESS,0.033894,0.088397,0.066553,1,1
4,PHOSPHOTRANSFERASE ACTIVITY ALCOHOL GROUP AS ACCEPTOR,0.0059384,0.088074,0.094963,1,1
4,NEGATIVE REGULATION OF CELLULAR METABOLIC PROCESS,0.03245,0.08758,0.067318,1,1
4,BIOCARTA MAPK PATHWAY,0.018398,0.087479,0.1035,1,1
4,KEGG PPAR SIGNALING PATHWAY,0.02843,0.08734,0.10773,1,1
4,KINASE ACTIVITY,0.0085714,0.08617,0.085103,1,1
4,SUBSTRATE SPECIFIC TRANSMEMBRANE TRANSPORTER ACTIVITY,0.015203,0.085281,0.10427,1,1
4,ESTABLISHMENT OF CELLULAR LOCALIZATION,0.010773,0.084643,0.078677,1,1
4,NUCLEOTIDE BINDING,0.025414,0.084125,0.071787,1,1
4,GOLGI ASSOCIATED VESICLE,0.0066042,0.083658,0.11667,1,1
4,ADENYL RIBONUCLEOTIDE BINDING,0.037747,0.080766,0.067809,1,1
4,CELLULAR LOCALIZATION,0.018836,0.080335,0.072715,1,1
4,REACTOME RESOLUTION OF AP SITES VIA THE MULTIPLE NUCLEOTIDE PATCH REPLACEMENT PATHWAY,0.021165,0.077095,0.098046,1,1
4,PROTEIN DIMERIZATION ACTIVITY,0.041967,0.070603,0.068942,1,1
4,PROTEIN SERINE THREONINE KINASE ACTIVITY,0.015953,0.063395,0.077343,1,1
4,REACTOME SIGNALING BY INSULIN RECEPTOR,0.0099891,0.061841,0.084884,1,1
5,IMMUNOLOGICAL SYNAPSE,0.00041602,0.42472,0.35484,1,1
5,REACTOME CRMPS IN SEMA3A SIGNALING,0.00023468,0.39791,0.56123,1,1
5,REACTOME RNA POL I PROMOTER OPENING,0.024846,0.37103,0.33513,1,1
5,REACTOME CD28 DEPENDENT VAV1 PATHWAY,0.00020448,0.33257,0.29401,1,1
5,REACTOME SIGNALING BY ACTIVATED POINT MUTANTS OF FGFR1,0.025994,0.32897,0.21155,1,1
5,BIOCARTA SKP2E2F PATHWAY,0.00035231,0.32408,0.30442,1,1
5,SA REG CASCADE OF CYCLIN EXPR,0.0013457,0.31952,0.27295,1,1
5,PID SYNDECAN 3 PATHWAY,0.0059384,0.31839,0.33779,1,1
5,REACTOME DEPOSITION OF NEW CENPA CONTAINING NUCLEOSOMES AT THE CENTROMERE,0.014841,0.29791,0.28209,1,1
5,REACTOME REGULATION OF KIT SIGNALING,0.014841,0.2963,0.30091,1,1
5,REACTOME INHIBITION OF INSULIN SECRETION BY ADRENALINE NORADRENALINE,0.0028957,0.29433,0.25995,1,1
5,KINESIN COMPLEX,4.8379e-05,0.29169,0.3297,1,1
5,REACTOME FGFR1 LIGAND BINDING AND ACTIVATION,0.038561,0.27352,0.15955,1,1
5,REACTOME RNA POL I TRANSCRIPTION,0.041967,0.27026,0.20067,1,1
5,MICROTUBULE MOTOR ACTIVITY,0.0073363,0.27006,0.23128,1,1
5,BIOCARTA BAD PATHWAY,0.00057693,0.26464,0.29221,1,1
5,REACTOME MEIOTIC RECOMBINATION,0.030383,0.26283,0.23542,1,1
5,MICROTUBULE ASSOCIATED COMPLEX,0.00019079,0.25996,0.26886,1,1
5,REGULATION OF T CELL ACTIVATION,0.025414,0.24585,0.22427,1,1
5,REACTOME SYNTHESIS SECRETION AND INACTIVATION OF GIP,0.0067808,0.24372,0.32121,1,1
5,BIOCARTA CDK5 PATHWAY,0.0097392,0.24255,0.20066,1,1
5,BIOCARTA TCRA PATHWAY,0.0028957,0.22585,0.19403,1,1
5,PID NFKAPPABATYPICALPATHWAY,0.0069616,0.21413,0.1809,1,1
5,REACTOME MEIOSIS,0.025414,0.2035,0.18904,1,1
5,PHOTOTRANSDUCTION,0.014841,0.2033,0.15342,1,1
5,CENTROSOME,0.00013917,0.20016,0.16844,1,1
5,NUCLEAR CHROMATIN,0.022165,0.19918,0.21072,1,1
5,REACTOME REGULATION OF WATER BALANCE BY RENAL AQUAPORINS,0.009256,0.18802,0.18602,1,1
5,REACTOME CD28 DEPENDENT PI3K AKT SIGNALING,0.0060989,0.18743,0.17527,1,1
5,REACTOME APOPTOSIS INDUCED DNA FRAGMENTATION,0.017137,0.18641,0.18566,1,1
5,MOTOR ACTIVITY,0.011904,0.18349,0.18416,1,1
5,S PHASE,0.011612,0.17674,0.14185,1,1
5,REACTOME INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1 E2F1,0.0053338,0.17468,0.17313,1,1
5,MITOTIC SPINDLE ORGANIZATION AND BIOGENESIS,0.007729,0.17376,0.20496,1,1
5,BIOCARTA P27 PATHWAY,0.0064317,0.1737,0.16608,1,1
5,REGULATION OF CHROMOSOME ORGANIZATION AND BIOGENESIS,0.00353,0.1694,0.17458,1,1
5,REACTOME SIGNALING BY FGFR3 MUTANTS,0.025994,0.16565,0.15209,1,1
5,BIOCARTA IL7 PATHWAY,0.040234,0.16115,0.17653,1,1
5,BIOCARTA MCM PATHWAY,0.0025817,0.16108,0.19082,1,1
5,REACTOME INSULIN SYNTHESIS AND PROCESSING,0.0022332,0.16005,0.29217,1,1
5,MICROTUBULE CYTOSKELETON,5.0226e-05,0.15903,0.16092,1,1
5,T CELL ACTIVATION,0.024288,0.15786,0.15671,1,1
5,REACTOME CGMP EFFECTS,0.021165,0.15741,0.1729,1,1
5,REACTOME AQUAPORIN MEDIATED TRANSPORT,0.015203,0.15483,0.15869,1,1
5,BIOCARTA CSK PATHWAY,0.012203,0.15115,0.12918,1,1
5,CHROMATIN,0.0059384,0.14983,0.14125,1,1
5,REACTOME INFLAMMASOMES,0.029068,0.14969,0.15251,1,1
5,MICROTUBULE ORGANIZING CENTER PART,0.00098941,0.14801,0.173,1,1
5,MICROTUBULE ORGANIZING CENTER,0.00034072,0.14579,0.13875,1,1
5,REACTOME E2F MEDIATED REGULATION OF DNA REPLICATION,0.009256,0.14567,0.14351,1,1
5,BIOCARTA RB PATHWAY,0.011326,0.14531,0.18774,1,1
5,SPINDLE MICROTUBULE,0.023205,0.13942,0.11547,1,1
5,TUBULIN BINDING,0.033166,0.13757,0.11548,1,1
5,NUCLEAR CHROMOSOME PART,0.0071468,0.1354,0.13362,1,1
5,S PHASE OF MITOTIC CELL CYCLE,0.03939,0.13485,0.13729,1,1
5,MICROTUBULE BINDING,0.0075304,0.13219,0.16379,1,1
5,REACTOME MITOTIC PROMETAPHASE,0.014486,0.13093,0.10861,1,1
5,NUCLEAR SPECK,0.033166,0.13079,0.10908,1,1
5,SPINDLE ORGANIZATION AND BIOGENESIS,0.012508,0.12852,0.17745,1,1
5,REACTOME EARLY PHASE OF HIV LIFE CYCLE,0.041093,0.12628,0.16243,1,1
5,REACTOME AKT PHOSPHORYLATES TARGETS IN THE CYTOSOL,0.025994,0.12594,0.16472,1,1
5,REACTOME CTLA4 INHIBITORY SIGNALING,0.0097392,0.12557,0.13348,1,1
5,PID PI3KPLCTRKPATHWAY,0.02166,0.12451,0.10589,1,1
5,BIOCARTA ACH PATHWAY,0.018398,0.11995,0.09165,1,1
5,CENTROSOME CYCLE,0.020205,0.11834,0.14,1,1
5,MRNA SPLICE SITE SELECTION,0.041093,0.11728,0.12374,1,1
5,CHROMOSOMAL PART,0.0014299,0.11615,0.11518,1,1
5,KINETOCHORE,0.031059,0.11275,0.09756,1,1
5,REACTOME CD28 CO STIMULATION,0.03939,0.11202,0.072045,1,1
5,REACTOME LOSS OF NLP FROM MITOTIC CENTROSOMES,0.0056288,0.11093,0.10561,1,1
5,NUCLEAR REPLICATION FORK,0.02068,0.11015,0.12057,1,1
5,REACTOME RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES,0.0057817,0.10849,0.099877,1,1
5,REACTOME TRANSCRIPTION,0.044685,0.10581,0.089665,1,1
5,PID FANCONI PATHWAY,0.020205,0.10481,0.10681,1,1
5,REACTOME INTRINSIC PATHWAY FOR APOPTOSIS,0.042857,0.10456,0.14866,1,1
5,PID FASPATHWAY,0.024288,0.10334,0.11854,1,1
5,REACTOME MITOTIC G2 G2 M PHASES,0.0062634,0.10051,0.10507,1,1
5,CENTROSOME ORGANIZATION AND BIOGENESIS,0.034637,0.088871,0.09718,1,1
5,CYTOSKELETAL PART,0.013465,0.087324,0.066648,1,1
5,REPLICATION FORK,0.047551,0.087157,0.1099,1,1
5,CHROMOSOME,0.0059384,0.083159,0.093483,1,1
5,MICROTUBULE ORGANIZING CENTER ORGANIZATION AND BIOGENESIS,0.043763,0.074553,0.10129,1,1
5,REACTOME CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION ,0.044685,0.063922,0.087461,1,1
